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Trauma is the leading cause of death and disability in United States for both children and
adults. In response to trauma, the body unleashes a set of coupled programs that affect
the functioning of vascular, immune and autonomous nervous systems. In pathological
cases, the integrated output of these programs can result in coagulopathy, systemic in-
flammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS)
and potentially even death. Nearly 35%-40% of trauma deaths occur due to uncontrolled
hemorrhage resulting from trauma-induced coagulopathy (TIC). TIC also plays an impor-
tant role in modulating inflammation, organ dysfunction and increased susceptibility to
sepsis. Clinical trials for treatment strategies targeting TIC have met with limited success.
The interlinked nature of coagulant and inflammatory responses, along with patient spe-
cific physiological variability, make the treatment of TIC challenging. Understanding TIC
requires an integrated multi-scale modeling framework which describes the relevant bio-
chemical networks within the context of the whole-body. Given the complexity and size,
embedding large, non-linear models of biochemical networks into a whole body model
creates a significant computational challenge.
Thus an objective of this work is to develop a framework that reduces the complexity
of high-dimensional mathematical models. We apply this framework to model biochem-
ical networks that are important in TIC. We first investigate the dynamics of coagulation
and understand the impact of protein C pathway on thrombin generation. Thereafter we
use this reduced order modeling technique to model complement and fibrinolysis. We
identify targets of therapeutic importance in complement and mechanisms that control
clot degradation in fibrinolysis. We show that we can capture the dynamics of these com-
plex but varied systems using the reduced order modeling framework.
In addition, we address the problem of training high-dimensional, non-linear models
of biological systems. Traditional gradient based methods often fail due to convergence
to a local optima or due to the lack of gradient knowledge. We present a novel optimiza-
tion method that is based on evolutionary algorithms to obtain near optimal parameters
within a limited number of function evaluations. We demonstrate that this method ob-
tains optimal solutions on a wide array of non-linear models, faster than existing meta
heuristic methods. Taken together this work provides a methodology to rapidly investi-
gate complex biochemical systems by simplifying the model design and experimentation
processes.
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2.1 Schematic of the connectivity of the reduced order coagulation model.
A trigger compound, e.g., TF/FVIIa initiates thrombin production (FIIa)
from prothrombin (fII). Once activated, thrombin catalyzes its own activa-
tion (amplification step), as well as its own inhibition via the conversion
of protein C to activated protein C (APC). APC and tissue factor pathway
inhibitor (TFPI) inhibit initiation and amplification, while antithrombin III
(ATIII) directly inhibits thrombin. All inhibition steps and trigger-induced
initiation were modeled using a rule-based approach. Likewise, the de-
pendence of amplification on other coagulation factors was also modeled
using a rule-based approach. The abundance of the highlighted species (in
the dashed boxes) was governed by an ordinary differential equation. All
other species were assumed to be constant. . . . . . . . . . . . . . . . . . . . 12
2.2 Schematic of rule-based effective control laws. Traditional enzyme ki-
netic expressions, e.g., Michaelis-Menten or multiple saturation kinetics
are multiplied by an enzyme activity control variable 0 ≤ v j ≤ 1. Control
variables are functions of many possible regulatory factors encoded by ar-
bitrary transfer functions of the form 0 ≤ f j (Z) ≤ 1. At each simulation
time step, the v j variables are calculated by evaluating integration rules
such as the max or min of the set of transfer functions f1, . . . , fn influencing
the activity of enzyme E j. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
2.3 Reduced order coagulation model training simulations. Reduced order
coagulation model parameters were estimated using particle swarm opti-
mization (PSO) without the protein C pathway as a function of prothrom-
bin. Solid lines denote the simulated mean value of the thrombin profile
for N = 20 independent particles, points denote experimental data. The
shaded region denotes the 99% confidence estimate of the mean simu-
lated thrombin value (uncertainty in the model simulation). (A,B,C) de-
pict training data and results for 150%, 100% and 50% of physiological
prothrombin levels in the absence of protein C pathway. The experimen-
tal training data was reproduced from the study of Butenas et al. [1][2].
All factors and control proteins in these experiments were at their physio-
logical concentration unless otherwise denoted. . . . . . . . . . . . . . . . . 16
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2.4 Reduced order coagulation model training simulations. Reduced order
coagulation model parameters were estimated using particle swarm opti-
mization (PSO) with the protein C pathway as a function of prothrombin.
Only APC pathway parameters were allowed to vary in these simulations
keeping the parameters estimated without protein C pathways constant.
Solid lines denote the simulated mean value of the thrombin profile for N
= 20 independent particles, points denote experimental data. The shaded
region denotes the 99% confidence estimate of the mean simulated throm-
bin value (uncertainty in the model simulation). (A,B,C) depict training
data and results for 150%, 100% and 50% of physiological prothrombin
levels in the presence of the protein C pathway. The experimental training
data was reproduced from the study of Butenas et al. [1][2]. All factors
and control proteins in these experiments were at their physiological con-
centration unless otherwise denoted. . . . . . . . . . . . . . . . . . . . . . . 17
2.5 Reduced order coagulation model predictions versus experimental data
for normal coagulation. The reduced order coagulation model param-
eter estimates were tested against data not used during model training.
Simulations of different levels of prothrombin and ATIII were compared
with experimental data in the absence of the protein C pathway. Solid
lines denote the simulated mean value of the thrombin profile for N = 20
independent particles, points denote experimental data. The shaded re-
gion denotes the 99% confidence estimate of the mean simulated thrombin
value (uncertainty in the model simulation). (A,B,C,D) prediction results
for (FII,ATIII): (50%,150%), (100%, 100%), (125%, 75%) and (150%, 50%) of
physiological prothrombin and ATIII levels in the absence of the protein
C pathway. The experimental validation data was reproduced from the
study of Butenas et al. [1][2]. All factors and control proteins were at their
physiological concentration unless otherswise denoted. . . . . . . . . . . . 19
2.6 Reduced order coagulation model predictions versus experimental data
with and without FVIII and FIX. The reduced order coagulation model pa-
rameter estimates were tested against data not used during model train-
ing. Simulations of normal thrombin formation with ATIII and the pro-
tein C pathway were compared with thrombin formation in the absence of
fVIII and fIX. Solid lines denote the simulated mean value of the thrombin
profile for N = 20 independent particles, points denote experimental data.
The shaded region denotes the 99% confidence estimate of the mean sim-
ulated thrombin value (uncertainty in the model simulation). (A,B) pre-
diction results for normal thrombin generation and thrombin generation
in hemophilia. All factors and control proteins were at their physiological
concentration unless others noted. The experimental validation data was
reproduced from the study of Allen et al. [3]. . . . . . . . . . . . . . . . . . . 20
xii
2.7 Reduced order coagulation model predictions of rFVIIa administration. A:
Simulations of thrombin formation in the presence of ATIII and the protein
C pathway were conducted for a range of trigger values (1x - 200x nomi-
nal) in the absence of fVIII and fIX. B: Comparison of thrombin generation
for normal versus hemophilia for 10x nominal trigger. Solid lines denote
the simulated mean value of the thrombin profile for N = 20 independent
particles. The peak thrombin time for normal coagulation (t∗) is less than
rFVIIa induced coagulation in hemophilia (t∗∗), while the peak thrombin
value was greater in normal coagulation. The shaded region denotes the
99% confidence estimate of the mean thrombin value (uncertainty in the
model simulation). All factors and control proteins were at their physio-
logical concentration unless others noted. . . . . . . . . . . . . . . . . . . . . 23
2.8 Reaction flux distribution as a function of time for thrombin gen-
eration under normal (left), hemophilia (center) and rFVIIa treated
hemophilia (right). Reaction flux was calculated for each particle at T =
0, 4, 6, 8, 10, 12, 14 min after the initiation of coagulation. Reaction fluxes
were calculated for each particle in the parameter ensemble (N = 20). Blue
colors denote low flux values while red colors denote high flux values. . . . 24
2.9 Global sensitivity analysis of the reduced order coagulation model with
respect to the model parameters. A: Sensitivity analysis of the throm-
bin peak time for different prothrombin levels (150%,100% and 50% of
the physiological value) as a function of activated protein C. B: Sensi-
tivity analysis of the thrombin exposure for different prothrombin levels
(150%,100% and 50% of the physiological value) as a function of activated
protein C. Points denote the mean total sensitivity value, while the area
around each point denotes the uncertainty in the sensitivity value. The
gray dashed line denotes the 45◦ degree diagonal, if sensitivity values are
equal for different conditions they will lie on the diagonal. Sensitivity val-
ues significantly above or below the diagonal indicate differentially impor-
tant model parameters. The radius of the shaded region around each total
sensitivity value was the maximum uncertainty in that value estimated by
the Sobol method. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
3.1 Proof-of-concept cell-free metabolic networks considered in this study.
Substrate S is converted to products P1 and P2 through a series of chem-
ical conversions catalyzed by enzyme(s) E j. The activity of the pathway
enzymes is subject to both positive and negative allosteric regulation. . . . 62
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3.2 Schematic of rule-based allosteric enzyme activity control laws. Tradi-
tional enzyme kinetic expressions, e.g., Michaelis–Menten or multiple sat-
uration kinetics, are multiplied by an enzyme activity control variable
0 ≤ v j ≤ 1. Control variables are functions of many possible regulatory
factors encoded by arbitrary functions of the form 0 ≤ f j (Z) ≤ 1. At each
simulation time step, the v j variables are calculated by evaluating integra-
tion rules such as the max or min of the set of factors f1, . . . influencing the
activity of enzyme E j. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
3.3 Kinetics of simple transformations in the presence of activation and inhi-
bition. A:The conversion of substrate S to product P by enzyme E was
activated by S . For a fixed control gain parameter κcontrol, the reaction
rate approached a step for increasing cooperativity control parameter η.
For activation simulations κcontrol =0.05 and η = {0.01, 0.1, 1, 2, 4, 6, 8, 10}.
B:The conversion of substrate S to product P by enzyme E with inhibitor
I. For a fixed control gain parameter κcontrol, the reaction rate approximated
non-competitive inhibition for increasing cooperativity control parameter
η. For the inhibition simulations κcontrol =1.5 and η = {0.01, 0.1, 1, 2, 4, 6, 8, 10}. 64
3.4 ON/OFF control simulations for Network A and Network B for an ensem-
ble of 100 kinetic parameter sets versus time. For each case, simulations
were conducted using kinetic and initial conditions generated randomly
from a hypothetical true parameter set. The gray area represents ± one
standard deviation surrounding the mean. Control parameters were fixed
during the ensemble calculations. A: End product P1 abundance versus
time for Network A. The abundance of P1 decreased with end product in-
hibition of E1 activity (Control-ON) versus the no inhibition case (Control-
OFF). B: End product P2 abundance versus time for Network B. Inhibition
of branch point E6 by end product P1 decreased P2 abundance (Control-
ON) versus the no inhibition case (Control-OFF). C: End product P1 abun-
dance versus time for Network A. Inhibition of branch point E6 by end
product P1 decreased P1 abundance (Control-ON) versus the no inhibition
case (Control-OFF). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
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3.5 Parameter estimation from synthetic data for the same and mismatched
allosteric control logic using particle swarm optimization (PSO). Synthetic
experimental data was generated from a hypothetical parameter set using
Network A, where substrate S , end product P1 and intermediate M5 were
sampled approximately every 20 minutes. For cases A,B 20 particles were
initialized with randomized parameters and allowed to search for 300 it-
erations. A,B: PSO estimated an ensemble of 20 parameters sets consistent
with the synthetic experimental data assuming the correct enzymatic and
control connectivity starting from randomized initial parameters. C,D:
In the presence of control mismatch (Network B control policy simulated
with Network A kinetic parameters) the ensemble of models did not de-
scribe the synthetic data. The synthetic data plotted here was unperturbed
by noise. However, we assumed a constant coefficient of variation of 10%
for the synthetic data during parameter estimation. . . . . . . . . . . . . . . 66
3.6 Schematic of the alternative allosteric control programs used in the struc-
tural particle swarm computation. Each network had the same enzy-
matic connectivity, initial conditions and kinetic parameters, but alterna-
tive feedback control structures for the first enzyme in the pathway. . . . . 67
3.7 Combined control and kinetic parameter search using modified particle
swarm optimization (PSO). A population of 100 particles was initialized
with randomized kinetic parameters and one of five possible control con-
figurations (Network A - E). Simulation error was minimized for a syn-
thetic data set (S , end product P1 and intermediate M5 sampled approxi-
mately every 20 min) generated using Network A. A: Simulation error ver-
sus parameter set angle for 100 particles biased toward the correct regula-
tory program (A,B,C,D,E) = (40%, 10%, 20%, 20% and 10%). B: Simulation
error versus parameter set angle for 100 uniformly distributed particles
(A,B,C,D,E) = (20%, 20%, 20%, 20% and 20%). C: Simulation error versus
parameter set angle for 100 negatively biased particles (A,B,C,D,E) = (10%,
40%, 10%, 20% and 20%). Network A (the correct structure) was preferen-
tially identified for positively and uniform biased particle distributions,
but misidentified in the presence of a large incorrect bias. . . . . . . . . . . 68
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3.8 Metabolic flux and control variables as a function of network type and
particle index at t = 100 min. The particle error, the control variables
governing E1, E3 and E6 activity (v1, v3 and v3) and the scaled metabolic
flux were calculated for the positively (top), uniformly (middle) and neg-
atively (bottom) biased particle swarms (N = 100). Blue denotes a low
value, while red denotes a high value for the respective quantity being
plotted. The particles from each swarm were sorted based upon simula-
tion error (low to high error). A: Model performance for the positively
biased particle swarm as a function of particle index. B: Model perfor-
mance for the uniformly biased particle swarm as a function of particle
index. C: Model performance for the negatively biased particle swarm
as a function of particle index. Models with significant control mismatch
showed distinct control and flux patterns versus those models with the
correct or closely related control policies. In particular, models with the
correct control policy showed stronger inhibition of E1 activity, leading to
decreased flux from S→P1. Conversely, models with significant mismatch
had increased E1 activity, leading to an altered flux distribution. This is
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CHAPTER 1
INTRODUCTION
Blood is perhaps the most recognized and studied biological component. Yet the com-
plexity encoded in it through millions of years of evolution still poses fascinating ques-
tions. Critical to our understanding of coagulopathy or related disorders are the mecha-
nisms that contribute to hemostasis. There have been a plethora of studies over the last
two and half centuries investigating hemostasis. Over this period the fundamental ques-
tion in hemostasis perhaps has transitioned from how does blood clot to why does blood
clot, when it does. Understanding this question is challenging partly due to the definition
of a normal hemostatic response. Under what circumstances is hemostasis considered
normal? What physiological conditions define it? If a normal hemostatic response is de-
fined, what perturbs this status quo? How do we quantify the variability that arises due
to these perturbations? To answer these questions we need to unravel the dynamics of
a complex biochemical phenomena that is tightly coupled with physiological conditions.
This motivates us to come up with a holistic yet detailed framework that can address
these questions.
Mathematical modeling is at the core in analyzing the emergent behavior of biolog-
ical systems. A wide array of mathematical paradigms have been developed that cap-
ture varying degree of biological complexity (or detail) [6, 7]. The choice of a modeling
paradigm thereby, is dictated by the pertinent biological question, the quality and quan-
tity of available data. On one end of the spectrum lie ordinary differential equation (ODE)
based models. These models require detailed mechanistic information and can capture
complex dynamics. At other end are a number of qualitative approaches that do not rely
on detailed mechanistic information but more on network topology. Examples of such
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approaches include graph models, Petri nets, constraint-based modeling and logic mod-
els like ones based on Boolean logic [7]. Such qualitative approaches can handle large
network structures more easily than ODE based models. However such models are gen-
erally inadequate in modeling detailed system dynamics.
Given such constraints, modeling hemostatic response during trauma induced coagu-
lopathy (TIC) poses an interesting challenge. The process of coagulation which is central
to hemostasis is an intricate physiochemical phenomena [8, 9]. The kinetics of coagula-
tion have been well studied under in vitro conditions. However in a coagulopathic state,
abnormal physiological conditions and additional biochemical interactions alter the dy-
namics of coagulation [10, 11]. These interconnected physiological and biochemical phe-
nomena operate on various scales of time and size. To capture the dynamics of these in-
terconnected phenomena, we require an integrated modeling framework that is detailed
and can also account for incomplete or missing data. However to describe such integrated
frameworks we rely on a large number of parameters and details of interacting species.
Due to incomplete information and computational constraints this is always not feasible.
Thus we need a paradigm that can reduce our dependency on parametric detail within
integrated modeling frameworks.
As a step towards this end, in this thesis, a reduced order modeling approach is de-
scribed that is able to model the dynamics of complex biochemical networks in sufficient
detail with fewer parameters. Traditional ODE models rely on saturated enzyme kinetics
like Michaelis-Menten kinetics in describing the network. In the reductionist approach,
using transfer function based logical rules helps encompass complex logic with few equa-
tions. The choice of species and their number is dictated by the pertinent question. For
example, a number of studies have shown the importance of protein C pathway in TIC.
Thus when we describe our reduced order model of coagulation we investigated the im-
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pact of protein C pathway on the overall coagulation dynamics. In a similar vein alternate
reduced order models of coagulation may be constructed based on the relevant question.
1.1 An outline of the thesis
The first paper in this thesis (chapter 2) describes an approach to build a reduced order
model of coagulation. The production of thrombin, a key protein in coagulation and fib-
rinolysis is tightly regulated through a number of positive and negative feed back loops.
To model thrombin generation, we survey the literature for existing mathematical frame-
works for biochemical networks. Through this survey we realize the need for a new
framework that reduces number of parameters yet one that captures overall dynamics of
the network. We describe a novel reduced modeling approach and capture thrombin dy-
namics with five equations and 23 parameters. This is an order of magnitude lesser than
previous approaches that required hundreds of parameters. In this study we focus on the
regulatory effects of protein C, a key component in coagulopathy and train our model on
in vitro experimental data with and without protein C. To test the predictive power of the
model we use hitherto unseen experimental data for thrombin generation. Remarkably
the model predicts thrombin generation with different initial conditions. The model also
provides insights into regulatory aspects of protein C and identifies mechanisms that are
critical to the formation of a stable clot.
In the next chapter (chapter 3) we use the same framework for metabolic modeling.
Through the use of logical rules and traditional kinetic modeling we model complex al-
losteric patterns. In chapter 4 we model complement, a key network in immune response.
C3a, C3b, C5a and C5b are important complement proteins that control both innate and
adaptive immune response. These proteins also interact with coagulation, fibrinolysis
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and other biological networks [12–15]. C5a, in particular, is a critical protein regulating
sepsis that results from TIC. Complement initiation occurs through three pathways that
involves formation of complex protein structures [16]. We use logical rules to reduce pa-
rameters involved in complement initiation and thereby capture the the dynamics of C3a
and C5a formation initiated through the lectin and alternate pathways. In chapter 5 we
model fibrinolysis using the same framework. Fibrinolysis follows coagulation wherein
the clot formed at the end of coagulation is broken down [17, 18]. The thrombin produced
during coagulation catalyzes the formation of a cross linked polymer called fibrin. During
fibrinolysis an enzyme called plasmin is activated which cleaves fibrin to fibrin degrada-
tion products. Fibrin along with platelets makes up a clot and is the key component in
determining the stability and strength of a clot. In a clinical setting, fibrin formation and
degradation are measured indirectly by measuring viscoelasticity of blood, thereby deter-
mining clot strength. The most common and widely used viscoelastic measure is called
Rotational Thromboelastometry (ROTEM) [19, 20]. In this study we used ROTEM data
from various patients to train our fibrinolysis models. Thereafter we predicted ROTEM
dynamics among patients whose data was not used for training. We surprisingly did well
and were also able to isolate key mechanisms involved in fibrinolysis. We finally present
a fast optimizer for estimating parameters in large biochemical networks. This technique
combines Dynamically Dimensioned Search (DDS) [21] and Particle Swarm Optimization
(PSO) [22]. On a model of coagulation with 326 parameters and 5 benchmark problems
that include commonly used test function for global optimization and 3 large biochemical
networks we outperform all the commonly known metaheuristics. Using this method it
is possible to generate near optimal solutions for integrated modeling frameworks with a
few expensive objective function evaluations. Taken together these reduced order mod-
els provide a building block in the construction of an integrated modeling framework for
coagulopathy.
4
CHAPTER 2
DYNAMIC MODELING OF THE HUMAN COAGULATION CASCADE USING
REDUCED ORDER EFFECTIVE KINETIC MODELS
Abstract
In this study 1, we present a novel modeling approach which combines ordinary differen-
tial equation (ODE) modeling with logical rules to simulate an archetype biochemical net-
work, the human coagulation cascade. The model consisted of five differential equations
augmented with several logical rules describing regulatory connections between model
components, and unmodeled interactions in the network. This formulation was more
than an order of magnitude smaller than current coagulation models, because many of
the mechanistic details of coagulation were encoded as logical rules. We estimated an en-
semble of likely model parameters (N = 20) from in vitro extrinsic coagulation data sets,
with and without inhibitors, by minimizing the residual between model simulations and
experimental measurements using particle swarm optimization (PSO). Each parameter
set in our ensemble corresponded to a unique particle in the PSO. We then validated the
model ensemble using thrombin data sets that were not used during training. The ensem-
ble predicted thrombin trajectories for conditions not used for model training, including
thrombin generation for normal and hemophilic coagulation in the presence of platelets
(a significant unmodeled component). We then used flux analysis to understand how
the network operated in a variety of conditions, and global sensitivity analysis to iden-
tify which parameters controlled the performance of the network. Taken together, the
hybrid approach produced a surprisingly predictive model given its small size, suggest-
1Adapted with permission from Sagar A and Varner JD, “Dynamic Modeling of the Human Coagulation
Cascade Using Reduced Order Effective Kinetic Models” (2015) Processes, 3:178–203
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ing the proposed framework could also be used to dynamically model other biochemical
networks, including intracellular metabolic networks, gene expression programs or po-
tentially even cell free metabolic systems.
2.1 Introduction
Developing mathematical models of biochemical networks is a significant facet of sys-
tems biology. Modeling approaches differ in their degree of detail, where the choice of
approach is often determined by prior knowledge, or model requirements [6]. Ordinary
differential equation (ODE) models are common tools for modeling biochemical systems
because of their ability to capture dynamics and encode mechanism. However, ODE
models typically come with difficult (or sometimes impossible) parameter identification
problems. For example, Gadkar et al., showed that even with near-perfect information, it
was often impossible to identify all the parameters in typical signal transduction models
[23]. However, it is not clear whether we actually need precise estimates for all model
parameters. Bailey suggested more than a decade ago, that achieving qualitative or even
quantitative understanding of biological systems should not require complete structural
and parametric knowledge [24]. Since Bailey’s complex biology with no parameters hy-
pothesis, Sethna showed that model performance is typically sensitive to only a few pa-
rameters, a characteristic seemingly universal to multi-parameter models referred to as
sloppiness [25]. Thus, reasonable predictions may be possible, despite parametric uncer-
tainty, if a few critical parameters are well-defined. For example, Tasseff et al., showed
in a model of Retinoic acid (RA) induced differentiation of HL-60 cells, that correct pre-
dictions were possible even when 75% of the parameters were known only to an order
of magnitude [26]. Perhaps more importantly, ODE models require significant mecha-
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nistic information, thereby limiting their utility in poorly understood systems, or con-
versely explode in size when considering multiple pathways or subsystems. Toward this
challenge, logical modeling is an emerging paradigm that encodes causal relationships
between model components using quasi-mechanistic non-linear transfer functions [27].
Logical models are highly flexible, and despite their simplicity, they have captured rich
behaviors in a variety of systems important to human health [28–30]. However, model-
ing complex dynamics with logical models is challenging. Thus, there is an unmet need
for a third approach which combines ODEs and logical models, where ODEs could en-
code mechanistic information, while missing or incomplete mechanistic knowledge can
be approximated using a logical approach.
In this study, we developed a hybrid approach which combined ODE modeling with
logical rules to model a well studied biochemical network, the human coagulation sys-
tem. Coagulation is an archetype proteolytic cascade involving both positive and nega-
tive feedback [31–33]. Coagulation is mediated by a family proteases in the circulation,
called factors and a key group of blood cells, called platelets. The central process in coag-
ulation is the conversion of prothrombin (fII), an inactive coagulation factor, to the master
protease thrombin (FIIa). Thrombin generation involves three phases, initiation, amplifi-
cation and termination [34, 35]. Initiation requires a trigger event, for example vessel in-
jury, which leads to the activation of factor VII (FVIIa). Two converging pathways, the ex-
trinsic and intrinsic cascades, then process and amplify this initial coagulation signal. The
extrinsic cascade is generally believed to be the main mechanism of thrombinogenesis in
the blood [36–38]. Initially, thrombin is produced upon cleavage of prothrombin by fluid
phase activated factor X (FXa), which itself has been activated by Tissue Factor/factor VII
(TF/FVIIa) [31]. Picomolar amounts of thrombin then activate the cofactors factors V and
VIII (fV and fVIII) and platelets, leading to the formation of the tenase and prothrom-
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binase complexes on activated platelets. These complexes amplify the early coagulation
signal by further activating FXa, and directly converting prothrombin to thrombin. There
are several control points in the cascade that inhibit thrombin formation, and eventually
terminate thrombin generation. Tissue Factor Pathway Inhibitor (TFPI) inhibits FXa for-
mation catalyzed by TF/FVIIa, while antithrombin III (ATIII) neutralizes several of the
proteases generated during coagulation, including thrombin. Thrombin itself also inad-
vertently plays a role in its own inhibition; thrombin, through interaction with throm-
bomodulin, protein C and endothelial cell protein C receptor (EPCR), converts protein
C to activated protein C (APC) which attenuates the coagulation response by proteolytic
cleavage of fV/FVa and fVIII/FVIIIa. Termination occurs after either prothrombin is con-
sumed, or thrombin formation is neutralized by inhibitors such as APC or ATIII.
Previous coagulation models have typically been formulated as systems of nonlinear
ordinary differential equations, using mass action or more complex kinetics, to describe
the rates of biochemical conversions [39–43]. Mechanistic ODE coagulation models from
our laboratory [44, 45] were built upon the earlier studies of Jones and Mann [46], Hockin
et al. [47], and later Butenas et al., [48] who developed and then subsequently refined
highly mechanistic coagulation models. Recently Papadopoulos and co-workers used
a phenomenological mathematical model for thrombin generation [49]. Using a set of
four ordinary differential equations they were able to derive an equation for temporal
evolution of thrombin generation. However the model has a greater focus on thrombin
generation and lesser emphasis on the influence of various regulatory elements on the
dynamics of coagulation. Unlike our hybrid approach it does not model regulatory detail
and thus may be unable to capture the roles of primary inhibitors like ATIII or protein C.
Thus in cases where we need to understand the dynamics of coagulation without complex
modeling or when there is incomplete mechanistic knowledge, the hybrid approach is a
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better candidate. The model also requires that the parameters are adjusted or fine tuned
for each data set unlike the hybrid approach where we use a single ensemble across all
experiments. However platelet modeling is a significant advantage of this model over
the hybrid approach. Future versions of the hybrid model can involve modeling platelets
as done by Papdopoulos et al., in their phenomenological model. Other laboratories have
also expanded upon Hockin et al., for example by exploring the intrinsic pathway, the
role of stochastic fluctuations in coagulation [50], and the dynamics of thrombin mediated
clot formation [51]. Other aspects of coagulation have also been modeled, such as platelet
biochemistry [52], multi-scale models of clot formation [53, 54], and transport inside clots
[55]. However, these previous studies were largely based upon extensive mechanistic
knowledge. This is possible because blood, while enormously complex, can be system-
atically interrogated. Other systems, such as intracellular signaling networks, are much
more difficult to experimentally interrogate. Towards this unmet need, we formulated a
hybrid modeling approach which combines ODEs and logical rules to model biochemical
processes for which a complete mechanistic understanding is missing. We tested this ap-
proach by modeling the human coagulation cascade. The hybrid model consisted of only
five differential equations augmented with several logical rules. Thus, the model was
more than an order of magnitude smaller than comparable purely ODE models in the lit-
erature. We estimated the model parameters from in vitro extrinsic coagulation data sets,
in the presence of ATIII, with and without the protein C pathway. We then compared the
model predictions with thrombin data sets, for both normal and hemophilic coagulation,
that were not used for model training. Once validated, we performed flux and sensitivity
analysis on the model to estimate which parameters were critical to model performance
in several conditions. The reduced order hybrid approach produced a surprisingly pre-
dictive coagulation model, suggesting this framework could potentially be used to model
other biochemical networks important to human health.
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2.2 Results
2.2.1 Formulation of Reduced Order Coagulation Models
We developed a reduced order extrinsic coagulation model to test our hybrid modeling
approach (Fig. 2.1). The core of our model was based upon the earlier work of Ismag-
ilov and coworkers [56–59], where we added initiation, factor dependence, and specific
inhibition terms to the earlier simplified model. A trigger event initiates thrombin for-
mation (FIIa) from prothrombin (fII) through a lumped initiation step. This step loosely
represents the initial activation of thrombin by activated FXa. Once activated, throm-
bin catalyzes its own formation (amplification step), and inhibition via the conversion of
protein C to activated protein C (APC). Antithrombin III (ATIII) inhibits amplification,
while APC and tissue factor pathway inhibitor (TFPI) potentially inhibit both initiation
and amplification. All initiation and inhibition processes, as well as the dependence of
amplification upon other coagulation factors, was approximated using our rule-based ap-
proach (Fig. 3.2). Individual regulatory contributions to the activity of pathway enzymes
were integrated into control coefficients (v’s) using an integration rule (min/max). These
control coefficients then modified the rates of model processes at each time step. Hill-
like transfer functions 0 ≤ f (Z) ≤ 1 quantified the contribution of components upon a
target process. Components were either individual inhibitor or activator levels or some
function of levels, e.g., the product of factor levels. In this study, Z corresponded to the
abundance of individual inhibitors or activators, with the exception of the dependence of
amplification upon specific coagulation factors (modeled as the product of factors). When
a process was potentially sensitive to multiple inputs, logical integration rules were used
to select which transfer functions influenced the process at any given time. In our proof
10
of concept model, we used a winner takes all strategy; the maximum or minimum trans-
fer function was selected at any given time step. However, other integration rules are
certainly possible. Taken together, while the reduced order coagulation model encodes
significant biological complexity, it is highly compact (consisting of only five differential
equations). Thus, it will serve as an excellent proof of principle example to study the
reduction of a highly complex human subsystem.
2.2.2 Identification of Model Parameters Using Particle Swarm Opti-
mization
A critical challenge for any dynamic model is the estimation of kinetic parameters. We es-
timated kinetic and control parameters simultaneously from eight in vitro time-series co-
agulation data sets with and without the protein C pathway. The residual between model
simulations and experimental measurements was minimized using particle swarm opti-
mization (PSO). A population of particles (N = 20) was initialized with randomized ki-
netic and control parameters and allowed to search for parameter vectors that minimized
the residual. However, not all parameters were varied simultaneously. We partitioned the
parameter estimation problem into two subproblems based upon the biological organiza-
tion of the training data; (i) estimation of parameters associated with thrombin formation
in the absence of the protein C pathway and (ii) estimation of parameters associated with
the protein C pathway. Only those parameters associated with each subproblem were
varied during the optimization procedure for that subproblem, e.g., thrombin parame-
ters were not varied during the protein C subproblem.The PSO procedure was run for 20
generations for each subproblem, where each generation was 1200 iterations. The best
particle from each generation was used to generate the particle population for the next
11
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Figure 2.1: Schematic of the connectivity of the reduced order coagulation
model. A trigger compound, e.g., TF/FVIIa initiates throm-
bin production (FIIa) from prothrombin (fII). Once activated,
thrombin catalyzes its own activation (amplification step), as
well as its own inhibition via the conversion of protein C to
activated protein C (APC). APC and tissue factor pathway in-
hibitor (TFPI) inhibit initiation and amplification, while an-
tithrombin III (ATIII) directly inhibits thrombin. All inhibition
steps and trigger-induced initiation were modeled using a rule-
based approach. Likewise, the dependence of amplification on
other coagulation factors was also modeled using a rule-based
approach. The abundance of the highlighted species (in the
dashed boxes) was governed by an ordinary differential equa-
tion. All other species were assumed to be constant.
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generation. We rotated the subproblems, starting with subproblem 1 in the first genera-
tion.
The experimental training data for parameter estimation was reproduced from the
experiments of Butenas and co-workers [1]. In these experiments thrombin generation
was initiated by FVIIa-TF using mean plasma concentrations of coagulation proteins and
inhibitors. To prepare FVIIa-TF, TF (0.5 nmol/L) was relipidated into 400 µmol/L of phos-
pholipid vesicles (PCPS) by incubation in 20 mmol/L HEPES, 150 mmol/L NaCl, and 2
mmol/L CaCl2 pH 7.4 (HBS/Ca2+) for 30 minutes at 37 ◦C. The relipidated TF was in-
cubated with 10 pmol/L factor VIIa for 20 minutes to allow the formation of FVIIa-TF.
Factors V, VIII and thrombomodulin (Tm) (when protein C activation is required) were
added to FVIIa-TF complex. Thrombin generation was then initiated by adding equal
volumes of this mixture with a mixture containing prothrombin, factor IX and factor X,
TFPI, AT-III and protein C (added when required), protein S (added when required) and
factor XI (added when required). In the experimental training data sets that we used
for parameter estimation 5 pmol/L FVIIa-TF was used along with 200 µmol/L of phos-
pholipid vesicles (PCPS) to initiate thrombin generation. When protein C pathway was
involved, protein C and protein S were at mean plasma concentrations and 0.1 nmol/L
Tm was used. All the other coagulation proteins and inhibitors i.e. factors X, IX, V, and
VIII, prothrombin, TFPI and AT-III were at their mean plasma concentration levels.
The reduced order coagulation model captured the role of initial prothrombin abun-
dance, and the decay of the thrombin signal following from ATIII activity (Fig. 2.3). How-
ever, we systematically under-predicted the thrombin peak and the strength of ATIII in-
hibition in this training data set. On the other hand, with fixed thrombin parameters,
we captured peak thrombin values and the decay of the thrombin signal (at least for the
150% fII case) in the presence of both ATIII and the protein C pathway (Fig. 2.4). Lastly,
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we were unable to capture global differences in initiation time across separate data sets
with a single ensemble of model parameters. These differences likely resulted from nor-
mal experimental variability. For example, different thrombin generation experiments
within the training data (at the same physiological factor levels) had significantly differ-
ent initiation times (data not shown). However, the inability to globally capture initiation
time also highlighted a potential shortcoming of the initiation module within the model.
To capture the variability in initiation time across training data sets, we included a con-
stant time-delay parameter (TD) for each data group. The delay parameter was constant
within a data set, but allowed to vary across training data sets. Introduction of the delay
parameter allowed the model to simulate multiple training data sets using a single en-
semble of model parameters. Taken together, the model identification results suggested
that our hybrid approach could reproduce a panel of thrombin generation data sets in
the neighborhood of physiological factor and inhibitor concentrations. However, it was
unclear whether the reduced order model could predict new data, without updating the
model parameters.
2.2.3 Validation of the Reduced Order Coagulation Model
We tested the predictive power of the reduced order coagulation model with validation
data sets not used during model training. Two validation data sets were used, thrombin
generation for various prothrombin and ATIII concentrations with the protein C path-
way, and thrombin generation in normal versus hemophilic plasma in the presence of the
protein C pathway. Lastly, we compared the qualitative output of the model to rFVIIa ad-
dition in the presence of hemophilia. The hemophilia case was an especially difficult test
as it was taken from a different study which used a plasma-based in vitro assay involving
15
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Figure 2.3: Reduced order coagulation model training simulations. Re-
duced order coagulation model parameters were estimated us-
ing particle swarm optimization (PSO) without the protein C
pathway as a function of prothrombin. Solid lines denote the
simulated mean value of the thrombin profile for N = 20 in-
dependent particles, points denote experimental data. The
shaded region denotes the 99% confidence estimate of the
mean simulated thrombin value (uncertainty in the model sim-
ulation). (A,B,C) depict training data and results for 150%,
100% and 50% of physiological prothrombin levels in the ab-
sence of protein C pathway. The experimental training data
was reproduced from the study of Butenas et al. [1][2]. All
factors and control proteins in these experiments were at their
physiological concentration unless otherwise denoted.
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Figure 2.4: Reduced order coagulation model training simulations. Re-
duced order coagulation model parameters were estimated us-
ing particle swarm optimization (PSO) with the protein C path-
way as a function of prothrombin. Only APC pathway param-
eters were allowed to vary in these simulations keeping the
parameters estimated without protein C pathways constant.
Solid lines denote the simulated mean value of the thrombin
profile for N = 20 independent particles, points denote exper-
imental data. The shaded region denotes the 99% confidence
estimate of the mean simulated thrombin value (uncertainty in
the model simulation). (A,B,C) depict training data and results
for 150%, 100% and 50% of physiological prothrombin levels in
the presence of the protein C pathway. The experimental train-
ing data was reproduced from the study of Butenas et al. [1][2].
All factors and control proteins in these experiments were at
their physiological concentration unless otherwise denoted.
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platelets instead of phospholipid vesicles (PCPS). All kinetic and control parameters were
fixed for the validation simulations. The only globally adjustable parameter TD, was fixed
within each validation data set but allowed to vary between data sets. The reduced or-
der model predicted the thrombin generation profile for ratios of prothrombin and ATIII
in the absence of the protein C pathway (Fig. 2.5). Simulations near the physiological
range (fII,ATIII) = (100%, 100%) or (125%,75%) tracked the measured thrombin values
(Fig. 2.5B and C). On the other hand, predictions for factor levels outside of the physio-
logical range (fII,ATIII) = (50%, 150%) or (150%, 50%), while qualitatively consistent with
measured thrombin values, did show significant deviation from the measurements (Fig.
2.5A and D). Likewise, simulations of thrombin generation in normal versus hemophilia
(missing both fVIII and fIX) were consistent with measured thrombin values (Fig. 2.6).
We modeled the dependence of thrombin amplification on factor levels using a product
rule (Z = f V × f X × f VIII × f IX), which was then was integrated using a min integration
rule into the control variable governing amplification. Thus, in the absence of fVIII or
fIX, the amplification control variable evaluated to zero, and the only thrombin produced
was from initiation (Fig. 2.6B). However, the decay of the thrombin signal was under-
predicted in the normal case (Fig. 2.6A), while the activated thrombin level was overpre-
dicted in hemophilia simulations, although thrombin generation was far less than normal
(Fig. 2.6B). Taken together, the reduced order model performed well in the physiologi-
cal range of factors, even with unmodeled components such as platelet activation in the
hemophilia data set.
The model ensemble predicted a direct correlation between thrombin generation and
rFVIIa addition in hemophilia (Fig. 2.7). In the current model, we cannot distinguish
between different initiation sources, e.g., TF/FVIIa versus rFVIIa, as we have only a
single lumped initiation source (trigger). Thus, we simulated the addition of rFVIIa in
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Figure 2.5: Reduced order coagulation model predictions versus experi-
mental data for normal coagulation. The reduced order co-
agulation model parameter estimates were tested against data
not used during model training. Simulations of different lev-
els of prothrombin and ATIII were compared with experi-
mental data in the absence of the protein C pathway. Solid
lines denote the simulated mean value of the thrombin pro-
file for N = 20 independent particles, points denote experimen-
tal data. The shaded region denotes the 99% confidence esti-
mate of the mean simulated thrombin value (uncertainty in the
model simulation). (A,B,C,D) prediction results for (FII,ATIII):
(50%,150%), (100%, 100%), (125%, 75%) and (150%, 50%) of
physiological prothrombin and ATIII levels in the absence of
the protein C pathway. The experimental validation data was
reproduced from the study of Butenas et al. [1][2]. All factors
and control proteins were at their physiological concentration
unless otherswise denoted.
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iological concentration unless others noted. The experimental
validation data was reproduced from the study of Allen et al.
[3].
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hemophilia by removing fVIII and fIX from the model, and modulating the initial level
of trigger. Simulations with a baseline level of trigger were consistent with the pre-
vious hemophilia simulations, where the only thrombin produced was from initiation
(Fig. 2.7A, 1× trigger). However, as we increased the trigger strength, the thrombin pro-
file began to approximate normal coagulation, showing a pronounced peak albeit with
a slower peak time (Fig. 2.7B, t∗∗ > t∗). Further increases in trigger strength resulted
in decreased thrombin peak time and increased maximum thrombin values (Fig. 2.7A,
50× trigger). Thus, for large trigger values (200×trigger), the hemophilic thrombin profile
approximated normal coagulation, where peak thrombin was achieved shortly after ad-
ministration and 95% of the thrombin was gone by 20 min after initiation. We performed
flux analysis to understand how the reduced order coagulation model balanced initia-
tion, amplification and termination of thrombin generation for normal and hemophilic
coagulation. Analysis of the reaction flux through the reduced order network for throm-
bin generation in normal, hemophilia and rFVIIa-treated hemophilia identified three dis-
tinct operational modes (Fig. 2.8). We calculated the flux through four lumped reactions,
initiation, amplification, thrombin-induced APC generation and total thrombin inhibi-
tion (including both APC and ATIII action). Directly after the addition of a trigger (e.g.,
TF/FVIIa or rFVIIa), the lumped initiation flux was the largest for all three cases. How-
ever, within a few minutes enough thrombin was generated by the initiation mechanism
to induce the amplification stage. During amplification, thrombin catalyzes its own for-
mation and inhibition by generating activated protein C (APC), a potent inhibitor of the
coagulation cascade. For normal coagulation, amplification and thrombin inhibition were
the dominate reactions by 6 min after initiation (Fig. 2.8, left). After 10 min, the dominate
reaction had shifted to thrombin inhibition (both ATIII and APC action). In hemophilia
(missing both fVIII and fIX), the amplification reaction did not occur, and thrombin was
produced only by initiation (Fig. 2.8, center). Initiation was quickly inhibited by APC,
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and the thrombin level stabilized (eventually decaying at longer times because of ATIII
activity). Lastly, when 50×trigger was used to induce thrombin formation in hemophilia
(absence of fVIII/fIX), initiation mechanisms dominated for up to 6 min following ini-
tiation (Fig. 2.8, right). Similar to hemophilia alone, no amplification occurred in the
50×trigger+hemophilia case, and the rate of thrombin generation was extinguished by
the combined action of ATIII and APC. Taken together, the hybrid modeling approach
captured the transition between the modes of thrombin generation, as well as the role that
inhibitors play in attenuating the thrombin generation rate. Thus, the transfer function
approach encoded the inhibitory logic of this cascade in the absence of specific mecha-
nism.
2.2.4 Global Sensitivity Analysis of the Reduced Order Coagulation
Model
We conducted a global sensitivity analysis to estimate which parameters controlled the
performance of the reduced order model. We calculated the sensitivity of the time to
maximum thrombin (peak time) and the thrombin exposure (area under the thrombin
curve) for different levels of prothrombin, and protein C (Fig. 2.9). Globally, 41% of
the parameters shifted in importance between the (fII,PC) = (50%, 0%) and (150%,100%)
cases for the peak thrombin time (Fig. 2.9A). The majority of these shifts involved the
interaction between increased prothrombin and the protein C pathway, while only 5%
were directly associated with increased prothrombin alone. The rate constant for throm-
bin amplification was the most important parameter controlling the peak thrombin time.
While this parameter was differentially important for different prothrombin levels, and in
the presence or absence of the activated protein C pathway, it was consistently the most
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Figure 2.7: Reduced order coagulation model predictions of rFVIIa admin-
istration. A: Simulations of thrombin formation in the presence
of ATIII and the protein C pathway were conducted for a range
of trigger values (1x - 200x nominal) in the absence of fVIII and
fIX. B: Comparison of thrombin generation for normal versus
hemophilia for 10x nominal trigger. Solid lines denote the sim-
ulated mean value of the thrombin profile for N = 20 indepen-
dent particles. The peak thrombin time for normal coagulation
(t∗) is less than rFVIIa induced coagulation in hemophilia (t∗∗),
while the peak thrombin value was greater in normal coagula-
tion. The shaded region denotes the 99% confidence estimate
of the mean thrombin value (uncertainty in the model simula-
tion). All factors and control proteins were at their physiologi-
cal concentration unless others noted.
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Figure 2.8: Reaction flux distribution as a function of time for thrombin
generation under normal (left), hemophilia (center) and rFVIIa
treated hemophilia (right). Reaction flux was calculated for
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sensitive parameter in the model. The saturation constant governing thrombin amplifi-
cation was the second most important parameter, followed by the initiation control gain
parameter. Other important parameters influencing the thrombin peak time included the
control gain for activated protein C formation, and the rate constant controlling ATIII
inhibition of thrombin activity. On the other hand, only 27% of the model parameters
were differentially sensitive between the (fII,PC) = (50%, 0%) and (150%,100%) cases for
thrombin exposure (Fig. 2.9B). Of these parameters, all of the shifts were associated with
the interplay between thrombin formation and the protein C pathway. The rate constant
controlling ATIII inhibition was the most important parameter controlling the thrombin
exposure. While this parameter was less important in the presence of protein C for 150%
prothrombin levels, it was significantly above all other parameters. Similar to the peak
time, for 150% prothrombin, the control gain for activated protein C formation was dif-
ferentially important along with the rate constant controlling amplification. However,
the amplification parameter was much less important for thrombin exposure versus peak
time.
2.3 Discussion
In this study, we developed a reduced order model of the human coagulation cascade. We
modeled coagulation because it is well studied, has a complex architecture, and has an
abundance of experimental data available for model identification and validation. How-
ever, coagulation was just a proof of concept test of our approach. The proposed hybrid
framework could also be used to dynamically model other biochemical networks, includ-
ing intracellular metabolic networks, gene expression programs or potentially even cell
free metabolic systems. The model consisted of five differential equations augmented
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Figure 2.9: Global sensitivity analysis of the reduced order coagulation
model with respect to the model parameters. A: Sensitivity
analysis of the thrombin peak time for different prothrom-
bin levels (150%,100% and 50% of the physiological value)
as a function of activated protein C. B: Sensitivity analysis
of the thrombin exposure for different prothrombin levels
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ity value, while the area around each point denotes the uncer-
tainty in the sensitivity value. The gray dashed line denotes the
45◦ degree diagonal, if sensitivity values are equal for different
conditions they will lie on the diagonal. Sensitivity values sig-
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important model parameters. The radius of the shaded region
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with several logical rules describing regulatory connections between model components
and unmodeled interactions in the network. We estimated model parameters from in
vitro extrinsic coagulation data sets, in the presence of ATIII, with and without the pro-
tein C pathway. To estimate parameters, the residual between model simulations and
experimental measurements was minimized using particle swarm optimization (PSO).
However, not all of the model parameters were uniquely identifiable, given the training
data. Instead, we estimated an ensemble of likely parameter sets (N = 20) from eight in
vitro time-series coagulation data sets with and without the protein C pathway. Ensemble
approaches have been used previously for other signal transduction models [60–64], and
for metabolic models [65] to estimate the impact of poorly constrained parameter values
or poorly understood network structure on simulation performance. Thus, ensemble ap-
proaches are common in the dynamic modeling community. However, a unique feature
of the current study is the direct connection between our particle swarm approach, and
the parameter ensemble; each particle in our swarm uniquely corresponded to a parame-
ter set in our ensemble. Thus, by constraining particles to operate in different parameter
regions, giving each particle a different parameter combination to explore, or perhaps
even suppling a different model formulation to each particle we can effectively traverse
through complex parameter and model spaces. We validated the ensemble using throm-
bin data sets taken from multiple laboratories for a variety of experimental conditions
not used during training. The ensemble predicted thrombin trajectories for conditions
not used for model training, including thrombin generation for normal and hemophilic
coagulation in the presence of platelets (a significant unmodeled component). We then
used flux analysis to understand how the network operated in a variety of conditions,
and global sensitivity analysis to identify which parameters controlled the performance
of the network. Flux analysis showed the logical rules formulation encoded the transi-
tions between initiation, amplification and termination of thrombin generation. Sensi-
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tivity analysis suggested that the amplification rate constant was more important to the
time to peak thrombin, while the ATIII inhibition constant controlled thrombin expo-
sure. Taken together, the proposed hybrid framework produced a surprisingly predictive
model, suggesting this approach could be used to effectively model other biochemical
networks important to human health.
Malfunctions in coagulation can have potentially fatal consequences. Aggressive clot-
ting involved with Coronary Artery Diseases (CADs), collectively accounts for 38% of all
deaths in North America [66]. Coagulation management during surgery can also be chal-
lenging, particularly with the increase in clinical use of antithrombotic drugs [67]. Insuffi-
cient coagulation due to genetic disorders such as hemophilia can also result in recurrent
bleeding. The coagulation factors VIII (fVIII) and IX (fIX) are deficient in Hemophilia
A and B, respectively [68–70]. People with mild hemophilia have 5-40% of the normal
clotting factor levels while severe hemophiliacs have <1% [70]. Hemophilia can be con-
trolled with regular infusions of the deficient clotting factors. However, clotting factor
replacement sometimes leads to the formation of fVIII and fIX inhibitors in vivo [71]. Al-
ternatively, recombinant factor VIIa (rFVIIa) has been used to treat bleeding disorders
[72, 73] including hemophilia with and without factor VIII/IX inhibitors [74]. However,
rFVIIa requires frequent administration (every 2-3 hr), and many questions remain about
its mechanism of action, its effective dosage [71], and its overall utility for the treatment
trauma-associated hemorrhage [75]. In this study, we did not model rFVIIa-induced co-
agulation directly. Rather, we modeled a general trigger which initiated the extrinsic co-
agulation cascade. Since we identified the model using TF/FVIIa, inherent to our rFVIIa
simulations (and the rate constant governing initiation) was the presence of TF. How-
ever, even with this complication, the model generated potentially useful insight into the
rFVIIa mechanism of action, and its possible shortcomings especially for the treatment
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of hemophilia. The addition of rFVIIa directly activated thrombin through the initiation
pathway. However, no amplification of the thrombin signal occurred without fVIII or fIX.
Thus, the peak thrombin signal was lower than normal coagulation, the peak thrombin
time was longer, and thrombin generation was eventually inhibited by the combined ac-
tion of ATIII and the protein C pathway. However, as the dose of rFVIIa increased, the
peak thrombin time decreased (eventually saturating around 200×nominal trigger), and
the peak thrombin value increased such that the thrombin profile resembled normal coag-
ulation. Butenas et al. performed an extensive in vitro study of rFVIIa-induced thrombin
generation under normal and hemophilic conditions [76]. They found qualitatively sim-
ilar trends, namely rFVIIa restored normal coagulation (even in the absence of TF) for
large enough rFVIIa doses, although rFVIIa-induced coagulation in hemophilia (even for
large rFVIIa doses) lagged the normal profile. These results suggest that rFVIIa adminis-
tration alone might not be able to initiate normal coagulation in recurrent bleeding, unless
the dosage is well above a critical threshold. However, defining this threshold, which is
likely patient specific, is difficult as there is tremendous patient to patient variability even
with a normal co agulation phenotype [77].
A number of mathematical models and computational simulations concerning coag-
ulation dynamics have been based on the Hockin-Mann model of coagulation. Recently,
Brummel-Ziedins and co-workers built a model that incorporated the Protein C (PC)
pathway into the Hockin-Mann network to investigate thrombin generation in cases of
familial PC deficiency [78]. Computational simulations using this model showed that
PC mutation caused an elevation in peak thrombin levels without changing the initiation
time or the slope of thrombin generation curve. Our hybrid model to a certain extent
captured this trend qualitatively. We were able to show the decrease in peak thrombin
concentration in the presence of PC pathway without any other inhibitors like ATIII.
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Danforth et al. computationally simulated normal thrombin generation using 5pM tis-
sue factor with all other factors at their mean physiological level [77]. The initiation time
in this simulation was approximately 4.4 minutes. When predicting the normal thrombin
generation curve using 0.2 nM of FVIIa we were able to show an approximate initiation
time around 5 minutes with a similar thrombin generation profile (Fig. 2.6A). In a ki-
netic modeling to study the effect of rfVIIa on thrombin generation [79] it was shown that
increasing amounts of FVIIa accelerated the initiation phase and the propagation phase
during thrombin generation. Analysis of thrombin generation curves showed that the
FVIIa controlled the maximal slope of thrombin curve along with peak thrombin time
and initiation time. Though we had issues in capturing the effect of FVIIa on initiation
time we were able to show that change in concentration of FVIIa affected the maximal
thrombin slope as well as propagation phase (Fig. 2.7A).
The performance of the proof of principle coagulation model was impressive given
its limited size. The most detailed mechanistic model of coagulation is the one by Luan
and co-workers built with 193 proteins and protein complexes that are interconnected by
301 reactions [45]. Akin to the hybrid model this model used normal thrombin data and
hemophilia data from Allen et al. [3]. However unlike the mechanistic model we used
this data for validation rather than training. Results from our model are surprisingly
comparable to the training simulations of the mechanistic model. The initiation time and
amplification of thrombin signal were accurately predicted in the normal case whereas
in the hemophilia case we correctly predict the initiation time but slightly over predict
the amplification signal. This performance is nearly similar to that of the detailed mech-
anistic model with 301 reactions. Despite the impressive performance, there are several
issues that could be further explored. First, the prediction of initiation time should be
investigated. We were able to estimate initiation time within a data set, but unable to
30
predict initiation time across independent data sets. This suggested that we should up-
date the initiation module to distinguish between different triggers, e.g., TF/FVIIa versus
rFVIIa alone, and to include key biological milestones such as FXa activation (a prereq-
uisite to thrombin formation). Next, there are several additional biological modules that
could be added to the core model presented here. First, we could include thrombin-
induced platelet activation and the role of activated platelets in amplification. We cap-
tured thrombin generation data in the presence of platelets, however, the initial shape of
the activation curve and the time-scale of activation was not always consistent with the
data. Platelets are activated by thrombin through the cleavage of the extracellular domain
of protease-activated receptors (PARs) on the platelet surface. Once activated, platelets
play an important role in amplification, and are key mediators of the positive feedback
driving amplification. Thus, this biology is a potentially important component of an ex-
panded model. We should also add the intrinsic pathway to the model. The intrinsic
pathway is triggered by contact activation of the plasma protease factor XI (fXI) by neg-
atively charged surfaces and by thrombin and upstream factors such as activated plasma
protease factor XII (FXIIa) [80, 81]. Activated platelets may also release polyphosphate
which directly activates fXII [82]. Arguably a minor player in acute bleeding, contact ac-
tivation could also be important in other wound healing contexts. Finally, to make the
model more clinically relevant, we should include the biochemical processes responsible
for clot formation and clot dissolution (fibrinolysis). Clot formation is driven by throm-
bin activity, while fibrinolysis is driven by plasmin activity, a key enzyme that cleaves
fibrin (one of the main materials in a clot). Similar to coagulation, fibrinolysis is managed
by several activating and inhibitory factors which control the balance between clot forma-
tion and dissolution. Tissue plasminogen activator (t-PA) and urokinase activate plasmin,
along with contact pathway factors such as fXIa. On the other hand, thrombin activatable
fibrinolysis inhibitor (TAFI) inhibits the degradation of fibrin by plasmin. Also, similar
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to coagulation, there is considerable fibrinolysis and contact pathway data sets that can
be used to train the model. Lastly, the choice of max/min integration rules or the partic-
ular form of the transfer functions could be generalized to include other rule types and
functions. Theoretically, an integration rule is a function whose domain is a set of transfer
function inputs, and whose range is v ∈ [0, 1]. Thus, integration rules other than max/min
could be used, such as the mean or the product, assuming the range of the transfer func-
tions is always f ∈ [0, 1]. Alternative integration rules such as the mean might have
different properties which could influence model identification or performance. For ex-
ample, a mean integration rule would be differentiable, which allows derivative-based
optimization approaches to be used. The particular form of the transfer function could
also be explored. We choose a Hill-like function because of its prominence in the systems
and synthetic biology community. However, the only mathematical requirement for a
transfer function is that it map a non-negative continuous or categorical variable into the
range f ∈ [0, 1]. Thus, many types of transfer functions are possible.
2.4 Materials and Methods
2.4.1 Formulation and Solution of the Model Equations
We used ordinary differential equations (ODEs) to model the time evolution of proteins
(xi) in our reduced order coagulation model:
dxi
dt
=
R∑
j=1
σi jr j (x, ,k) i = 1, 2, . . . ,M (2.1)
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where R denotes the number of reactions,M denotes the number of protein species in the
model. The quantity r j (x, ,k) denotes the rate of reaction j. Typically, reaction j is a non-
linear function of biochemical species abundance, as well as unknown kinetic parameters
k (K × 1). The quantity σi j denotes the stoichiometric coefficient for species i in reaction j.
If σi j > 0, species i is produced by reaction j. Conversely, if σi j < 0, species i is consumed
by reaction j, while σi j = 0 indicates species i is not connected with reaction j. The system
material balances were subject to the initial conditions x (to) = xo, which were specified by
the experimental setup.
Each reaction rate was written as the product of two terms, a kinetic term (r¯ j) and a
control term (v j) that depends on multiple regulators:
r j (x, ,k) = r¯ jv j (2.2)
We used multiple saturation kinetics to model the reaction term r¯ j:
r¯ j = kmaxj i
∏
s∈m−j
xs
K js + xs
 (2.3)
where kmaxj denotes the maximum rate for reaction j, i denotes the scaled enzyme activity
which catalyzes reaction j, and K js denotes the saturation constant for species s in reaction
j. The product in Eqn. (3.4) was carried out over the set of reactants for reaction j (denoted
as m−j ).
The control term v j depended upon the combination of factors which influenced the
activity of enzyme i. For each enzyme, we used a rule-based approach to select from
competing control factors (Fig. 3.2). If an enzyme was activated by m metabolites, we
33
modeled this activation as:
v j = max
(
f1 j (Z) , . . . , fmj (Z)
)
(2.4)
where 0 ≤ fi j (Z) ≤ 1 was a regulatory transfer function that calculated the influence of
metabolite i on the activity of enzyme j. Conversely, if enzyme activity was inhibited by
m metabolites, we modeled this inhibition as:
v j = 1 −max
(
f1 j (Z) , . . . , fmj (Z)
)
(2.5)
Lastly, if an enzyme had both m activating and n inhibitory factors, we modeled the con-
trol term as:
v j = min
(
u j, d j
)
(2.6)
where:
u j = max
j+
(
f1 j (Z) , . . . , fmj (Z)
)
(2.7)
d j = 1 −max
j−
(
f1 j (Z) , . . . , fn j (Z)
)
(2.8)
The quantities j+ and j− denoted the sets of activating and inhibitory factors for enzyme
j. If a process has no modifying factors, we set v j = 1. There are many possible functional
forms for 0 ≤ fi j (Z) ≤ 1. However, in this study, each individual transfer function took
the form:
fi
(
Z j, ki j
)
=
kηi jZηj
1 + kηi jZηj
(2.9)
where Z j denotes the abundance of the j factor (e.g., metabolite abundance), and ki j and
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η are control parameters. ki j was the species gain parameter, while η was a cooperativity
parameter (similar to a Hill coefficient). Applying the general framework to the reduced
coagulation network resulted in five ordinary differential equations:
dx1
dt
= −
(
rinitvinit + rampvamp
)
(2.10)
dx2
dt
= rampvamp + rinitvinit − rinh,AT IIIvinh,AT III (2.11)
dx3
dt
= −rapcvapc (2.12)
dx4
dt
= rapcvapc (2.13)
dx5
dt
= −rinh,AT IIIvinh,AT III (2.14)
where x = ( f II, FIIa, PC, APC, AT III)T . The terms r∗v∗ in the balance equations denote
corrected kinetic expressions for initiation, amplification and inhibition processes. The
rate of initiation r¯init was modeled as:
r¯init = kinit (trigger)
x1
Kinit, f II + x1
(2.15)
where kinit, Kinit, f II are the rate and saturation constants governing initiation, respectively.
The rate of initiation was modified by vinit, the control parameter governing initiation.
Initiation was sensitive to the level of trigger (activator) and TFPI (inhibitor):
vinit = min
(
f −init (TFPI) , f
+
init (trigger)
)
(2.16)
where the transfer functions f took the form of Eqn (3.10). The rate of thrombin amplifi-
cation was given by:
r¯amp = kamp (x2)
x1
Kamp, f II + x1
(2.17)
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where kamp, Kamp, f II denote the rate and saturation constants governing amplification, re-
spectively. The amplification control term, which modified amplification rate, was mod-
eled as a combination of multiple inhibition terms and one activation term:
vamp = min
(
f −amp (TFPI) , f
−
amp (x4) , f
+
amp
(
Zamp
))
(2.18)
where Zamp = f V × f X × f VIII × f IX. Although f +amp
(
Zamp
)
is an activating term, we
included it in the min integration rule; the factors inZamp were essential for amplification
(if any of these factors was missing the amplification reaction would not occur). Thus, the
factors in Zamp were required components, a classification that we implemented by the
min selection rule. The rate activated protein C formation was given by:
r¯apc = kAPC, f ormation (TM)
x3
K f ormation,PC + x3
(2.19)
where kAPC, f ormation and K f ormation,PC denote the rate and saturation constants governing acti-
vated protein C formation, respectively and TM denotes the thrombomodulin abundance.
We modeled the control term which governed APC formation as a single thrombin-
dependent activation term:
vapc = max
(
f +apc (x2)
)
(2.20)
Lastly, we included direct irreversible inhibition of FIIa by ATIII:
r¯inh,AT III = kAT III,inhibition
(
x5x
γ
2
)
(2.21)
where γ was estimated to be γ = 1.26. For ATIII inhibition of FIIa, the control variables
vinh,AT III was taken to be unity. The model equations were encoded using the Python pro-
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gramming language and solved using the ODEINT routine of the SciPy module [83]. The
model files can be downloaded from http://www.varnerlab.org.
2.4.2 Estimation of Model Parameters From Experimental Data
Model parameters were estimated by minimizing the difference between simulations and
experimental thrombin measurements (squared residual):
min
k
T∑
τ=1
S∑
j=1
(
xˆ j (τ) − x j (τ,k)
ω j (τ)
)2
(2.22)
where xˆ j (τ) denotes the measured value of species j at time τ, x j (τ,k) denotes the sim-
ulated value for species j at time τ, and ω j (τ) denotes the experimental measurement
variance for species j at time τ. The outer summation is with respect to time, while the
inner summation is with respect to state. We minimized the model residual using Particle
swarm optimization (PSO) [22]. PSO uses a swarming metaheuristic to explore parameter
spaces. A strength of PSO is its ability to find the global minimum, even in the presence of
potentially many local minima, by communicating the local error landscape experienced
by each particle collectively to the swarm. Thus, PSO acts both as a local and a global
search algorithm. For each iteration, particles in the swarm compute their local error by
evaluating the model equations using their specific parameter vector realization. From
each of these local points, a globally best error is identified. Both the local and global
error are then used to update the parameter estimates of each particle using the rules:
∆i = θ1∆i + θ2r1 (Li − ki) + θ3r2 (G − ki) (2.23)
ki = ki + ∆i (2.24)
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where (θ1, θ2, θ3) are adjustable parameters, Li denotes the local best solution found by
particle i, and G denotes the best solution found over the entire population of parti-
cles. The quantities r1 and r2 denote uniform random vectors with the same dimen-
sion as the number of unknown model parameters (K × 1). In thus study, we used
(θ1, θ2, θ3) = (1.0, 0.05564, 0.02886). The quality of parameter estimates was measured us-
ing goodness of fit (model residual). The particle swarm optimization routine was imple-
mented in the Python programming language. All plots were made using the Matplotlib
module of Python [84].
2.4.3 Global Sensitivity Analysis of Model Performance
We conducted a global sensitivity analysis, using the variance-based method of Sobol, to
estimate which parameters controlled the performance of the reduced order model [85].
We computed the total sensitivity index of each parameter relative to two performance
objectives, the peak thrombin time and the area under the thrombin curve (thrombin ex-
posure). We established the sampling bounds for each parameter from the minimum and
maximum value of that parameter in the parameter set ensemble. We used the sampling
method of Saltelli et al. [86] to compute a family of N (2d + 2) parameter sets which obeyed
our parameter ranges, where N was the number of trials, and d was the number of pa-
rameters in the model. In our case, N = 10,000 and d = 22, so the total sensitivity indices
were computed from 460,000 model evaluations. The variance-based sensitivity analysis
was conducted using the SALib module encoded in the Python programming language
[87].
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CHAPTER 3
DYNAMIC MODELING OF CELL-FREE BIOCHEMICAL NETWORKS USING
EFFECTIVE KINETIC MODELS
Abstract
Cell-free systems 1 offer many advantages for the study, manipulation and modeling of
metabolism compared to in vivo processes. Many of the challenges confronting genome-
scale kinetic modeling can potentially be overcome in a cell-free system. For example,
there is no complex transcriptional regulation to consider, transient metabolic measure-
ments are easier to obtain, and we no longer have to consider cell growth. Thus, cell-free
operation holds several significant advantages for model development, identification and
validation. Theoretically, genome-scale cell-free kinetic models may be possible for in-
dustrially important organisms, such as E. coli, if a simple, tractable framework for inte-
grating allosteric regulation with enzyme kinetics can be formulated. Toward this unmet
need, we present an effective biochemical network modeling framework for building dy-
namic cell-free metabolic models. The key innovation of our approach is the integration
of simple effective rules encoding complex allosteric regulation with traditional kinetic
pathway modeling. We tested our approach by modeling the time evolution of several
hypothetical cell-free metabolic networks. We found that simple effective rules, when
integrated with traditional enzyme kinetic expressions, captured complex allosteric pat-
terns such as ultrasensitivity or non-competitive inhibition in the absence of mechanistic
information. Second, when integrated into network models, these rules captured classic
regulatory patterns such as product-induced feedback inhibition. Lastly, we showed, at
1Adapted with permission from Wayman JA, Sagar A, and Varner JD, “Dynamic modeling of cell-free
biochemical networks using effective kinetic models” (2015) Processes, 3:138-160
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least for the network architectures considered here, that we could simultaneously esti-
mate kinetic parameters and allosteric connectivity from synthetic data starting from an
unbiased collection of possible allosteric structures using particle swarm optimization.
However, when starting with an initial population that was heavily enriched with in-
correct structures, our particle swarm approach could converge to an incorrect structure.
While only an initial proof-of-concept, the framework presented here could be an impor-
tant first step toward genome-scale cell-free kinetic modeling of the biosynthetic capacity
of industrially important organisms.
3.1 Introduction
Mathematical modeling has long contributed to our understanding of metabolism.
Decades before the genomics revolution, mechanistically, structured metabolic models
arose from the desire to predict microbial phenotypes resulting from changes in intracel-
lular or extracellular states [88]. The single cell E. coli models of Shuler and coworkers
pioneered the construction of large-scale, dynamic metabolic models that incorporated
multiple, regulated catabolic and anabolic pathways constrained by experimentally de-
termined kinetic parameters [89]. Shuler and coworkers generated many single cell ki-
netic models, including single cell models of eukaryotes [90, 91], minimal cell architec-
tures [92], as well as DNA sequence based whole-cell models of E. coli [93]. Conversely,
highly abstracted kinetic frameworks, such as the cybernetic framework, represented a
paradigm shift, viewing cells as growth-optimizing strategists [94]. Cybernetic models
have been highly successful at predicting metabolic choice behavior, e.g., diauxie behav-
ior [95], steady-state multiplicity [96], as well as the cellular response to metabolic engi-
neering modifications [97]. Unfortunately, traditional, fully structured cybernetic models
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also suffer from an identifiability challenge, as both the kinetic parameters and an ab-
stracted model of cellular objectives must be estimated simultaneously. However, recent
cybernetic formulations from Ramkrishna and colleagues have successfully treated this
identifiability challenge through elementary mode reduction, though the techniques re-
place detailed biological mechanism with an optimization heuristic [98, 99].
In the post genomics world, large-scale stoichiometric reconstructions of microbial
metabolism popularized by static, constraint-based modeling techniques such as flux
balance analysis (FBA) have become standard tools [100]. Since the first genome-scale
stoichiometric model of E. coli, developed by Edwards and Palsson [101], well over 100
organisms, including industrially important prokaryotes such as E. coli [102] or B. subtilis
[103], are now available [104]. Stoichiometric models rely on a pseudo-steady-state as-
sumption to reduce unidentifiable genome-scale kinetic models to an underdetermined
linear algebraic system, which can be solved efficiently even for large systems. Tradi-
tionally, stoichiometric models have also neglected explicit descriptions of metabolic reg-
ulation and control mechanisms, instead opting to describe the choice of pathways by
prescribing an objective function on metabolism. Interestingly, similar to early cyber-
netic models, the most common metabolic objective function has been the optimization
of biomass formation [105], although other metabolic objectives have also been estimated
[106]. Recent advances in constraint-based modeling have overcome the early shortcom-
ings of the platform, including capturing metabolic regulation and control [107]. Thus,
modern constraint-based approaches have proven extremely useful in the discovery of
metabolic engineering strategies and represent the state of the art in metabolic modeling
[108, 109]. However, genome-scale kinetic models of industrial important organisms such
as E. coli have yet to be constructed.
Cell-free systems offer many advantages for the study, manipulation and modeling of
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metabolism compared to in vivo processes. Central amongst these advantages is direct
access to metabolites and the microbial biosynthetic machinery without the interference
of a cell wall. This allows us to control as well as interrogate the chemical environment
while the biosynthetic machinery is operating, potentially at a fine time resolution. Sec-
ond, cell-free systems also allow us to study biological processes without the complica-
tions associated with cell growth. Cell-free protein synthesis (CFPS) systems are arguably
the most prominent examples of cell-free systems used today [110]. However, CFPS is not
new; CFPS in crude E. coli extracts has been used since the 1960s to explore fundamentally
important biological mechanisms [111, 112]. Today, cell-free systems are used in a variety
of applications ranging from therapeutic protein production [113] to synthetic biology
[114]. Interestingly, many of the challenges confronting genome-scale kinetic modeling
can potentially be overcome in a cell-free system. For example, there is no complex tran-
scriptional regulation to consider, transient metabolic measurements are easier to obtain,
and we no longer have to consider cell growth. Thus, cell-free operation holds several sig-
nificant advantages for model development, identification and validation. Theoretically,
genome-scale cell-free kinetic models may be possible for industrially important organ-
isms, such as E. coli or B. subtilis, if a simple, tractable framework for integrating allosteric
regulation with enzyme kinetics can be formulated.
In this study, we present an effective biochemical network modeling framework for
building dynamic cell-free metabolic models. The key innovation of our approach is
the seamless integration of simple effective rules encoding complex regulation with tra-
ditional kinetic pathway modeling. This integration allows the description of complex
regulatory interactions, such as time-dependent allosteric regulation of enzyme activity,
in the absence of specific mechanistic information. The regulatory rules are easy to un-
derstand, easy to formulate and do not rely on overarching theoretical abstractions or
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restrictive assumptions. We tested our approach by modeling the time evolution of sev-
eral hypothetical cell-free metabolic networks. In particular, we tested whether our ef-
fective modeling approach could describe classically expected enzyme kinetic behavior,
and second whether we could simultaneously estimate kinetic parameters and regulatory
connectivity, in the absence of specific mechanistic knowledge, from synthetic experimen-
tal data. Toward these questions, we explored five hypothetical cell-free networks. Each
network shared the same enzymatic connectivity, but had different allosteric regulatory
connectivity. We found that simple effective rules, when integrated with traditional en-
zyme kinetic expressions, captured complex allosteric patterns such as ultrasensitivity or
non-competitive inhibition in the absence of mechanistic information. Second, when in-
tegrated into network models, these rules captured classical regulatory patterns such as
product-induced feedback inhibition. Lastly, we showed, at least for the network archi-
tectures considered here, that we could simultaneously estimate kinetic parameters and
allosteric connectivity from synthetic data starting from an unbiased collection of possible
allosteric structures using particle swarm optimization. However, when starting with an
initial population that was heavily enriched with incorrect structures, our particle swarm
approach could converge to an incorrect structure. While only an initial proof-of-concept,
the framework presented here could be an important first step toward genome-scale cell-
free kinetic modeling of the biosynthetic capacity of industrially important organisms.
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3.2 Results
3.2.1 Formulation and properties of effective cell-free metabolic mod-
els.
We developed two proof-of-concept metabolic networks to investigate the features of our
effective biochemical network modeling approach (Fig. 3.1). In both examples, substrate
S was converted to the end products P1 and P2 through a series of enzymatically catalyzed
reactions, including a branch point at hypothetical metabolite M2. Several of these reac-
tions involved cofactor dependence (AH or A), and various allosteric regulatory mecha-
nisms modified the activity of pathway enzymes. Network A included feedback inhibi-
tion of the initial pathway enzyme (E1) by pathway end products P1 and P2 (Fig. 3.1A).
On the other hand, network B involved feedback inhibition of E1 by P2 and E6 by P1 (Fig.
3.1B). In both networks, branch point enzymes E3 and E6 were subject to feed-forward ac-
tivation by reduced cofactor AH. Lastly, it is known experimentally that cell-free systems
have a finite operational lifespan. Loss of biosynthetic capability could be a function of
many factors, e.g., cofactor or metabolite limitations. We modeled the loss of biosynthetic
capability as a non-specific first-order decay of enzyme activity.
Allosteric regulation of enzyme activity was modeled by combining individual regu-
latory contributions to the activity of pathway enzymes into a control coefficient using an
integration rule (Fig. 3.2). This strategy is similar in spirit to the Constrained Fuzzy Logic
(cFL) approach of Lauffenburger and coworkers which has been used to effectively model
signal transduction pathways important in human health [115]. In our formulation, Hill-
like transfer functions 0 ≤ f (Z) ≤ 1 were used to calculate the influence of factor abun-
dance upon target enzyme activity. In this context, factors can be individual metabolite
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levels or some function, e.g., the product of metabolite levels. However, more generally,
factors can also correspond to non-modeled influences, categorial variables or other ab-
stract quantities. In the current study, we simply let Z correspond to the abundance of
individual metabolites, however in general this can be a complex function of both mod-
eled and unmodeled factors. When an enzyme was potentially sensitive to more than one
regulatory input, logical integration rules were used to select which regulatory transfer
function influenced enzyme activity at any given time. Thus, our test networks involved
important features such as cofactor recycling, enzyme activity and metabolite dynamics,
as well as multiple overlapping allosteric regulatory mechanisms.
The rule-based regulatory strategy approximated the behavior of classical allosteric
activation and inhibition mechanisms (Fig. 3.3). We considered the enzyme catalyzed
conversion of substrate S to a product P, where the overall reaction rate was modeled
as the product of a Michaelis-Menten term and an effective allosteric control variable re-
flecting the particular regulatory interaction. We first explored feed-forward substrate
activation of enzyme activity (for both positive and negative cooperativity). Consistent
with classical data, the rule-based strategy predicted a sigmoidal relationship between
substrate abundance and reaction rate as a function of the cooperativity parameter (Fig.
3.3A). For cooperativity parameters less than unity, increased substrate abundance de-
creased the maximum reaction rate. This was consistent with the idea that substrate bind-
ing decreased at regulatory sites, which negatively impacted substrate binding at the ac-
tive site. On the other hand, as the cooperativity parameter increased past unity, the rate
of conversion of substrate S to product P by enzyme E approached a step function. In
the presence of an inhibitor, the rule-based strategy predicted non-competitive like be-
havior as a function of the cooperativity parameter (Fig. 3.3B). When the control gain
parameter, κi j in Eqn. (3.10), was greater than unity, the inhibitory force was directly
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proportional to the cooperativity parameter, η in Eqn. (3.10). Thus, as the cooperativity
parameter increased, the maximum reaction rate decreased (Fig. 3.3B). Interestingly, our
rule-based approach was unable to directly simulate competitive inhibition of enzyme
activity. Taken together, the rule-based strategy captured classical regulatory patterns
for both enzyme activation and inhibition. Thus, we are able to model complex kinetic
phenomena such as ultrasensitivity, despite an effective description of reaction kinetics.
End product yield was controlled by feedback inhibition, while product selectivity
was controlled by branch point enzyme inhibition (Fig. 3.4). A critical test of our mod-
eling approach was to simulate networks with known behavior. If we cannot reproduce
the expected behavior of simple networks, then our effective modeling strategy, and par-
ticularly the rule-based approximation of allosteric regulation, will not be feasible for
genome-scale cell-free problems. We considered two cases, control ON/OFF, for each
network configuration. Each of these cases had identical kinetic parameters and initial
conditions; the only differences between the cases were the allosteric regulation rules and
the control parameters associated with these rules. As expected, end product accumula-
tion was larger for network A when the control was OFF (no feedback inhibition of E1
by P1 and P2), as compared to the ON case (Fig. 3.4A). We found this behavior was ro-
bust to the choice of underlying kinetic parameters, as we observed that same qualitative
response across an ensemble of 100 randomized parameter sets, for fixed control param-
eters. The control ON/OFF response of network B was more subtle. In the OFF case,
the behavior was qualitatively similar to network A. However, for the ON case, flux was
diverted away from P2 formation by feedback inhibition of E6 activity at the M2 branch
point by P1 (Fig. 3.4B). Lower E6 activity at the M2 branch point allowed more flux toward
P1 formation, hence the yield of P1 also increased (Fig. 3.4C). Again, the control ON/OFF
behavior of network B was robust to changes in kinetic parameters, as the same quali-
46
tative trend was conserved across an ensemble of 100 randomized parameters, for fixed
control parameters. Taken together, these simulations suggested that the rule-based al-
losteric control concept could robustly capture expected feedback behavior for networks
with uncertain kinetic parameters.
3.2.2 Estimating parameters and effective allosteric regulatory struc-
tures.
A critical challenge for any dynamic model is the estimation of kinetic parameters. For
metabolic processes, there is also the added challenge of identifying the regulation and
control structures that manage metabolism. Of course, these issues are not independent;
any description of enzyme activity regulation will be a function of system state, which
in turn depends upon the kinetic parameters. For cell-free systems, regulated gene ex-
pression has been removed, however, enzyme activity regulation is still operational. We
explored this linkage by estimating model parameters from synthetic data using both net-
work structures. We generated synthetic measurements of the substrate S, intermediate
M5 and end product P1 approximately every 20 min using network A. This data set is
similar to published cell-free studies, both in terms of network coverage and sampling
frequency [110]. We then generated an ensemble of model parameter estimates by min-
imizing the difference between model simulations and the synthetic data using particle
swarm optimization (PSO), starting from random initial parameter guesses. The estima-
tion of kinetic parameters was sensitive to the choice of regulatory structure (Fig. 3.5).
PSO identified an ensemble of parameters that bracketed the mean of the synthetic mea-
surements in less than 1000 iterations when the control structure was correct (Fig. 3.5A
and B). However, with control mismatch (network B simulated with network A param-
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eters), model simulations were not consistent with the synthetic data (Fig. 3.5C and D).
Taken together, these results suggested that we could perhaps simultaneously estimate
both parameters and network control architectures, as incorrect control structures would
be manifest as poor model fits.
We modified our particle swarm identification strategy to simultaneously search over
both kinetic parameters and putative control structures. In addition to our initial net-
works, we constructed three additional presumptive network models, each with the same
enzymatic connectivity but different allosteric regulation of the pathway enzymes (Fig.
3.6). We then initialized a population of particles, each with one of the five potential
regulatory programs and randomized kinetic parameters. Thus, we generated an initial
population of particles that had both different kinetic parameters as well as different con-
trol structures. We biased the distribution of the particle population according to our a
prior belief of the correct regulatory program. To this end, we considered three different
priors, a uniform distribution where each putative regulatory structure represented 20%
of the population and two mixed distributions that were either positively or negatively
biased towards the correct structure (network A). In both the positively biased and uni-
form cases the PSO clearly differentiated between the true or closely related structures
and those that were materially different (Fig. 3.7). As expected, the positively biased
population (40% of the initial particle population seeded with network A) gave the best
results, where the correct structure was preferentially identified (Fig. 3.7A). On the other
hand, when given a uniform distribution, the PSO approach identified a combination of
network A and network C as the most likely control structures (Fig. 3.7B). Network A
and C differ by the regulatory connection between the end product P2 and enzyme E1; in
network A, end product P2 was assumed to inhibit E1, while in network C, end product
P2 activated E1. Lastly, when the initial population was heavily biased towards incorrect
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structures (initial population seeded with 90% incorrect structures), the particle swarm
misidentified the correct allosteric structure (Fig. 3.7C). Interestingly, while each particle
swarm identified parameter sets that minimized the simulation error, the estimated pa-
rameter values were not necessarily similar to the true parameters. The angle between
the estimated and true parameters was not consistently small across the swarms (iden-
tical parameters would give an angle of zero). This suggested that our particle swarm
approach identified a sloppy ensemble, i.e., parameter estimates that were individually
incorrect but collectively exhibited the correct model behavior.
We calculated control program output and scaled metabolic flux for the positively,
uniformly and negatively biased particle swarms (Fig. 3.8). Network A and network C
models from the positively (Fig. 3.8A) and uniformly (Fig. 3.8B) biased particle swarms
showed similar operational patterns, despite differences in kinetic parameters and control
structures. While models from the negatively biased population had error values similar
to the correct structures in the previous swarms, they have different flux and control pro-
files (Fig. 3.8C). In all cases, regardless of network configuration or parameter values, the
rate of enzyme decay was small compared to the other fluxes, and all networks had qual-
itatively similar trends for E3 and E6 control. Moreover, consistent with the correct model
structure, production of end product P1 was the preferred branch for all model config-
urations. However, there was variability in P2 production flux across the population of
models, especially for the uniform swarm when compared with the other cases. High
P1 branch flux resulted in end product inhibition of E1 in both network A and network
C, however in network D and E, high P1 flux induced E1 activation. These trends were
manifested in different flux profiles, where the negatively biased population appeared
more uniform across the population compared with the other swarms, and had higher E1
specific activity. Interestingly, the behavior of network A and network C highlighted an
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artifact of our integration rule; both a positive or negative feedback connection from P2
to E1 were ignored because the P1 inhibition of E1 dominated. Thus, while theoretically
distinct, network A and network C appeared operationally to the PSO algorithm to be the
same network. On the other hand, networks B, D and E showed distinct behavior that
was not consistent with the true network. These architectures exhibited either limited
inhibition (network B) or activation (network D and E) of E1 activity, resulting in signif-
icantly different metabolic flux profiles. However, the PSO was able to find low error
parameter solutions, despite the mismatch in the control structures (error values similar,
but not better than the best network A and network C estimates). Taken together, these
results suggested that a uniform sampling approach could potentially yield an unbiassed
estimate of both kinetic parameters and control structures. However, the negatively bi-
ased particle swarm results illustrated a potential shortcoming of the approach, namely
convergence to a local error minimum despite a significantly incorrect control structure.
This suggested that estimated model structures will need to be further evaluated, for ex-
ample by generating falsifiable experimental designs which could distinguish between
low error solutions.
3.3 Discussion
In this study, we presented an effective kinetic modeling strategy to dynamically simu-
late cell-free biochemical networks. Our proposed strategy integrated traditional kinetic
modeling with an effective rules based approach to dynamically describe metabolic regu-
lation and control. We tested this approach by developing kinetic models of hypothetical
cell-free metabolic networks. In particular, we tested whether our effective modeling ap-
proach could describe classically expected behavior, and second whether we could simul-
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taneously estimate kinetic parameters and regulatory connectivity, in the absence of spe-
cific mechanistic knowledge, from synthetic experimental data. Toward these questions,
we explored five hypothetical cell-free networks. In each network, a substrate S was con-
verted to the end products P1 and P2 through a series of enzymatically catalyzed reactions,
including a branch point at a hypothetical metabolite M2. Each network also included
the same cofactors and cofactor recycle architecture. However, while all five networks
shared the same enzymatic connectivity, each had different allosteric regulatory connec-
tivity. We found that simple effective rules, when integrated with traditional enzyme
kinetic expressions, could capture complex allosteric patterns such as ultrasensitivity, or
non-competitive inhibition in the absence of specific mechanistic information. Moreover,
when integrated into network models, these rules captured classical regulatory patterns
such as product-induced feedback inhibition. Lastly, we simultaneously estimated kinetic
parameters and discriminated between competing regulatory structures, using synthetic
data in combination with a modified particle swarm approach. If we considered all puta-
tive regulatory architectures to be equally likely, we were able to estimate a sloppy ensem-
ble of models with the correct architecture and kinetic parameters. Thus, we identified
parameter values that were different from their true values, but nonetheless produced
reasonable model performance (low error). This suggested that we captured important
parameter combinations (stiff combinations), while simultaneously missing other param-
eter combinations (sloppy combinations). This was similar to the earlier study of Brown
and Sethna [116], which showed that reasonable model predictions were possible, despite
sometimes only order of magnitude parameter estimates, if the stiff parameter combina-
tions were well constrained.
The proposed modeling strategy shares features with other popular techniques, but
also has several key differences. At its core, our effective modeling approach is sim-
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ilar to regulatory constraint-based methods, and to the cybernetic modeling paradigm
developed by Ramkrishna and colleagues. Covert, Palsson and coworkers drastically im-
proved the predictability of constraint-based approaches by integrating Boolean rules into
the calculation of metabolic fluxes [117]. If the regulated intracellular flux problem is cou-
pled with time-dependent extracellular balances, these models can predict complex be-
havior such as diauxie growth or the switch between aerobic and anaerobic metabolism.
Another important feature of this approach is that it scales with biological complexity.
For example, Covert et al. showed that a genome-scale model of E. coli augmented with
a Boolean rule layer, correctly predicted approximately 80% of the outcomes of a high-
throughput growth phenotyping experiment in E. coli. Further, they showed that they
could learn new biology by iteratively refining the model and its associated rules [118].
However, while regulated flux balance analysis is a powerful technique, it does not easily
allow the calculation of time-resolved metabolite abundance. Additionally, the Boolean
rules which populate the regulatory layer are limited to ON/OFF decisions; for quali-
tative predictions of gene expression this is a reasonable limitation. However, Boolean
rules will likely be less effective at capturing dynamic allosteric regulation in a cell-free
metabolic system. On the other hand, the strength of cybernetic models is the integra-
tion of optimal metabolic control heuristics with traditional kinetic pathway modeling.
Cybernetic models are highly predictive; they have successfully predicted mutant behav-
ior from limited wild-type data [97, 119, 120], steady-state multiplicity [96], strain specific
metabolic function [99] and have been used in bioprocess control applications [121]. How-
ever, cybernetic control heuristics are not mechanistic, instead they are the output of an
optimal decision with respect to a set of hypothetical physiological objectives. Thus, they
are abstractions which are difficult to translate into a specific biological mechanism. Our
approach addresses the shortcomings of both regulatory constraint-based models and cy-
bernetic models. First, similar to cybernetic models, the core of our approach is a kinetic
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model. Thus, we are able to directly calculate the time evolution of metabolism, for ex-
ample the dynamic abundance of network metabolites. Second, similar to regulatory flux
balance analysis, our control laws describe specific mechanistic motifs, such as activation
or inhibition of enzyme activity. However, our rules are continuous, thus they potentially
allow a finer grained description of metabolic regulation and control mechanisms. Lastly,
we can naturally incorporate unmodeled factors and categorical factors or combinations
thereof into our control law formulations. Though requiring a more complex description
of cellular metabolism, our approach may even be extended to simulate cell-based sys-
tems by incorporating the same control laws into transcription factor activation and gene
expression regulation.
There are several critical questions that should be explored following this proof-of-
concept study. It is unclear how parameter identification will scale to genome-scale net-
works, and second it is unclear how we will identify allosteric connectivity at a genome-
scale. The enzymatic connectivity for genome-scale cell-free networks can easily be es-
tablished by stripping away the growth and cell wall machinery from whole cell genome
reconstructions. Then metabolic fluxes can be transformed into kinetic expressions us-
ing heuristics such multiple saturation kinetics, which are then modified by our rule-
based control variables. This leaves a large number of unknown kinetic constants that
must be estimated from time-resolved metabolite measurements. Ensemble modeling is
a well-established approach for parameter identification in large-scale deterministic mod-
els. Liao and coworkers developed a method that generates an ensemble of kinetic mod-
els that all approach the same steady-state, one determined by fluxomics measurements
[65]. The best subpopulation of candidate models were selected based on their agreement
with further measurements of genetically perturbed systems. Our work relies on heuristic
search optimization to identify kinetic models consistent with steady-state and dynamic
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time-series measurements of cellular species [26, 44, 61, 63, 64, 122]. Instead of estimat-
ing a single yet highly uncertain parameter set, both approaches estimate an ensemble of
parameter sets whose model behavior recapitulates experimental measurements. Here,
we showed that particle swarm optimization quickly identified an ensemble of model pa-
rameters, at least for proof-of-concept metabolic networks using synthetic data. This sug-
gested that we can expect reasonable model predictions, despite only partial parameter
knowledge, as network size grows if we have properly designed experiments. Brown and
Sethna showed in a model of signal transduction that good predictions were possible de-
spite only order of magnitude estimates of parameter values [116]. Sethna and coworkers
later showed that model performance is often controlled by only a few parameter com-
binations, a characteristic seemingly universal to multi-parameter models referred to as
sloppiness [25]. We have also demonstrated sloppy behavior in a wide variety of signal
transduction processes [26, 44, 61, 63, 64, 122]. Thus, given our previous experience with
models containing hundreds of unknown parameters, we expect parameter estimation to
be a manageable challenge assuming we have good quality experimental data.
A second critical challenge will be the estimation of allosteric connectivity at a genome
scale. The regulation of glycolytic enzymes, such as phosphofructokinase I, has been
studied for many years [123, 124]. The allosteric regulation of metabolic enzymes can
also be established from organism specific databases, such as EcoCyc [125], or more gen-
eral allosteric databases, such as the AlloSteric Database [126]. However, for those en-
zymes that have not been well studied, we will need to infer allosteric interactions from
experimental data. In general, the reverse engineering of regulatory network structure
from data is a difficult problem. Recently, Sauer and colleagues have developed a sys-
tematic, model-based approach for the identification of allosteric regulation in vivo [127].
They tested the effects of many putative allosteric protein-metabolite interactions on the
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performance of a kinetic model of glycolysis against dynamic metabolomic and fluxomic
measurements. A method similar to this may be easily applied to cell-free systems in
order to identify relevant in vitro allosteric interactions. Because omics measurements of
cell-free environments are easy to obtain, identification of large-scale allosteric control
structures may be possible. Also, there are many different approaches from the reverse
engineering of gene regulatory networks that perhaps could be adopted to this problem,
however this remains an open question. For example, one could imagine designing pulse
chase experiments which maximally distinguish between competing allosteric models,
similar to the earlier work of Kremling et al [128], or iteratively estimating model struc-
tures similar to Doyle and coworkers [129]. Lastly, the choice of max/min integration
rules or the particular form of the transfer functions could be generalized to include other
rule types and functions. Theoretically, an integration rule is a function whose domain
is a set of transfer function inputs, and whose range is v ∈ [0, 1]. Thus, integration rules
other than max/min could be used, such as the mean or the product, assuming the range
of the transfer functions is always f ∈ [0, 1]. Alternative integration rules such as the
mean might have different properties which could influence model identification or per-
formance. For example, a mean integration rule would be differentiable, which allows
derivative-based optimization approaches to be used. The particular form of the transfer
function could also be explored. We choose a Hill-like function because of its prominence
in the systems and synthetic biology community. However, the only mathematical re-
quirement for a transfer function is that it map a non-negative continuous or categorical
variable into the range f ∈ [0, 1]. Thus, many types of transfer functions are possible.
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3.4 Materials and Methods
3.4.1 Formulation and solution of the model equations.
We used ordinary differential equations (ODEs) to model the time evolution of metabolite
(xi) and scaled enzyme abundance (i) in hypothetical cell-free metabolic networks:
dxi
dt
=
R∑
j=1
σi jr j (x, ,k) i = 1, 2, . . . ,M (3.1)
di
dt
= −λii i = 1, 2, . . . ,E (3.2)
where R denotes the number of reactions, M denotes the number of metabolites and E
denotes the number of enzymes in the model. The quantity r j (x, ,k) denotes the rate of
reaction j. Typically, reaction j is a non-linear function of metabolite and enzyme abun-
dance, as well as unknown kinetic parameters k (K × 1). The quantity σi j denotes the
stoichiometric coefficient for species i in reaction j. If σi j > 0, metabolite i is produced by
reaction j. Conversely, if σi j < 0, metabolite i is consumed by reaction j, while σi j = 0 in-
dicates metabolite i is not connected with reaction j. Lastly, λi denotes the scaled enzyme
degradation constant. The system material balances were subject to the initial conditions
x (to) = xo and  (to) = 1 (initially we have 100% cell-free enzyme abundance).
Each reaction rate was written as the product of two terms, a kinetic term (r¯ j) and a
regulatory term (v j):
r j (x, ,k) = r¯ jv j (3.3)
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We used multiple saturation kinetics to model the reaction term r¯ j:
r¯ j = kmaxj i
∏
s∈m−j
xs
K js + xs
 (3.4)
where kmaxj denotes the maximum rate for reaction j, i denotes the scaled enzyme activity
which catalyzes reaction j, and K js denotes the saturation constant for species s in reaction
j. The product in Eqn. (3.4) was carried out over the set of reactants for reaction j (denoted
as m−j ).
The allosteric regulation term v j depended upon the combination of factors which
influenced the activity of enzyme i. For each enzyme, we used a rule-based approach
to select from competing control factors (Fig. 3.2). If an enzyme was activated by m
metabolites, we modeled this activation as:
v j = max
(
f1 j (Z) , . . . , fmj (Z)
)
(3.5)
where 0 ≤ fi j (Z) ≤ 1 was a regulatory transfer function that calculated the influence of
metabolite i on the activity of enzyme j. Conversely, if enzyme activity was inhibited by
a m metabolites, we modeling this inhibition as:
v j = 1 −max
(
f1 j (Z) , . . . , fmj (Z)
)
(3.6)
Lastly, if an enzyme had both m activating and n inhibitory factors, we modeled the reg-
ulatory term as:
v j = min
(
u j, d j
)
(3.7)
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where:
u j = max
j+
(
f1 j (Z) , . . . , fmj (Z)
)
(3.8)
d j = 1 −max
j−
(
f1 j (Z) , . . . , fn j (Z)
)
(3.9)
The quantities j+ and j− denoted the sets of activating and inhibitory factors for enzyme
j. If an enzyme had no allosteric factors, we set v j = 1. There are many possible functional
forms for 0 ≤ fi j (Z) ≤ 1. However, in this study, each individual transfer function took
the form:
fi (x) =
κ
η
i jZηj
1 + κηi jZηj
(3.10)
whereZ j denotes the abundance of the j factor (e.g., metabolite abundance), and κi j and η
are control parameters. The κi j parameter represents a species gain parameter, while η is a
cooperativity parameter (similar to a Hill coefficient). In the case η > 1, the allosteric inter-
action displays positive cooperativity. For η < 1, the interaction is negatively cooperative.
Finally, if η = 1, the interaction displays no cooperativity. The effect of different values
of η on reaction rate can be seen in Figure 3.3. The model equations were encoded us-
ing the Octave programming language and solved using the LSODE routine in Octave (v
3.8.1; www.octave.org). In some cases, metabolic fluxes (or other quantities) were scaled
according to:
rˆ j (t = τ) =
(
r j −min r
max r −min r
)∣∣∣∣
t=τ
(3.11)
where 0 ≤ rˆ j (t = τ) ≤ 1 denotes the scaled value for flux j evaluated at time τ. We have
used this scaling in a variety of other contexts [64, 130].
58
Estimation of model parameters and structures from synthetic experi-
mental data.
Model parameters were estimated by minimizing the difference between simulations and
synthetic experimental data (squared residual):
min
k
T∑
τ=1
S∑
j=1
(
xˆ j (τ) − x j (τ,k)
ω j (τ)
)2
(3.12)
where xˆ j (τ) denotes the measured value of species j at time τ, x j (τ,k) denotes the sim-
ulated value for species j at time τ, and ω j (τ) denotes the experimental measurement
variance for species j at time τ. The outer summation is respect to time, while the in-
ner summation is with respect to state. We approximated a realistic model identification
scenario, assuming noisy experimental data, limited sampling resolution (approximately
20 minutes per sample) and a limited number of measurable metabolites. We assumed a
constant coefficient of variation of 10% for the synthetic data set.
We minimized the model residual using particle swarm optimization (PSO) [22]. PSO
uses a swarming metaheuristic to explore parameter spaces. A strength of PSO is its ability
to find the global minimum, even in the presence of potentially many local minima, by
communicating the local error landscape experienced by each particle collectively to the
swarm. Thus, PSO acts both as a local and a global search algorithm. For each iteration,
particles in the swarm compute their local error by evaluating the model equations using
their specific parameter vector realization. From each of these local points, a globally best
error is identified. Both the local and global error are then used to update the parameter
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estimates of each particle using the rules:
∆i = θ1∆i + θ2r1 (Li − ki) + θ3r2 (G − ki) (3.13)
ki = ki + ∆i (3.14)
where ∆i denotes the perturbation to the vector of parameters ki for particle i. (θ1, θ2, θ3)
are adjustable parameters, Li denotes the best local solution found by particle i, and G de-
notes the best solution found over the entire population of particles. The quantities r1 and
r2 denote uniform random vectors with the same dimension as the number of unknown
model parameters (K × 1). In this study, we used (θ1, θ2, θ3) = (1.0, 0.05564, 0.02886). The
quality of parameter estimates was measured using two criteria, goodness of fit (model
residual) and angle between the estimated parameter vector k j and the true parameter set
k∗:
α j = cos−1
(
k j · k∗
k jk∗
)
(3.15)
If the candidate parameter set k j were perfect, the residual between the model and syn-
thetic data and the angle between k j and the true parameter set k∗ would be equal to
zero.
We modified our PSO implementation to simultaneously search over kinetic parame-
ters and putative model control structures. In the combined case, each particle potentially
carried a different model realization in addition to a different kinetic parameter vector.
We kept the update rules the same (along with the update parameters). Thus, each par-
ticle competed on the basis of goodness of fit, which allowed different model structures
to contribute to the overall behavior of the swarm. We considered five possible model
structures (A through E), where network A was the correct formulation (used to generate
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the synthetic data). We considered a population of 100 particles, where each particle in
the swarm was assigned a model structure, and a random parameter vector. The PSO
algorithm, model equations, and the objective function were encoded and solved in the
Octave programming language (v 3.8.1; www.octave.org).
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Figure 3.1: Proof-of-concept cell-free metabolic networks considered in
this study. Substrate S is converted to products P1 and P2
through a series of chemical conversions catalyzed by en-
zyme(s) E j. The activity of the pathway enzymes is subject to
both positive and negative allosteric regulation.
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Figure 3.2: Schematic of rule-based allosteric enzyme activity con-
trol laws. Traditional enzyme kinetic expressions, e.g.,
Michaelis–Menten or multiple saturation kinetics, are multi-
plied by an enzyme activity control variable 0 ≤ v j ≤ 1. Control
variables are functions of many possible regulatory factors en-
coded by arbitrary functions of the form 0 ≤ f j (Z) ≤ 1. At each
simulation time step, the v j variables are calculated by evaluat-
ing integration rules such as the max or min of the set of factors
f1, . . . influencing the activity of enzyme E j.
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Figure 3.3: Kinetics of simple transformations in the presence of activation
and inhibition. A:The conversion of substrate S to product P by
enzyme E was activated by S . For a fixed control gain param-
eter κcontrol, the reaction rate approached a step for increasing
cooperativity control parameter η. For activation simulations
κcontrol =0.05 and η = {0.01, 0.1, 1, 2, 4, 6, 8, 10}. B:The conversion
of substrate S to product P by enzyme E with inhibitor I. For
a fixed control gain parameter κcontrol, the reaction rate approx-
imated non-competitive inhibition for increasing cooperativity
control parameter η. For the inhibition simulations κcontrol =1.5
and η = {0.01, 0.1, 1, 2, 4, 6, 8, 10}.
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Figure 3.4: ON/OFF control simulations for Network A and Network B
for an ensemble of 100 kinetic parameter sets versus time. For
each case, simulations were conducted using kinetic and initial
conditions generated randomly from a hypothetical true pa-
rameter set. The gray area represents ± one standard deviation
surrounding the mean. Control parameters were fixed during
the ensemble calculations. A: End product P1 abundance ver-
sus time for Network A. The abundance of P1 decreased with
end product inhibition of E1 activity (Control-ON) versus the
no inhibition case (Control-OFF). B: End product P2 abundance
versus time for Network B. Inhibition of branch point E6 by
end product P1 decreased P2 abundance (Control-ON) versus
the no inhibition case (Control-OFF). C: End product P1 abun-
dance versus time for Network A. Inhibition of branch point
E6 by end product P1 decreased P1 abundance (Control-ON)
versus the no inhibition case (Control-OFF).
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Figure 3.5: Parameter estimation from synthetic data for the same and mis-
matched allosteric control logic using particle swarm optimiza-
tion (PSO). Synthetic experimental data was generated from a
hypothetical parameter set using Network A, where substrate
S , end product P1 and intermediate M5 were sampled approx-
imately every 20 minutes. For cases A,B 20 particles were ini-
tialized with randomized parameters and allowed to search
for 300 iterations. A,B: PSO estimated an ensemble of 20 pa-
rameters sets consistent with the synthetic experimental data
assuming the correct enzymatic and control connectivity start-
ing from randomized initial parameters. C,D: In the presence
of control mismatch (Network B control policy simulated with
Network A kinetic parameters) the ensemble of models did not
describe the synthetic data. The synthetic data plotted here was
unperturbed by noise. However, we assumed a constant coef-
ficient of variation of 10% for the synthetic data during param-
eter estimation.
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Figure 3.7: Combined control and kinetic parameter search using modi-
fied particle swarm optimization (PSO). A population of 100
particles was initialized with randomized kinetic parameters
and one of five possible control configurations (Network A -
E). Simulation error was minimized for a synthetic data set (S ,
end product P1 and intermediate M5 sampled approximately
every 20 min) generated using Network A. A: Simulation er-
ror versus parameter set angle for 100 particles biased toward
the correct regulatory program (A,B,C,D,E) = (40%, 10%, 20%,
20% and 10%). B: Simulation error versus parameter set an-
gle for 100 uniformly distributed particles (A,B,C,D,E) = (20%,
20%, 20%, 20% and 20%). C: Simulation error versus parame-
ter set angle for 100 negatively biased particles (A,B,C,D,E) =
(10%, 40%, 10%, 20% and 20%). Network A (the correct struc-
ture) was preferentially identified for positively and uniform
biased particle distributions, but misidentified in the presence
of a large incorrect bias.
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Figure 3.8: Metabolic flux and control variables as a function of network
type and particle index at t = 100 min. The particle error, the
control variables governing E1, E3 and E6 activity (v1, v3 and v3)
and the scaled metabolic flux were calculated for the positively
(top), uniformly (middle) and negatively (bottom) biased par-
ticle swarms (N = 100). Blue denotes a low value, while red
denotes a high value for the respective quantity being plotted.
The particles from each swarm were sorted based upon simu-
lation error (low to high error). A: Model performance for the
positively biased particle swarm as a function of particle index.
B: Model performance for the uniformly biased particle swarm
as a function of particle index. C: Model performance for the
negatively biased particle swarm as a function of particle in-
dex. Models with significant control mismatch showed distinct
control and flux patterns versus those models with the correct
or closely related control policies. In particular, models with
the correct control policy showed stronger inhibition of E1 ac-
tivity, leading to decreased flux from S→P1. Conversely, mod-
els with significant mismatch had increased E1 activity, leading
to an altered flux distribution. This is especially apparent in the
negatively biased particle swarm.
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CHAPTER 4
REDUCED ORDER MODELING AND ANALYSIS OF THE HUMAN
COMPLEMENT SYSTEM
Abstract
Complement 1 is an important pathway in innate immunity, inflammation, and many dis-
ease processes. However, despite its importance, there are few validated mathematical
models of complement activation. In this study, we developed an ensemble of experi-
mentally validated reduced order complement models. We combined ordinary differen-
tial equations with logical rules to produce a compact yet predictive model of comple-
ment activation. The model, which described the lectin and alternative pathways, was
an order of magnitude smaller than comparable models in the literature. We estimated
an ensemble of model parameters from in vitro dynamic measurements of the C3a and
C5a complement proteins. Subsequently, we validated the model on unseen C3a and C5a
measurements not used for model training. Despite its small size, the model was sur-
prisingly predictive. Global sensitivity and robustness analysis suggested complement
was robust to any single therapeutic intervention. Only the simultaneous knockdown of
both C3 and C5 consistently reduced C3a and C5a formation from all pathways. Taken
together, we developed a validated mathematical model of complement activation that
was computationally inexpensive, and could easily be incorporated into pre-existing or
new pharmacokinetic models of immune system function. The model described exper-
imental data, and predicted the need for multiple points of therapeutic intervention to
fully disrupt complement activation.
1Adapted with permission from Sagar A, Dai W, Minot M, Varner JD (2016) ”Reduced order modeling
and analysis of the human complement system” PLoS ONE Submitted
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4.1 Introduction
Complement is an important pathway in innate immunity. It plays a significant role in in-
flammation, host defense as well as many disease processes. Complement was discovered
in the late 1880s where it was found to ’complement’ the bactericidal activity of natural
antibodies [131]. However, research over the past decade has suggested the importance
of complement extends beyond innate immunity. For example, complement contributes
to tissue homeostasis [132]. It has also has been linked with several diseases including
Alzheimers, Parkinson’s, multiple sclerosis, schizophrenia, rheumatoid arthritis and sep-
sis [10, 133]. Complement also plays positive and negative roles in cancer; attacking tu-
mor cells with altered surface proteins in some cases, while potentially contributing to tu-
mor growth in others [134, 135]. Lastly, several other important biochemical systems are
integrated with complement including the coagulation cascade, the autonomous nervous
system and inflammation [135]. Thus, complement is important in a variety of beneficial
and potentially harmful functions in the body. Despite its importance, there have been
few approved complement specific therapeutics, largely because of safety concerns and
challenging pharmacokinetic constraints, however, progress is being made [136].
The complement cascade involves many soluble and cell surface proteins, receptors
and regulators [137, 138]. The outputs of complement are the Membrane Attack Complex
(MAC), and the inflammatory mediator proteins C3a and C5a. The membrane attack
complex, generated during the terminal phase of the response, forms transmembrane
channels which disrupt the membrane integrity of targeted cells, leading to cell lysis and
death. On the other hand, the C3a and C5a proteins act as a bridge between innate and
adaptive immunity, and play an important role in regulating inflammation [134]. Com-
plement activation takes places through three pathways: the classical, the lectin and the
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alternate pathways. The classical pathway is triggered by antibody recognition of foreign
antigens or other pathogens. A multimeric protein complex C1 binds antibody-antigen
complexes and undergoes a conformational change, leading to an activated form with
proteolytic activity. The activated C1-complex cleaves soluble complement proteins C4
and C2 into C4a, C4b, C2a and C2b, respectively. The C4a and C2b fragments bind to
form the C4bC2a protease, also known as the classical pathway C3 convertase (CP C3
convertase). The lectin pathway is initiated through the binding of L-ficolin or Mannose
Binding Lectin (MBL) to carbohydrates on the surfaces of bacterial pathogens. These
complexes, in combination with mannose-associated serine proteases 1 and 2 (MASP-
1/2), also cleave C4 and C2, leading to additional CP C3 convertase. Thus, the classical
and lectin pathways, initiated by different cues on foreign surfaces, converge at the CP C3
convertase. On the other hand, the alternate pathway is activated by a ’tickover’ mecha-
nism in which complement protein C3 is spontaneously hydrolyzed to form an activated
intermediate C3w; C3w recruits factor B and factor D, leading to the formation of C3wBb.
C3wBb cleaves C3 into C3a and C3b, where the C3b fragment further recruits additional
factor B and factor D to form C3bBb, the alternate C3 convertase (AP C3 convertase)
[139]. The role of classical and alternate C3 convertases is varied. First, AP C3 conver-
tases mediate signal amplification. AP C3 convertases cleave C3 into C3a and C3b; the
C3b fragment is then free to form additional alternate C3 convertases, thereby forming
a positive feedback loop. Next, AP/CP C3 convertases link complement initiation with
the terminal phase of the cascade through the formation of C5 convertases. Both classi-
cal and alternate C3 convertases can recruit C3b subunits to form the classical pathway
C5 convertase (C4bC2aC3b, CP C5 convertase), and the alternate pathway C5 convertase
(C3bBbC3b, AP C5 convertase), respectively. Both C5 convertases cleave C5 into the C5a
and C5b fragments. The C5b fragment, along with the complement proteins C6, C7, C8
and multiple C9s, form the membrane attack complex. On the other hand, both C3a and
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C5a are important inflammatory signals involved in several responses [137, 138]. Thus,
the complement cascade attacks invading pathogens, while acting as a beacon for adap-
tive immunity.
The complement cascade is regulated by plasma and host cell surface proteins which
balance host safety with effectiveness. The initiation of the classical pathway via com-
plement protein C1 is controlled by the C1 Inhibitor (C1-Inh); C1-Inh irreversibly binds
to and deactivates the active subunits of C1, preventing chronic complement activation
[140]. Regulation of upstream processes in the lectin and alternate pathways also occurs
through the interaction of the C4 binding protein (C4BP) with C4b, and factor H with
C3b [141]. Interestingly, both factor H and C4BP are capable of binding their respective
targets while in convertase complexes as well. At the host cell surface, membrane co-
factor protein (MCP or CD46) can interact with C4b and C3b, which protects the host
cell from complement self-activation [142]. Delay accelerating factor (DAF or CD55) also
recognizes and dissociates both C3 and C5 convertases on host cell surfaces [143]. More
generally the well known inflammation regulator Carboxypeptidase-N has broad activity
against the complement proteins C3a, C4a, and C5a, rendering them inactive by cleavage
of carboxyl-terminal arginine and lysine residues [144]. Although Carboxypeptidase-N
does not directly influence complement activation, it silences the important inflammatory
signals produced by complement. Lastly, assembly of the MAC complex itself can be in-
hibited by vitronectin and clusterin in the plasma, and CD59 at the host surface [145, 146].
Thus, there are many points of control which influence complement across the three acti-
vation pathways.
Developing quantitative mathematical models of complement could be crucial to fully
understanding its role in the body. Traditionally, complement models have been formu-
lated as systems of linear or non-linear ordinary differential equations (ODEs). For ex-
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ample, Hirayama et al., modeled the classical complement pathway as a system of linear
ODEs [147], while Korotaevskiy and co-workers modeled the classical, lectin and alter-
nate pathways as a system of non-linear ODEs [148]. More recently, large mechanistic
models of sections of complement have also been proposed. For example, Liu et al., an-
alyzed the formation of the classical and lectin C3 convertases, and the regulatory role
of C4BP using a system of 45 non-linear ODEs with 85 parameters [149]. Zewde and
co-workers constructed a detailed mechanistic model of the alternative pathway which
consisted of 107 ODEs and 74 kinetic parameters and delineated between the fluid, host
and pathogen surfaces [146]. However, these previous studies involved large models
with little experimental validation. Thus, while these models are undoubtably impor-
tant theoretical tools, it is unclear if they can describe or quantitatively predict comple-
ment measurements. The central challenge of complement model identification is the
estimation of model parameters from experimental measurements. Unlike other impor-
tant cascades, such as coagulation where there are well developed experimental tools and
publicly available data sets, the data for complement is relatively sparse. Data sets with
missing or incomplete data, and limited dynamic data also make the identification of
large mechanistic complement models difficult. Thus, reduced order approaches which
describe the biology of complement using a limited number of species and parameters
could be important for pharmacokinetic model development, and for our understanding
of the varied role of complement in the body.
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4.2 Results
In this study, we estimated an ensemble of experimentally validated reduced order com-
plement models using multiobjective optimization. The modeling approach combined
ordinary differential equations with logical rules to produce a complement model with a
limited number of equations and parameters. The reduced order model, which described
the lectin and alternative pathways, consisted of 18 differential equations with 28 param-
eters. Thus, the model was an order of magnitude smaller and included more pathways
than comparable models in the literature. We estimated an ensemble of model param-
eters from in vitro time series measurements of the C3a and C5a complement proteins.
Subsequently, we validated the model on unseen C3a and C5a measurements not used
for model training. Despite its size, the model was surprisingly predictive. After valida-
tion, we performed global sensitivity and robustness analysis to estimate which parame-
ters and species controlled model performance. Sensitivity analysis suggested CP C3 and
C5 convertase parameters were critical, while robustness analyses suggested complement
was robust to any single therapeutic intervention; only the knockdown of both C3 and C5
consistently reduced C3a and C5a formation for all cases. Taken together, we developed a
reduced order complement model that was computationally inexpensive, and could eas-
ily be incorporated into pre-existing or new pharmacokinetic models of immune system
function. The model described experimental data, and predicted the need for multiple
points of intervention to disrupt complement activation.
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4.2.1 Reduced order complement network.
The complement model described the alternate and lectin pathways (Fig. 4.1). A trigger
event initiated the lectin pathway (encoded as a logical rule), which activated the cleavage
of C2 and C4 into C2a, C2b, C4a and C4b, respectively. Classical Pathway (CP) C3 conver-
tase (C4aC2b) then catalyzed the cleavage of C3 into C3a and C3b. The alternate pathway
was initiated through the spontaneous hydrolysis of C3 into C3a and C3b. The C3b frag-
ments generated by hydrolysis (or by CP C3 convertase) could then form the alternate
pathway (AP) C3 convertase (C3bBb). We did not consider C3w, nor the formation of
the initial alternate C3 convertase (C3wBb). Rather, we assumed C3w was equivalent to
C3b and only modeled the formation of the main AP C3 convertase. Both the CP and AP
C3 convertases catalyzed the cleavage of C3 into C3a and C3b. A second C3b fragment
could then bind with either the CP or AP C3 convertase to form the CP or AP C5 conver-
tase (C4bC2aC3b or C3bBbC3b). Both C5 convertases catalyzed the cleavage of C5 into
the C5a and C5b fragments. In this study, we simplified the model by assuming both fac-
tor B and factor D were in excess. However, we did explicitly account for the action of two
other control proteins, factor H and C4BP. Lastly, we did not consider MAC formation,
instead we stopped at C5a and C5b. Lectin pathway activation, and C3/C5 convertase
activity were modeled using a combination of saturation kinetics and non-linear transfer
functions, which resulted in a significant size reduction of the model, while maintaining
performance. Binding interactions were modeled using mass-action kinetics, where we
assumed all binding was irreversible. Thus, while the reduced order complement model
encoded significant biology, it was highly compact consisting of only 18 differential equa-
tions and 28 model parameters. Next, we estimated an ensemble of model parameters
from time series measurements of the C3a and C5a complement proteins.
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Figure 4.1: Simplified schematic of the human complement system. The
complement cascade is activated through three pathways: the
classical, the lectin, and the alternate pathways. Complement
initiation results in the formation of classical or alternative C3
convertases, which amplify the initial complement response
and signal to the adaptive immune system by cleaving C3 into
C3a and C3b. C3 convertases further react to form C5 conver-
tases which catalyze the cleavage of the C5 complement pro-
tein to C5a and C5b. C5b is critical to the formation of the
membrane attack complex (MAC), while C5a recruits an adap-
tive immune response.
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4.2.2 Estimating an ensemble of reduced order complement models.
A critical challenge for the development of any dynamic model is the estimation of model
parameters. We estimated an ensemble of complement model parameters using in vitro
time-series data sets generated with and without zymosan, a lectin pathway activator
[4]. The residual between model simulations and experimental measurements was min-
imized using the Pareto Optimal Ensemble Technique (JuPOETs) [150] starting from a
initial guess generated by the dynamic optimization with particle swarms (DOPS) rou-
tine. Unless otherwise specified, all initial conditions were assumed to be at their mean
physiological values. While we had significant training data, the parameter estimation
problem was underdetermined (we were not able to uniquely determine model param-
eters). Thus, instead of using the best-fit yet uncertain parameter set, we estimated an
ensemble of probable parameter sets to quantify model uncertainty (N = 2100, see mate-
rials and methods). The complement model ensemble captured the behavior of both the
alternate and lectin pathways (Fig. 4.2). To estimate alternate pathway model parame-
ters, we used C3a and C5a measurements in the absence of zymosan (Fig. 4.2A and B).
On the other hand, lectin pathway parameters were estimated from C3a and C5a mea-
surements in the presence of 1mg/ml zymosan (Fig. 4.2C and D). The reduced order
model reproduced a panel of alternate and lectin pathway data sets in the neighborhood
of physiological factor and inhibitor concentrations. The model fit for parameter sets esti-
mated by JuPOETs, quantified by the Akaike information criterion (AIC), was statistically
significantly different than a random parameter control for each case at a 95% confidence
level. However, it was unclear whether the reduced order model could predict new data,
without updating the model parameters. To address this question, we fixed the model
parameters and simulated data sets not used for model training.
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Figure 4.2: Reduced order complement model training. An ensemble of
model parameters were estimated using multiobjective opti-
mization from C3a and C5a measurements with and without
zymosan [4]. The model was trained using C3a and C5a data
generated from the alternative pathway (A–B) and lectin path-
way initiated with 1 mg/ml zymosan (C–D). The solid black
lines show the simulated mean value of C3a or C5a for the en-
semble, while the dark shaded region denotes the 99% confi-
dence interval of mean. The light shaded region denotes the
99% confidence interval of the simulated C3a and C5a concen-
tration. All initial conditions were assumed to be at their phys-
iological serum levels unless otherwise noted.
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We tested the predictive power of the reduced order complement model with data
not used during model training (Fig. 4.3). Six validation cases were considered, three
for C3a and C5a each, respectively. Similar to model training, we compared the AIC for
each prediction case to a randomized parameter family. All model parameters and initial
conditions were fixed for the validation simulations (with the exception of zymosan, and
other experimentally mandated changes). The ensemble of reduced order models pre-
dicted the qualitative dynamics of C3a formation (Fig. 4.3, top), and C5a formation (Fig.
4.3, bottom) at three inducer concentrations. For each training case, the AIC was statisti-
cally significantly different than the random parameter control for a 95% confidence level.
The rate of C3a formation and C3a peak time were directly proportional to initiator dose.
Similarly, the C5a plateau and rate of formation were also directly proportional to initia-
tor dose, with the lag time being indirectly proportional to initiator exposure for both C3a
and C5a. However, there were shortcomings with model performance. First, while the
overall C3a trend was captured (within the 99% confidence interval), the C3a dynamics
were too fast with the exception of the low dose case. We believe the C3a time scale was
related to our choice of training data, how we modeled the tickover mechanism, and fac-
tor B and D limitation. We trained the model using either no or 1 mg/ml zymosan, but
predicted cases in a different initiator range; comparing training to prediction, the model
performance e.g., the shape of the C3a trajectory was biased towards either high or very
low initiator doses. Next, tickover was modeled as a first-order generation processes
where C3wBb formation and activity was lumped into the AP C3 convertase. Thus, we
skipped an important upstream step which could influence AP C3 convertase formation
by attenuating the rate C3 cleavage into C3a and C3b. We also assumed both factor B and
factor D were not limiting, thereby artificially accelerating the rate of AP C3 convertase
formation. The C5a predictions followed a similar trend as C3a; we captured the long-
time C5a behavior but over predicted the time scale of C5 cleavage. However, because
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the C5a time scale depends strongly upon C3 convertase formation, we can likely correct
the C5 issues by fixing the rate of C3 cleavage. Despite these shortcomings, we qualita-
tively predicted experimental measurements not used for model training typically within
the 99% confidence of the ensemble, for three inducer levels. Next, we used global sensi-
tivity and robustness analysis to determine which parameters and species controlled the
performance of the complement model.
4.2.3 Global analysis of the reduced order complement model.
We conducted sensitivity analysis to estimate which parameters controlled the perfor-
mance of the reduced order complement model. We calculated the total sensitivity of
the C3a and C5a residual to changes in model parameters with and without zymosan
(Fig. 4.4). In the absence of zymosan (where only the alternative pathway is active),
the most sensitive parameter was the rate constant governing the assembly of the AP C3
convertase, as well as the rate constant controlling basal C3b formation via the tickover
mechanism. The C5a trajectory was sensitive to the AP C5 convertase kinetic parame-
ters (Fig. 4.4A). Interestingly, neither the rate nor the saturation constant governing AP
C3 convertase activity were sensitive in the absence of zymosan. Thus, C3a formation
in the alternative pathway was more heavily influenced by the spontaneous hydrolysis
of C3, rather than AP C3 convertase activity, in the absence of zymosan. In the pres-
ence of zymosan, the C3a residual was controlled by the formation and activity of the
CP C3 convertase, as well as tickover and degradation parameters. On the other hand,
the C5a residual was controlled by the formation and activity of CP C5 convertase, and
tickover C3b formation in the presence of zymosan (Fig. 4.4B). The lectin initiation pa-
rameters were sensitive, but to a lesser extent than CP convertase kinetic parameters and
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Figure 4.3: Reduced order complement model predictions. Simulations
of C3a and C5a generated in the lectin pathway using 0.1
mg/ml, 0.01 mg/ml, and 0.001 mg/ml zymosan were com-
pared with the corresponding experimental measurements.
The solid black lines show the simulated mean value of C3a
or C5a for the ensemble, while the dark shaded region denotes
the 99% confidence interval of mean. The light shaded region
denotes the 99% confidence interval of the simulated C3a and
C5a concentration. All initial conditions were assumed to be at
their physiological serum levels unless otherwise noted.
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tickover C3b formation. Thus, sensitivity analysis suggested that CP C3/C5 convertase
formation and activity dominated in the presence of zymosan, but tickover parameters
and AP C5 convertase were more important without initiator. AP C3 convertase assem-
bly was important, but its activity was not. Next, we compared the sensitivity results to
current therapeutic approaches; pathways involving sensitive parameters have been tar-
geted for clinical intervention (Fig. 4.4C). In particular, the sensitivity analysis suggested
AP/CP C5 convertase inhibitors, or interventions aimed at attenuating C3 or C5 would
most strongly influence complement performance. Thus, there was at least a qualitative
overlap between sensitivity and the potential of biochemical efficacy. However, total sen-
sitivity coefficients quantify how simultaneous changes in many parameters e.g., rate or
saturation constants affect model performance (in this case model fit). To better under-
stand the role of each parameter, and parameter combination, we explored how finite
changes in parameter combinations influenced model performance.
Pairwise parameter perturbations identified crosstalk within the complement model
(Fig. 4.5). We perturbed each pairwise combination of parameters by 10%, and calcu-
lated the distance between the perturbed and nominal state for each parameter set in the
ensemble. We then clustered the mean response of each parameter combination based
upon the euclidian distance between the perturbed and nominal states into low (green),
medium (red) and high (blue) response clusters. A low response (white) meant the pa-
rameter perturbations did not significantly change the system state compared with the
nominal case. Four of the 28 parameters (or approximately 14% of the overall model
parameters) were in the high response cluster (Fig. 4.5, blue cluster). These parameters
included the rate constant controlling the basal formation of C3b (#12), C3a degradation
(#26) as well as the catalytic rate constant governing CP C3 convertase activity (#22). The
only C5 related parameter in the high response group was the rate constant controlling
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model. Sensitivity analysis was conducted on the two objec-
tives used for model training. A: Sensitivity of the C3a and
C5a residual w/o zymosan. B: Sensitivity of the C3a and C5a
residual with 1 mg/ml zymosan. The bars denote the mean
total sensitivity index for each parameter, while the error bars
denote the 95% confidence interval. C: Pathways controlled by
the sensitivity parameters. Bold black lines indicate the path-
way involves one or more sensitive parameters, while the red
lines show current therapeutics targets. Current complement
therapeutics were taken from the review of Morgan and Harris
[5].
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the formation of CP C5 convertase (#15). Approximately, 36%, or 10 of the 28 model
parameters, were clustered in the medium impact cluster (Fig. 4.5, red cluster). Three
parameters (#10, #1, #27) were especially important in this cluster; The reaction order
governing CP C3 convertase activity was important (#10), along with the rate constant
controlling C4a and C4b formation from C4 in the lectin initiation pathway (#1), and the
constant controlling the inhibitory action of C4BP (#27). Lastly, 50% of the model param-
eters were clustered in the low response cluster (Fig. 4.5, green cluster). Many of these
parameters influenced complement activation; for example, parameter #23 (the CP C3
convertase saturation constant) was important, just not to the extent of other model pa-
rameters. Pairwise synergistic interactions between parameters were also identified. For
example, in the high impact cluster, three synergistic relationships were identified, a sin-
gle positive and two negative cases. Parameters #12 (rate constant governing basal C3b
formation) and #15 (formation of CP C5 conevertase) acted synergistically to increase the
system response. On the other hand, simultaneously changing parameters #12 and #22 or
#15 and #26 decreased the system response relative to a single perturbation. However, the
most striking examples of synergy occurred in the medium impact cluster; for example,
simultaneously increasing parameters #13 (rate constant governing AP C3 convertase for-
mation) and #19 (saturation constant governing AP C5 convertase activity) significantly
changed the model state. Changes in parameter #3 (rate constant governing C2a and
C2b formation from C2) showed both positive and negative synergistic effects depending
upon the other parameter that was perturbed. Taken together, [FINISH ME]. However,
sensitivity coefficients quantify how changes in parameters e.g., rate or saturation con-
stants affect model performance. To more closely simulate a clinical intervention e.g.,
administration of anti-complement inhibitors, we performed robustness analysis in the
absence and presence of flow.
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Robustness analysis in the absence of flow suggested there was no single intervention
that inhibited complement activation in the presence of both initiation pathways (Fig.
4.6). Robustness coefficients quantify the response of a protein to a macroscopic struc-
tural or operational perturbation to a biochemical network. Here, we computed how the
C3a and C5a trajectories responded to a decrease in the initial abundance of C3 and/or
C5 with and without lectin initiator. We simulated the addition of different doses of anti-
complement inhibitor cocktails by decreasing the initial concentration of C3, C5 or the
combination of C3 and C5 by 50%, 90% and 99%. This would be conceptually analo-
gous to the administration of a C3 inhibitor e.g., Compstatin alone or combination with
Eculizumab (Fig. 4.4C). The response of the complement model to different knock-down
magnitudes was non-linear; a 90% knock-down had an order of magnitude more impact
than a 50% knock-down. As expected, a C5 knockdown had no effect on C3a formation
for either the alternate (Fig. 4.6A) or lectin pathways (Fig. 4.6B). However, C3a and to a
greater extent C5a abundance decreased with decreasing C3 concentration in the alternate
pathway (Fig. 4.6A). This agreed with the sensitivity results; changes in AP C3-convertase
formation affected the downstream dynamics of C5a formation. Thus, if we only consid-
ered the alternate pathway, C3 alone could be a reasonable target, especially given that
C5a formation was surprisingly robust to C5 levels in the alternate pathway. Yet, when
both pathways were activated, C5a levels were robust to the initial C3 concentration (Fig.
4.6B); even 1% of the nominal C3 was able to generate enough AP/CP C5 convertase to
maintain C5a formation. Thus, the only reliable intervention that consistently reduced
both C3a and C5a formation for all cases was a knockdown of both C3 and C5. For ex-
ample, a 90% decrease of both C3 and C5 reduced the formation of C5a by an order of
magnitude, while C3a was reduced to a lesser extent (Fig. 4.6B).
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Figure 4.5: Pairwise sensitivity and clustering of complement model pa-
rameters in the presence of 1 mg/ml zymosan. The response of
the complement model was calculated for each parameter com-
bination following a 10% increase in parameter combinations
in the presence of 1 mg/ml zymosan. The model parameters
were clustered into high (blue), medium (red) and low (green)
response clusters based upon the euclidian distance between
the perturbed and nominal system state.
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Figure 4.6: Robustness analysis of the complement model. Robustness co-
efficients were calculated for a 50%, 90% and 99% reduction
in C3, C5, or C3 and C5 initial conditions. A: Mean robust-
ness index for C3a and C5a generated from the alternate path-
way (w/o zymosan). B: Mean robustness index for C3a and
C5a generated from the lectin and alternate pathway (1 mg/ml
zymosan). The color describes the degree of reduction of C3a
or C5a following the network perturbation. Robustness coeffi-
cients were calculated using all parameter sets with Pareto rank
less than five (N = 65). Mean robustness values were reported.
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4.3 Discussion
In this study, we estimated an ensemble of experimentally validated reduced order com-
plement models using multiobjective optimization. The modeling approach combined
ordinary differential equations with logical rules to produce a complement model with a
limited number of equations and parameters. The reduced order model, which described
the lectin and alternative pathways, consisted of 18 differential equations with 28 param-
eters. Thus, the model was an order of magnitude smaller and included more pathways
than comparable mathematical models in the literature. We estimated an ensemble of
model parameters from in vitro time series measurements of the C3a and C5a complement
proteins. Subsequently, we validated the model on unseen C3a and C5a measurements
that were not used for model training. Despite its small size, the model was surprisingly
predictive. After validation, we performed global sensitivity and robustness analysis to
estimate which parameters and species controlled model performance. These analyses
suggested complement was robust to any single therapeutic intervention. The only inter-
vention that consistently reduced C3a and C5a formation for all cases was a knockdown
of both C3 and C5. Taken together, we developed a reduced order complement model
that was computationally inexpensive, and could easily be incorporated into pre-existing
or new pharmacokinetic models of immune system function. The model described ex-
perimental data, and predicted the need for multiple points of intervention to disrupt
complement activation.
Despite its importance, there has been a paucity of validated mathematical models of
complement pathway activation. To our knowledge, this study is one of the first comple-
ment models that combined multiple initiation pathways with experimental validation
of important complement products like C5a. However, there have been several theoret-
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ical models of components of the cascade in the literature. Liu and co-workers modeled
the formation of C3a through the classical pathway using 45 non-linear ODEs [149]. In
contrast, in this study we modeled lectin mediated C3a formation using only five ODEs.
Though we did not model all the initiation interactions in detail, especially the cross-talk
between the lectin and classical pathways, we successfully captured C3a dynamics with
respect to different concentrations of lectin initiators. The model also captured the dy-
namics of C3a and C5a formed from the alternate pathway using only seven ODEs. The
reduced order model predictions of C5a were qualitatively similar to the theoretical com-
plement model of Zewde et al., which involved over 100 ODEs [146]. However, we found
that the C3a produced in the alternate pathway was nearly three orders of magnitude
greater than the C5a generated. While this was in agreement with the experimental data
[4], it differed from the theoretical predictions made by Zewde et al., who showed C3a
was eight orders of magnitude greater than the C5a concentration [146]. In our model,
the time profile of both C3a and C5a generated changed with respect to the quantity of
zymosan (the lectin pathway initiator). In particular, the C3a peak time was directly pro-
portional to initiator, while the lag phase for generation was inversely proportional to
the initiator concentration. Korotaevskiy et al. showed a similar trend using a theoretical
model of complement, albeit for much shorter time scales [148]. Thus, the reduced or-
der complement model performed at least as well as existing larger mechanistic models,
despite being significantly smaller.
Global analysis of the complement model suggested potentially important therapeu-
tic targets. Complement malfunctions are implicated in a spectrum of diseases, however
the development of complement specific therapeutics has been challenging [5, 133]. Pre-
viously, we have shown that mathematical modeling and analysis can be useful tools to
estimate therapeutically important mechanisms [44, 63, 151, 152]. In this study, we an-
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alyzed a validated ensemble of reduced order complement models to better understand
the strengths and weaknesses of the cascade. In the presence of an initiator, C3a and
C5a formation was sensitive to CP C3/C5 convertase assembly and activity, and to a
lesser extent lectin initiation parameters. Formation of the CP convertases can be inhib-
ited by targeting upstream protease complexes like MASP-1,2 from the lectin pathway (or
C1r, C1s from classical pathway). For example, Omeros, a protease inhibitor that targets
the MASP-2 complex, has been shown to inhibit the formation of downstream conver-
tases [153]. Lampalizumab and Bikaciomab, which target factor B and factor D respec-
tively, or naturally occurring proteins such as Cobra Venom Factor (CVF), an analogue
of C3b, could also attenuate AP convertase formation [154–156]. Removing supporting
molecules could also destabilize the convertases. For example, Novelmed Therapeutics
developed the antibody, NM9401 against propedin, a small protein that stabilizes alter-
nate C3 convertase [157]. Lastly, convertase catalytic activity could be attenuated using
small molecule protease inhibitors. All of these approaches are consistent with the results
of the sensitivity analysis. On the other hand, robustness analysis suggested C3a and C5a
generation could only be significantly attenuated by modulating the free levels of C3 and
C5. The most commonly used anti-complement drug Eculizumab, targets the C5 protein
[5]. Several other antibodies targeting C5 are also being developed; for example, LFG316
targets C5 in Age-Related Macular Degeneration [158], while Mubodina is used to treat
Atypical Hemolytic-Uremic Syndrome (aHUS) [159]. Other agents such as Coversin [160]
or the aptamer Zimura [161] could also be used to knockdown C5. The peptide inhibitor
Compstatin and its derivatives are promising approaches for the inhibition of C3 [162].
However, while the knockdown of C3 and C5 affect C3a and C5a levels downstream, the
abundance, turnover rate and population variation of these proteins make them difficult
targets [163, 164]. For example, the eculizumab dosage must be significantly adjusted
during the course of treatment for aHUS [165]. A validated complement model, in com-
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bination with personalized pharmacokinetic models of immune system function, could
be an important development for the field.
The performance of the complement model was impressive given its limited size.
However, there are several questions that should be explored further. A logical pro-
gression for this work would be to expand the network to include the classical pathway
and the formation of the membrane attack complex (MAC). However, time course mea-
surements of MAC abundance (and MAC formation dynamics) are scarce, making the
inclusion of MAC challenging. On the other hand, inclusion of classical pathway activa-
tion is straightforward. Liu et al., have shown cross-talk between the activation of the
classical and lectin pathways through C reactive proteins (CRP) and L-ficolin (LF) under
inflammation conditions [149]. Thus, inclusion of these species, in addition to a lumped
activation term for the classical pathway should allow us to capture classical activation.
Next, we should address the C3a time scale issue. We believe the C3a time scale was re-
lated to our choice of training data, how we modeled the tickover mechanism, and factor
B and D limitation. Tickover was modeled as a first-order generation processes where
C3wBb formation and activity was lumped into the AP C3 convertase. Thus, we skipped
an important step which could strongly influence AP C3 convertase formation by slowing
down the rate C3 cleavage into C3a and C3b. The model should be expanded to include
the C3wBb intermediate, where C3wBb catalyzes C3 cleavage at a slow rate compared
to normal AP or CP C3 convertases. We also assumed both factor B and factor D were
not limiting, thereby artificially accelerating the rate of AP C3 convertase formation. This
shortcoming could be addressed by including balances around factor B and D, and in-
cluding these species in the appropriate kinetic rates. The C5a predictions also had an
accelerated time scale. However, because the C5a time scale depended strongly upon C3
convertase formation, we can likely correct the C5 issues by fixing the rate of C3 cleav-
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age. Lastly, we should also consider including the C2-bypass pathway, which was not
included in the model. The C2-bypass mediates lectin pathway activation, without the
involvement of MASP-1/2. Thus, this pathway could be important for understanding
the role of MASP-1/2 inhibitors on complement activation.
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4.4 Materials and Methods
4.4.1 Formulation and solution of the complement model equations.
We used ordinary differential equations (ODEs) to model the time evolution of comple-
ment proteins (xi) in the reduced order model:
1
τi
dxi
dt
=
R∑
j=1
σi jr j (x, ,k) i = 1, 2, . . . ,M (4.1)
where R denotes the number of reactions and M denotes the number of proteins in the
model. The quantity τi denotes a time scale parameter for species i which captures un-
modeled effects. For the current study, τ scaled with the level of initiator (z) for C5a and
C5b; τi = z/z∗ for i = C5a, C5b where z∗ was 1mg/ml, τi = 1 for all other species. The quan-
tity r j (x, ,k) denotes the rate of reaction j. Typically, reaction j is a non-linear function
of biochemical and enzyme species abundance, as well as unknown model parameters k
(K × 1). The quantity σi j denotes the stoichiometric coefficient for species i in reaction j.
If σi j > 0, species i is produced by reaction j. Conversely, if σi j < 0, species i is consumed
by reaction j, while σi j = 0 indicates species i is not connected with reaction j. Species
balances were subject to the initial conditions x (to) = xo.
Rate processes were written as the product of a kinetic term (r¯ j) and a control term (v j)
in the complement model. The kinetic term for the formation of C4a, C4b, C2a and C2b,
lectin pathway activation, and C3 and C5 convertase activity was given by:
r¯ j = kmaxj i
 xηsKηjs + xηs
 (4.2)
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where kmaxj denotes the maximum rate for reaction j, i denotes the abundance of the
enzyme catalyzing reaction j, η denotes a cooperativity parameter, and K js denotes the
saturation constant for species s in reaction j. We used mass action kinetics to model
protein-protein binding interactions within the network:
r¯ j = kmaxj
∏
s∈m−j
x−σs js (4.3)
where kmaxj denotes the maximum rate for reaction j, σs j denotes the stoichiometric coef-
ficient for species s in reaction j, and s ∈ m j denotes the set of reactants for reaction j. We
assumed all binding interactions were irreversible.
The control terms 0 ≤ v j ≤ 1 depended upon the combination of factors which in-
fluenced rate process j. For each rate, we used a rule-based approach to select from
competing control factors. If rate j was influenced by 1, . . . ,m factors, we modeled this
relationship as v j = I j
(
f1 j (·) , . . . , fmj (·)
)
where 0 ≤ fi j (·) ≤ 1 denotes a regulatory transfer
function quantifying the influence of factor i on rate j. The function I j (·) is an integration
rule which maps the output of regulatory transfer functions into a control variable. Each
regulatory transfer function was modeled using a Hill function. In this study, we used
I j ∈ {min,max} [166]. If a process has no modifying factors, v j = 1. The model equations
were implemented in Julia and solved using the CVODE routine of the Sundials package
[167, 168]. The model code and parameter ensemble is freely available under an MIT
software license and can be downloaded from the Varnerlab website [169].
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Complement activation under flow conditions.
We estimated the dynamics of complement activation under flow using a two-
compartment model, with variable compartment volumes. We considered a main com-
partment (m), and a wound compartment (w), where complement was activated in the
wound compartment by the addition of a pathogenic surface. In the main compartment,
the balance for species i (xm,i) was given by:
Vm
τi
dxm,i
dt
=
 R∑
j=1
σi jr j (xm, ,k)
Vm − km,w,ixm,i + kw,m,ixw,i −Cxm,i (4.4)
where Vm denotes the volume of the main compartment, kp,q,i denotes transfer constant
governing the transfer of species i from compartment p to compartment q, and C de-
notes the clearance constant from the main compartment. We assumed complement fac-
tors were synthesized in the main compartment. The balance governing species i in the
wound compartment was given by:
Vw
τi
dxw,i
dt
=
 R∑
j=1
σi jr j (xw, ,k)
Vw − kw,m,ixw,i + km,w,ixm,i − Bxw,i (4.5)
where Vw denotes the volume of the wound compartment, and B denotes the rate of blood
loss from the wound compartment. Lastly, because of the volume loss through clearance
in the main compartment, and bleeding from the wound compartment, the volumes of
each compartment were dynamic modeled:
dVm
dt
= Im + Fw,m − Fm,w −C (4.6)
dVw
dt
= Iw + Fm,w − Fw,m − B (4.7)
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where Im, Iw denote the rate of liquid input into the main and wound compartment.
4.4.2 Estimating complement model parameters.
We estimated a single initial parameter set using the Dynamic Optimization with Parti-
cle Swarms (DOPS) technique [170]. DOPS is a novel hybrid meta-heuristic which com-
bines a multi-swarm particle swarm method with the dynamically dimensioned search
approach of Shoemaker and colleagues [171]. DOPS minimized the squared residual be-
tween simulated and C3a and C5a measurements with and without zymosan as a single
objective. The best fit set estimated by DOPS served as the starting point for multiob-
jective ensemble generation using Pareto Optimal Ensemble Technique in the Julia pro-
gramming language (JuPOETs) [150]. JuPOETs is a multiobjective approach which in-
tegrates simulated annealing with Pareto optimality to estimate model ensembles on or
near the optimal tradeoff surface between competing training objectives. JuPOETs mini-
mized training objectives of the form:
O j(k) =
T j∑
i=1
(
Mˆi j − yˆi j(k)
)2
+
M′i j −max yi jM′i j
2 (4.8)
subject to the model equations, initial conditions and parameter bounds L ≤ k ≤ U. The
first term in the objective function measured the shape difference between the simulations
and measurements. The symbol Mˆi j denotes a scaled experimental observation (from
training set j) while the symbol yˆi j denotes the scaled simulation output (from training
set j). The quantity i denotes the sampled time-index and T j denotes the number of time
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points for experiment j. The scaled measurement is given by:
Mˆi j = Mi j −miniMi jmaxiMi j −miniMi j (4.9)
Under this scaling, the lowest measured concentration become zero while the highest
equaled one, where a similar scaling was defined for the simulation output. The second-
term in the objective function quantified the absolute error in the estimated concentration
scale, where the absolute measured concentration (denoted byM′i j) was compared with
the largest simulated value. In this study, we minimized two training objectives, the
total C3a and C5a residual w/o zymosan (O1) and the total C3a and C5a residual for 1
mg/ml zymosan (O2). JuPOETs identified an ensemble of N = 2100 parameter sets which
were used for model simulations and uncertainty quantification subsequently. JuPOETs
is open source, available under an MIT software license. The JuPOETs source code is
freely available from the JuPOETs GitHub repository [172]. The objective functions used
in this study are available in the GitHub model repository [169].
The simulation and prediction performance of the complement model was measured
using the Akaike information criterion (AIC) [173]. In this study, we implemented the
AIC as:
AIC = 2Np + Nm ln
 1M∑
τ
(xτ − yτ)2
 (4.10)
where Np,Nm denotes the number of parameters, and the number of experimental mea-
surements, respectively. The summation term in Eq. (5.12) denotes the residual between
the model simulation (x) and experimental measurements (y), where the residual is nor-
malized by the scale of the experimental data (M). We compared the AIC for the model
parameters estimated in this study, with a random parameter control generated to have a
similar order of magnitude. The mean and standard deviation of the AIC was calculated
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over the parameter ensemble and the random parameter control were reported in this
study.
Pairwise sensitivity analysis and clustering.
We perturbed each pair of model parameters by 10% of their nominal value, and then
calculated the euclidian distance between the perturbed and nominal system states for
physiological conditions. We repeated this calculation for each member of the param-
eter ensemble, and calculated the mean differences between the perturbed and nomi-
nal states. We then clustered the resulting log10 transformed mean distances using the
Clustergram routine in MATLAB (The Mathworks, Natick MA). We considered three
clusters, high, medium and low displacement.
Robustness analysis.
Robustness coefficients quantify the response of a marker to a structural or operational
perturbation to the network architecture. Robustness coefficients were calculated as
shown previously [26]. Log-transformed robustness coefficients denoted by αˆ
(
i, j, to, t f
)
were defined as:
αˆ
(
i, j, to, t f
)
= log10
(∫ t f
to
xi (t) dt
)−1 (∫ t f
to
x( j)i (t) dt
) (4.11)
Here, to and t f denote the initial and final simulation time, while i and j denote the indices
for the marker and the perturbation, respectively. A value of αˆ
(
i, j, to, t f
)
> 0, indicates in-
creased marker abundance, while αˆ
(
i, j, to, t f
)
< 0 indicates decreased marker abundance
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following perturbation j. If αˆ
(
i, j, to, t f
)
∼ 0, perturbation j did not influence the abun-
dance of marker i. In this study, we perturbed the initial condition of C3 or C5 or a combi-
nation of C3 and C5 by 50%, 90% and 99% and measured the area under the curve (AUC)
of C3a or C5a with and without lectin initiator. We computed the robustness coefficients
for a subset of the parameter ensemble (N = 65) and reported the mean robustness value.
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CHAPTER 5
EFFECTIVE MODELING OF THE HUMAN COAGULATION AND FIBRINOLYTIC
PATHWAYS
5.1 Introduction
Trauma 1 is the leading cause of death and disability, surpassing all other causes com-
bined, for persons 36 years old and younger [174], accounting for 30% of the years of life
lost in the United States at an economic burden of $671 billion a year, in health care costs
and lost productivity [175]. Hemorrhage accounts for 40% of all trauma deaths, where the
control of bleeding is especially challenging in the presence of blood coagulation disor-
ders, collectively known as coagulopathy [176]. However, adverse outcomes associated
with coagulopathy are not limited to death from acute blood loss. Organ dysfunction,
multiple organ failure and increased susceptibility to sepsis [177] are all potential con-
sequences of prolonged shock resulting from coagulopathy [178]. Following a wound,
the immediate response of the body is to activate the coagulation cascade, which in turn
generates a clot through the fibrinolysis network.
The coagulation cascade, which is activated following a wound, is mediated by a
family proteases in the circulation, called factors and a key group of blood cells, called
platelets. The central process in coagulation is the conversion of prothrombin (fII), an in-
active coagulation factor, to the master protease thrombin (FIIa). Thrombin generation in-
volves three phases, initiation, amplification and termination [34, 35]. Initiation requires a
trigger event, for example vessel injury, which leads to the activation of factor VII (FVIIa).
1Adapted with permission from Sagar A, LeCover R, Brummel-Ziedins KE, Orfeo T, Varner JD et al.
(2017) ”Dynamic Modeling of Fibrinolysis using Reduced Order Effective Kinetic Models” In preparation
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Two converging pathways, the extrinsic and intrinsic cascades, then process and amplify
this initial coagulation signal. The extrinsic cascade is generally believed to be the main
mechanism of thrombinogenesis in the blood [36–38]. Initially, thrombin is produced
upon cleavage of prothrombin by fluid phase activated factor X (FXa), which itself has
been activated by TF/FVIIa [31]. Picomolar amounts of thrombin then activate the cofac-
tors factors V and VIII (fV and fVIII) and platelets, leading to the formation of the tenase
and prothrombinase complexes on activated platelets. These complexes amplify the early
coagulation signal by further activating FXa, and directly converting prothrombin to
thrombin. There are several control points in the cascade that inhibit thrombin formation,
and eventually terminate thrombin generation. Tissue Factor Pathway Inhibitor (TFPI)
inhibits FXa formation catalyzed by TF/FVIIa, while antithrombin III (ATIII) neutralizes
several of the proteases generated during coagulation, including thrombin. Thrombin it-
self also inadvertently plays a role in its own inhibition; thrombin, through interaction
with thrombomodulin, protein C and endothelial cell protein C receptor (EPCR), con-
verts protein C to activated protein C (APC) which attenuates the coagulation response
by proteolytic cleavage of fV/FVa and fVIII/FVIIIa. Termination occurs after either pro-
thrombin is consumed, or thrombin formation is neutralized by inhibitors such as APC
or ATIII. Activated thrombin plays a dual role in blood clot formation. First, it catalyzes
the cleavage of fibrinogen to fibrin, a key component of a blood clot, thereby promot-
ing clot formation. Activated thrombin also activates thrombin-activatable fibrinolysis
inhibitor (TAFI), which inhibits the activity of plasmin, an important enzyme present in
blood that degrades many blood plasma proteins, including fibrin clots. Counter balanc-
ing the role of activated thrombin is tissue plasminogen activator (tPA), which activates
plasmin, thereby promoting the break down of blood clots. Thus, a delicate balance exists
between activated thrombin and tPA that controls the rate of clot formation. Too much
activated thrombin leads to hypo-fibrinolysis (excessive clot formation resulting in stroke
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or heart attack risk), while too little or excess tPA leads to hyper-fibrinolysis (inadequate
clot formation resulting in increased, sometimes catastrophic bleeding). There are excel-
lent reviews of both coagulation and fibrinolysis, see [67, 179].
We have worked to understand the coagulation cascade, using both mechanistic mod-
els e.g., [44, 180], and more recently reduced order modeling approaches [166]. Longstaff
and Thelwell proposed a very simple model for fibrinolysis, in which the process was rep-
resented as two steps, with plasminogen being converted to plasmin by tPA, and fibrin
degraded by plasmin [181]. While computationally easy to evauluate, this model greatly
oversimplifies the process, and completely neglects the role of PAI-1. Fibrinolysis has
been previous modeled in great detail through a 3D stochastic mutltiscale model which
predicted difference in lysis speeds based on clot morphology, but this model focuses
only clot lysis rather than formation and degredation [182]. Reifman et al modeled fibrin
generation with mass action kinetics using 80 ODEs to investigate the effacy of differ-
ent prothombin complex concentrates [79]. They used an interesting method to model
the complex kinetics of TAFI inhibiting fibrinolysis: they emperically fit a curve to the
clot lysis time as a function of TAFI concentration, and then correspondingly reduced the
tPA effective concentration to account for the effects of TAFI. While this model decently
predicted the final fibrin levels, it did a poor job of capturing the shape of the fibrin gen-
eration curves.
In this study, we developed a reduced order of model of coagulation and fibrinoly-
sis. We created a function to transform the biochemical species concentrations predicted
by the model into a ROTEM signal. We trained the model on ROTEM curves at various
concentrations of tPA, and then successfully predicted previously unseen data. We used
a variance based method to identify the most sensitive parameters. We then clustered
the parameters using a hierarichal clustering method to determine the interactions be-
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tween parameters. We found that our reduced order model was successful in predicting
ROTEM curves. We believe that this is the first study to connect a kinetic model with
ROTEM curves, a key development, as ROTEM is playing an increasingly large role both
in surgery and in assessing the coagulation state of a patient. Future refinements include
adding platelets to the model as activated platelets greatly influence the activation rates
of prothrombin and FX [183].
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Figure 5.1: Schematic of the fibrinolysis model.
5.2 Results
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Figure 5.2: Fibrinolysis and coagulation model training and prediction.
5.2.1 Sensitivity analysis.
We calculated total order sensitivity coefficients by the method of Sobol with respect to
the area under the ROTEM curve to understand which parameter changes would have
the most dramatic effect on model output (5.3). We found that among the kinetic param-
eters, the rate constants for fibrin and protofibril association had a large effect, as well as
the rate constant for plasmin/anti-plasmin association. The turnover number for tPA was
the most sensitive parameter, and the turnover number for plasmin also was found to be
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sensitive. The majority of the control parameters were found to be fairly non-sensitive,
with the exception of the parameters controlling TAFI. When we considered initial condi-
tions, we found that the model was much more sensitive to the starting concentration of
tPA than the initial concentrations of plasminogen or TAFI. We recalculated the total or-
der sensitivity coefficients for a patient experiencing severe hemodilution and found that
the model was still highly sensitive to changes in the initial concentration of tPA, but had
decreased slightly in sensitivity to the concentration of plasminogen. In this hemodiluted
case, the sensitivities of the kinetic parameters remained nearly unaltered, but sensitivity
of the TAFI control parameters decreased. While the method of Sobol was useful in ex-
plaining changes in the area under of the curve, we also sought to examine the changes
to the shape of the ROTEM curve.
We used the method of Morris, combined with functional principle component anal-
ysis to examine how changes in parameter values altered the ROTEM curve (5.4). This
method found that the control parameters related to thrombin generation and inhibition,
as well as the rate constant for antithrombin inhibiting activation of thrombin to have
large effects on the curve shape, as signified by large values of the estimate of the mean
of the distribution of the absolute values of the elementary effects. The estimate of these
parameters’ elementary effects had large standard deviations, indicating that they effect
the model output in a non-linear way. All of these parameters determine the amount of
thrombin available, so it is logical that changes in their values would dramatically alter
the ROTEM curve. While the turnover number was found to be very sensitive by the
method of Sobol in changing the area under the ROTEM curve, the method of Morris
found it to only have a moderate effect on the shape of the ROTEM curve. While both
of these techniques informed us about how single parameter changes affected the model
output, we wished to investigate interactions between multiple parameters, as it is very
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Figure 5.3: Global sensitivity analysis of the fibrinolysis model.
rare in biological systems for only one element to change while the rest are held perfectly
constant.
We used hierarchical clustering to examine the effects of pairwise perturbing the
model parameters (5.5). This resulted in three clusters of parameters, each shown in a
different color with parameters which had the largest impact on the ROTEM curve in
green, moderate impact in blue, and small impact in red. The parameters in the cluster
with the largest impact are all parameters related to clot formation and dissolution, with
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Figure 5.4: Morris analysis of fibrinolysis model response.
the exception of the rate constant for ATIII inhibiting thrombin. Changes in these param-
eters in combination with nearly any other parameter in the model resulted in significant
changes in the ROTEM curve, suggesting that they may be robust therapeutic targets.
The moderate impact cluster includes rate constants for plasminogen activation as well
as clot formation, thrombin formation, and initiation. There is one interaction of interest
in this cluster: a proportionate increase in the rate constant for amplification cancels out
a change in the control parameters for TFPI. This perhaps arises because both parameters
have opposing effects on thrombin generation. The cluster containing parameters with
the smallest impact contains a larger number of control parameters, as well as the rate
constants for the interactions between uPA and plasminogen. Among all the control pa-
rameters used in the model, only three were found to have a moderate or high impact:
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those controlling either FXIII or TAFI. We then wished to observe the effects of the initial
conditions on the model output.
We again used hierarchical clustering to observe the results of pairwise altering the
model initial conditions (5.6). We found that doubling the initial concentration of tPA, in
combination with increasing any other initial condition, resulted in a large change in the
predicted ROTEM curve. Plasminogen and TAFI, which both had moderately sized to-
tal order sensitivity coefficients, as estimated by the method of Sobol, both had different
effects, which combined with other changes in initial conditions. The initial amount of
fibrinogen present also played a significant role in the model’s output, especially when
changes in the amount of fibrinogen were combined with a change in tPA levels. How-
ever, altering the concentration of many of the enzymes involved in the coagulation cas-
cade (FV, FVIII, FX, FIX) did not result in large changes, unless paired with a change in
another species which had a powerful effect on its own, such as tPA or fibrinogen.
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Figure 5.5: Clustergram analysis of fibrinolysis model response to changes
in model parameters.
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Figure 5.6: Clustergram analysis of fibrinolysis model response to changes
in initial conditions.
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5.3 Discussion
In this study, we constructed a reduced order model of fibrinolysis, which considered the
dynamics of thrombin activation. We then created a function to transform the concentra-
tions into ROTEM curves, and estimated kinetic and control parameters for the models
using a Pareto Optimal Ensemble Technique. We then validated the model by measuring
its performance on datasets that were not used in the parameter estimation. We then per-
formed sensitivity analysis to observe which targets in the system could potentially be
therapeutic targets.
Both the total order sensitivity constants and the hierarchical clustering identify tPA’s
kcat as sensitive, even under dilution conditions. Therefore, it could potentially serve as
a therapeutic target. Additionally, the initial condition of tPA was very sensitive in both
cases, suggesting that if a drug could render tPA inactive or increase its concentration, clot
breakdown times could be significantly altered. The drug Alteplase (Cathflow Activase)
does exactly that, given that it consists of recombinant version of tPA [184]. The method
of Morris found that the rate constant of ATIII inhibiting thrombin to have a large effect
on model output, which is consistent with heparin causing a conformation change in
ATIII and altering its catalytic properties so that the reaction between it and thrombin
goes much faster [185].
In the present model, the formation of a clot is represented by the formation of fiber,
which is formed by protofibrils. The polymerization of protofibrils into oligomers, and
the growth of the oligomers into a clot could potentially be included to further refine the
model. Furthermore, the rate at which plasmin breaks down a clot is a function of the
clot’s structure [186]. Future work could include generating different types of fibers, with
differing kinetic properties with respect to plasmin. Additionally, the role of platelets was
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completely neglected in the clot formation process. It is challenging to include platelets in
a kinetic model, as their concentration is many orders of magnitude smaller than the pro-
teins involved in coagulation and fibrinolysis (femtomolar vs nanomolar), so instead of
directly modeling the kinetics of activation, we can perhaps model the fraction of platelets
activated, and use that to modify the control terms.
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5.4 Materials and Methods
5.4.1 Materials.
Full-length (residues 1-263) recombinant tissue factor (Tf) was purchased from Haema-
tologic Technologies (Essex Junction VT, USA). 1,2-Dioleolyl-sn-Glycero-3-Phospho-L-
Serine (PS) and 1,2-Dioleoyl-sn-Glycero-3-Phosphocholine (PC) were purchased from
Avanti Polar Lipids, Inc. (Alabaster AL, USA). Preparations of phospholipid vesicles
(PCPS) composed of 75% PC and 25% PS were made as described [187] as was the
TF/PCPS reagent [188]. Corn trypsin inhibitor (CTI) was purified in-house [188] as was
D-Phe-Pro-Arg-CH2Cl (FPR-ck) [189]. Tissue plasminogen activator (t-PA) (two chain)
was purchased from Molecular Innovations, Inc., MI, USA). α2-antiplasmin was pur-
chased from Enzyme Research Labs Inc. (IN, USA) and plasmin from Haematologic
Technologies Inc. (Essex Junction VT,USA). Aprotinin was purchased from Sekisui Di-
agnostics (Stamford CT, USA). Units of transfusion plasma were obtained from the Uni-
versity of Vermont Medical Center Blood Bank Plasma from each unit was distributed
into aliquots and immediately frozen at -80oC until used.
5.4.2 Assays.
Assays assessing the functional level of fibrinogen were performed by the University of
Vermont Medical Center Clinical Laboratory. ELISA methods were used to assess pro-
tein antigen levels: plasminogen (PG-EIA, Affinity Biologicals ON, Canada); thrombin
activatable fibrinolysis inhibitor (TAFI) (Zymutest (TAFI) Total Ag, Hyphen Biomedical,
Nevville sur Olse, FR); plasminogen activator inhibitor 1 (PAI-1) (R&D Systems Inc., MN,
115
USA). α-thrombin-antithrombin complex (α-TAT) levels were determined via in house
ELISA as described previously [190]. Plasmin-antiplasmin (PAP) complex levels were de-
termined using the Imunoclone PAP ELISA (Sekisui Diagnostics CT, USA) with the fol-
lowing modification. A stock of 6 µM PAP complex was generated in house by reacting 9
µM α2 antiplasmin (Enzyme Research Labs Inc., IN, USA) with 6 µM plasmin (Haemato-
logic Technologies Inc., VT,USA). Quantitative formation of PAP was confirmed via SDS-
PAGE analysis. This stock was used in place of the kit calibrator to generate a standard
curve.
5.4.3 Viscoelastometry.
Citrate plasmas were recalcified (15 mM CaCl2 final, volume change of 1.5%) for 3 min at
37oC. The tissue factor reagent (20 µL, 5 pM final) and t-PA (20 µL, 2 nM, 4 nM or 8 nM
final) or 20 µL buffer (no t-PA control) were prealiquoted as separate drops into 8 ROTEM
cups. Each reaction was run in duplicate. 300 µL of recalcified plasma was then added
to each cup and data collection initiated. The contents of ROTEM cups were collected as
described previously [190, 191].
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5.4.4 Fibrinolysis model equations.
We used ordinary differential equations (ODEs) to model the time evolution of fibrinoly-
sis and coagulation proteins (xi) in the reduced order model:
dxi
dt
=
R∑
j=1
σi jr j (x, ,k) i = 1, 2, . . . ,M (5.1)
A(x) = Ao +A1(x)
[ F (x)2
K(x)2 + F (x)2
]
(5.2)
whereR denotes the number of reactions,M denotes the number of proteins in the model,
xi denotes the concentration of species i, andA denotes the output function which trans-
forms biochemical model species into a ROTEM signal. The quantity r j (x, ,k) denotes
the rate of reaction j. Typically, reaction j is a non-linear function of biochemical (x) and
enzyme () species abundance, as well as unknown model parameters k (K × 1). The
quantity σi j denotes the stoichiometric coefficient for species i in reaction j. If σi j > 0,
species i is produced by reaction j. Conversely, if σi j < 0, species i is consumed by reac-
tion j, while σi j = 0 indicates species i is not connected with reaction j. Species balances
were subject to the initial conditions x (to) = xo.
Rate processes were written as the product of a kinetic term (r¯ j) and a control term
(v j). Enzyme catalyzed rates were modeled using multiple saturation kinetics:
r¯ j = kmaxj i
∏
s∈m−j
(
xs
K js + xs
)
(5.3)
where kmaxj denotes the maximum rate for reaction j, i denotes the abundance of the
enzyme catalyzing reaction j, K js denotes the saturation constant for species s in reaction
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j, and s ∈ m−j . We used mass action kinetics to model protein-protein binding interactions
within the network:
r¯ j = kmaxj
∏
s∈m−j
x−σs js (5.4)
where kmaxj denotes the maximum rate for reaction j, σs j denotes the stoichiometric coef-
ficient for species s in reaction j, and s ∈ m j denotes the set of reactants for reaction j. We
assumed all binding interactions were irreversible.
The control terms 0 ≤ v j ≤ 1 depended upon the combination of factors which in-
fluenced rate process j. For each rate, we used a rule-based approach to select from
competing control factors. If rate j was influenced by 1, . . . ,m factors, we modeled this
relationship as v j = I j
(
f1 j (·) , . . . , fmj (·)
)
where 0 ≤ fi j (·) ≤ 1 denotes a regulatory transfer
function quantifying the influence of factor i on rate j. The function I j (·) is an integration
rule which maps the output of regulatory transfer functions into a control variable. In
this study, we used I j ∈ {min,max} and hill-like transfer functions [166]. If a rate process
had no modifying factors, v j = 1.
The output functionA(x) transforms the biochemical species abundance predicted by
the model into a ROTEM signal. Modeling the connection between blood rheology and
the local fibrin concentration is complex and beyond the scope of this study. Instead,
we developed an empirical model which consisted of a scale function, which captured
the amplitude of the ROTEM signal, and a shape function which captured the signal
shape. The quantity Ao denotes the baseline ROTEM measurement which we assumed
was constant across plasma samples (Ao ' 1.5). On the other hand, the shape function:
0 ≤ F (x)
2
K(x)2 + F (x)2 ≤ 1 (5.5)
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was modified by a scale function. The quantity F (x) denotes the unweighted sum of
fibrin species in the model, while the saturation function K(x) was given by:
K(tPA) = 5000 − 375 × (tPA) (5.6)
The scale functionA1(x) was given by:
A1(x) =

t ≤ td 0
t > td S × [1 − exp(−τ (t − td))] (5.7)
where
τ = 0.0035 ×
[
1 − FIIa
max(FII)
]
(5.8)
The material model delay parameter, td = N (µd, σd), was identified from the training data.
The scale parameter S, modeled as a linear function of tPA abundance, was defined as:
S(tPA) = N (µ1, σ1) − N (µ2, σ2) × (tPA) (5.9)
where the intercept and slope distributions were modeled as Gaussian distributions,
where the mean and standard deviation for each distribution (µi, σi) were estimated di-
rectly from the training data. The model and output equations were implemented in the
Julia programming language and solved using the ODE23s routine of the ODE package
[167]. The model code and parameter ensemble is freely available under an MIT software
license and can be downloaded from http://www.varnerlab.org.
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5.4.5 Estimating fibrinolysis model parameters.
We estimated an ensemble of model parameters using Pareto Optimal Ensemble Tech-
nique in the Julia programming language (JuPOETs) [150]. JuPOETs is a multiobjective
approach which integrates simulated annealing with Pareto optimality to estimate model
ensembles on or near the optimal tradeoff surface between competing training objectives.
JuPOETs minimized training objectives of the form:
O j(k) =
T j∑
i=1
(
Mˆi j − yˆi j(k)
)2
+
M′i j −max yi jM′i j
2 (5.10)
subject to the model equations, initial conditions and parameter bounds L ≤ k ≤ U. The
first term in the objective function measured the shape difference between the simulations
and measurements. The symbol Mˆi j denotes a scaled experimental observation (from
training set j) while the symbol yˆi j denotes the scaled simulation output (from training
set j). The quantity i denotes the sampled time-index and T j denotes the number of time
points for experiment j. The scaled measurement is given by:
Mˆi j = Mi j −miniMi jmaxiMi j −miniMi j (5.11)
Under this scaling, the lowest measured concentration become zero while the highest
equaled one, where a similar scaling was defined for the simulation output. The second-
term in the objective function quantified the absolute error in the estimated concentration
scale, where the absolute measured concentration (denoted byM′i j) was compared with
the largest simulated value. In this study, we minimized three training objectives, the
total error estimated for tPA = 0, 2, 4, 8 nM for three plasmas from our plasma data set.
JuPOETs identified an ensemble of N ' 2500 parameter sets which were used for model
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simulations and uncertainty quantification subsequently. JuPOETs is open source, avail-
able under an MIT software license. The JuPOETs source code is freely available from
the JuPOETs GitHub repository at https://github.com/varnerlab/POETs.jl. The objec-
tive functions used in this study are available in the GitHub model repository available
from http://varnerlab.org.
The simulation and prediction performance of the fibrinolysis model was measured
using the Akaike information criterion (AIC) [173]. In this study, we implemented the
AIC as:
AIC = 2Np + Nm ln
 1M∑
τ
(xτ − yτ)2
 (5.12)
where Np,Nm denotes the number of parameters, and the number of experimental mea-
surements, respectively. The summation term in Eq. (5.12) denotes the residual between
the model simulation (x) and experimental measurements (y), where the residual is nor-
malized by the scale of the experimental data (M). We compared the AIC for the model
parameters estimated in this study, with a random parameter control generated to have a
similar order of magnitude. The mean and standard deviation of the AIC was calculated
over the parameter ensemble reported in this study.
5.4.6 Sensitivity analysis.
We conducted global sensitivity analysis to estimate which parameters controlled the per-
formance of the reduced order model. We computed the total variance-based sensitivity
index of each parameter relative to the training residual for the C3a/C5a alternate and
C3a/C5a lectin objectives using the Sobol method [85]. sThe sampling bounds for each
parameter were established from the minimum and maximum value for that parameter
121
in the parameter ensemble. We used the sampling method of Saltelli et al. to compute
a family of N (2d + 2) parameter sets which obeyed our parameter ranges, where N was
the number of trials per parameters, and d was the number of parameters in the model
[192]. In our case, N = 400 and d = 28, so the total sensitivity indices were computed using
23,200 model evaluations. The variance-based sensitivity analysis was conducted using
the SALib module encoded in the Python programming language [87].
5.4.7 Morris Sensitivity Analysis
We performed global sensitivity analysis to determine which parameters controlled the
shape of the ROTEM curve output by the model. We generated parameters using the
Morris method, with the parameters bounded by the minimum and maximum values
they took in the rank one parameter sets generated by JuPOETS [193]. A total of N (p + 1)
parameter sets were generated, with N = 1000 and p = 47 in our case, for a total of 48,000
model evaluations.We ran the model with the generated parameter sets, and then trans-
formed the ROTEM curves using fPCA (functional principle component analysis), as im-
plemented by the R package fdapace, to extract the principle component scores. This
technique allowed us to remove the time dimension and to observe how the changes in
parameters effected the shape of the ROTEM curve [194]. We then used the principle
component scores to calculate µ∗, the absolute value of the mean of the elementary effect,
and σ, the variance of the elementary effect. We opted to use the absolute values of the
means of the elementary effects so that effects with opposite signs would not cancel each
other out and artificially decrease the estimate of the mean of the elementary effect [195].
We then scaled µ∗ and σ so that the smallest value became zero and the largest value
became one, using the same scaling as used for the scaled experimental measurements.
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This method sensitivity analysis was conducted using the SALib module encoded in the
Python programming language [87]. We then used k-means clustering to group the pa-
rameters into four clusters, and colored the graph by cluster color. We used four clusters
as it resulted in the best average silhouette score [196].
5.4.8 Clustering.
We perturbed each pair of model parameters to five times their nominal value, and
then calculated the euclidean distance between the perturbed and nominal curves for
physiological conditions. We clustered the log10 transformed distances using the
Clustergram routine in Matlab (The Mathworks, Natick MA). For the initial conditions,
we perturbed them to one half and two times their nominal values in a pair wise fashion.
We clustered the log10 distances with a linear shift to make all of the values positive.
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CHAPTER 6
DYNAMIC OPTIMIZATION WITH PARTICLE SWARMS (DOPS): A META-
HEURISTIC FOR PARAMETER ESTIMATION IN BIOCHEMICAL MODELS
Abstract
Mathematical modeling is a powerful tool to analyze, and design biochemical networks.
However, the estimation of biochemical model parameters is a significant challenge. Pa-
rameter estimation typically involves expensive function evaluations and noisy data,
making it difficult to quickly obtain optimal solutions. Biochemical models often also
have many local extrema which further complicates parameter estimation. Toward these
challenges, we developed Dynamic Optimization with Particle Swarms (DOPS), a novel
hybrid meta-heuristic that combined multi-swarm particle swarm optimization with dy-
namically dimensioned search (DDS) 1. DOPS uses a multi-swarm particle swarm opti-
mization technique to generate candidate solution vectors, the best of which is greedily
updated using dynamically dimensioned search. We tested DOPS using a combination of
classic optimization test functions, biochemical benchmark problems and real-world bio-
chemical models. We performedT = 25 trials withN = 4000 function evaluations per trial,
and compared the performance of DOPS with other commonly used meta-heuristics such
as differential evolution (DE), simulated annealing (SA) and dynamically dimensioned
search (DDS). On average, DOPS outperformed other common meta-heuristics on the
optimization test functions, benchmark problems and a model of the human coagulation
cascade. Taken together, DOPS is a promising meta-heuristic approach for the estimation
1Adapted with permission from Sagar A, Shoemaker CA, Varner J (2016) ”Dynamic Optimization with
Particle Swarms (DOPS): A meta- heuristic for parameter estimation in biochemical models” Biotechnol J
In review
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of biochemical model parameters in relatively few function evaluations. DOPS source
code is available for download under a MIT license at http://www.varnerlab.org.
6.1 Introduction
Cells process nutrients and respond to changes in their environment using complex en-
zyme catalyzed biochemical networks. Mathematical modeling has evolved as a power-
ful paradigm to analyze, and ultimately design these complex networks [197–201]. Math-
ematical modeling of biochemical networks is often an iterative process. First, models
are formulated from existing biochemical knowledge, and then model parameters are es-
timated using experimental data [202–204]. Parameter estimation is typically framed as
a non-linear optimization problem wherein the residual (or objective function) between
experimental measurements and model simulations is minimized using an optimization
strategy [205]. Optimal parameter estimates are then used to predict unseen experimen-
tal data. If the validation studies fail, model construction and calibration are repeated
iteratively until satisfactory results are obtained. As our biological knowledge increases,
model formulation may not be as significant a challenge, but parameter estimation will
likely remain difficult.
Parameter estimation is a major challenge to the development of biochemical models.
Parameter estimation has been a well studied engineering problem for decades [206–209].
However, the complex dynamics of large biological systems and noisy, often incomplete
experimental data sets pose a unique estimation challenge. Often optimization problems
involving biological systems are non-linear and multi-modal i.e., typical models have
multiple local minima or maxima [203, 205]. Non-linearity coupled with multi-modality
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renders local optimization techniques such as pattern search [210], Nelder-Mead simplex
methods [211], steepest descent or Levenberg-Marquardt [212] incapable of reliably ob-
taining globally optimal solutions as these methods often terminate at local minimum.
Though deterministic global optimization techniques (for example algorithms based on
branch and bound) can handle non-linearity and multi-modality [213, 214], the absence
of derivative information, discontinuous objective functions, non-smooth regions or the
lack of knowledge about the objective function hampers these techniques.
Meta-heuristics like Genetic Algorithms (GAs) [215], Simulated Annealing (SA) [216],
Evolutionary Programming [217] and Differential Evolution (DE) [218–221] have all
shown promise on non-linear multi-modal problems [222]. These techniques do not make
any assumptions, nor do they require, a priori information about the structure of the ob-
jective function. Meta-heuristics are often very effective at finding globally optimal or
near optimal solutions. For example, Mendes et al. used SA to estimate rate constants
for the inhibition of HIV proteinase [223], while Modchang et al. used a GA to estimate
parameters for a model of G-protein-coupled receptor (GPCR) activity [224]. Parameter
estimates obtained using the GA stratified the effectiveness of two G-protein agonists, N6-
cyclopentyladenosine (CPA) and 5’-N-ethylcarboxamidoadenosine (NECA). Tashkova et
al. compared different meta-heuristics for parameter estimation on a dynamic model of
endocytosis; DE was the most effective of the approaches tested [225]. Banga and co-
workers have also successfully applied scatter-search to estimate model parameters [226–
228]. Hybrid approaches, which combine meta-heuristics with local optimization tech-
niques, have also become popular. For example, Villaverde et al. developed the enhanced
scatter search (eSS) method [229], which combined scatter and local search methods, for
parameter estimation in biological models [230]. However, despite these successes, a ma-
jor drawback of most meta-heuristics remains the large number of function evaluations
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required to explore parameter space. Performing numerous potentially expensive func-
tion evaluations is not desirable (and perhaps not feasible) for many types of biochemical
models. Alternatively, Tolson and Shoemaker found, using high-dimensional watershed
models, that perturbing only a subset of parameters was an effective strategy for estimat-
ing parameters in expensive models [21]. Their approach, called Dynamically Dimen-
sioned Search (DDS), is a simple stochastic single-solution heuristic that estimates nearly
optimal solutions within a specified maximum number of function (or model) evalua-
tions. Thus, while meta-heuristics are often effective at estimating globally optimal or
nearly optimal solutions, they require a large number of function evaluations to converge
to a solution.
In this study, we developed Dynamic Optimization with Particle Swarms (DOPS), a
novel hybrid meta-heuristic that combines the global search capability of multi-swarm
particle swarm optimization with the greedy refinement of dynamically dimensioned
search (DDS). The objective of DOPS is to obtain near optimal parameter estimates
for large biochemical models within a relatively few function evaluations. DOPS uses
multi-swarm particle swarm optimization to generate nearly optimal candidate solutions,
which are then greedily updated using dynamically dimensioned search. We tested DOPS
using a combination of classic optimization test functions, biochemical benchmark prob-
lems and real-world biochemical models. First, we tested the performance of DOPS on
the Ackley and Rosenbrock functions, and published biochemical benchmark problems.
Next, we used DOPS to estimate the parameters of a model of the human coagulation
cascade. On average, DOPS outperformed other common meta-heuristics like differen-
tial evolution, simulated annealing, single-swarm particle swarm optimization, and dy-
namically dimensioned search on the optimization test functions, benchmark problems
and the coagulation model. For example, DOPS recovered the nominal parameters for
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the benchmark problems using an order of magnitude fewer function evaluations than
eSS in all cases. It also produced parameter estimates for the coagulation model that pre-
dicted unseen coagulation data sets. Thus, DOPS is a promising hybrid meta-heuristic for
the estimation of biochemical model parameters in relatively few function evaluations.
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6.2 Results
DOPS explores parameter space using a combination of global methods.
DOPS is a novel hybrid meta-heuristic which combines a multi-swarm particle swarm
method with the dynamically dimensioned search approach of Shoemaker and colleagues
(Fig. 6.3).
The goal of DOPS is to estimate optimal or near optimal parameter vectors for high-
dimensional biological models within a specified number of function evaluations. To-
ward this objective, DOPS begins by using a multi-swarm particle swarm search and
then dynamically switches, using an adaptive switching criteria, to the DDS approach.
The particle swarm search uses multiple sub-swarms wherein the update to each particle
(corresponding to a parameter vector estimate) is influenced by the best particle amongst
the sub-swarm, and the current globally best particle. Particle updates occur within sub-
swarms for a certain number of function evaluations, after which the sub-swarms are
reorganized. This sub-swarm mixing is similar to the regrouping strategy described by
Zhao et al. [231]. DOPS switches out of the particle swarm phase based upon an adaptive
switching criteria that is a function of the rate of error convergence. If the error repre-
sented by the best particle does decrease for a threshold number of function evaluations,
DOPS switches automatically to the DDS search phase. The DDS search is initialized with
the globally best particle from the particle swarm phase, thereafter, the particle is greed-
ily updated by perturbing a subset of dimensions for the remaining number of function
evaluations. The identity of the parameters perturbed is chosen randomly, with fewer
parameters perturbed the higher the number of function evaluations.
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6.2.1 DOPS minimized benchmark problems using fewer function
evaluations.
On average, DOPS performed similarly or outperformed the four other meta-heuristics
for the Ackley and Rastrigin test functions (Fig. 6.4). The Ackley and Rastrigin functions
both have multiple local extrema and attain a global minimum value of zero.
In each case, we fixed the maximum number of function evaluations at N = 4000
and ran T = 25 independent experiments with different initial parameter vectors. DOPS
found optimal or near optimal solutions for both the 10-dimensional Ackley (Fig. 6.4A)
and Rastrigin (Fig. 6.4B) functions within the budget of function evaluations. In each
of the 10-dimensional cases, other meta-heurtistics such as DDS and DE also performed
well. However, DOPS consistently outperformed all other approaches tested. This per-
formance difference was more pronounced as the dimension of the search problem in-
creased; for a 300-dimensional Rastrigin function, DOPS was the only approach to find
an optimal or near optimal solution within the function evaluation budget (Fig. 6.4B).
DOPS also had a lower variability in the best value obtained (Fig. A.8), faster conver-
gence (Fig. A.5, Fig. A.6) and less stochasticity (Fig. A.7) across multiple runs when
compared to other metaheuristics. We also checked for statistical significance by doing a
pairwise 2-sample t-test at 0.5% significance level. In each case we found that the p-value
was close to zero disproving the null hypothesis and confirming the statistical significance
of our results. Taken together, DOPS performed at least as well as other meta-heuristic
approaches on small dimensional test problems, but seemed especially suited to large di-
mensional search spaces. Next, we tested DOPS on benchmark biochemical models of
varying complexity.
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Villaverde and co-workers published a set of benchmark biochemical problems to
evaluate parameter estimation methods [230]. They ranked the example problems by
computational cost from most to least expensive. We evaluated the performance of DOPS
on problems from the least and most expensive categories. The least expensive prob-
lem (henceforth referred to as CHO model) was a metabolic model of Chinese Hamster
Ovary (CHO) with 35 metabolites, 32 reactions and 117 parameters [232]. The biochem-
ical reactions were modeled using modular rate laws and generalized Michaelis-Menten
kinetics. On the other hand, the expensive problem was a genome scale kinetic model
of Saccharomyces cerevisiae with 261 reactions, 262 variables and 1759 parameters [233]
(henceforth referred to as yeast model). In both cases, synthetic time series data gener-
ated with known parameter values, was used to estimate model parameters. For yeast
model, the time series data consisted of 44 observables, and for problem B4 the data cor-
responded to 13 different metabolite measurement sets. We fixed the number of function
evaluations atN = 4000, and trained both models against the synthetic experimental data.
DOPS produced good fits to the synthetic data (Fig. A.1 and Fig. A.2), and recapitulated
the nominal parameter values using only N ≤ 4000 function evaluations (Fig. A.4). On
the other hand, enhanced scatter search (eSS) with a local optimizer took on order 105
function evaluations for the same problems. Thus, DOPS estimated the parameters in
benchmark biochemical models, and recovered the original parameters from synthetic
data, using fewer function evaluations. Next, we compared the performance of DOPS
with the four other meta-heuristics for a model of the human coagulation cascade.
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6.2.2 DOPS estimated the parameters of a human coagulation model.
Coagulation is an archetype biochemical network that is highly interconnected, contain-
ing both negative and positive feedback (Fig. 6.5). The biochemistry of coagulation,
though complex, has been well studied [234–240], and reliable experimental protocols
have been developed to interrogate the system [241–244]. Coagulation is mediated by a
family proteases in the circulation, called factors and a key group of blood cells, called
platelets. The central process in coagulation is the conversion of prothrombin (fII), an in-
active coagulation factor, to the master protease thrombin (FIIa). Thrombin generation in-
volves three phases, initiation, amplification and termination. Initiation requires a trigger
event, for example a vessel injury which exposes tissue factor (TF), which leads to the ac-
tivation of factor VII (FVIIa) and the formation of the TF/FVIIa complex. Two converging
pathways, the extrinsic and intrinsic cascades, then process and amplify this initial coag-
ulation signal. There are several control points in the cascade that inhibit thrombin for-
mation, and eventually terminate thrombin generation. Tissue Factor Pathway Inhibitor
(TFPI) inhibits upstream activation events, while antithrombin III (ATIII) neutralizes sev-
eral of the proteases generated during coagulation, including thrombin. Thrombin itself
also inadvertently plays a role in its own inhibition; thrombin, through interaction with
thrombomodulin, protein C and endothelial cell protein C receptor (EPCR), converts pro-
tein C to activated protein C (APC) which attenuates the coagulation response by prote-
olytic cleavage of amplification complexes. Termination occurs after either prothrombin
is consumed, or thrombin formation is neutralized by inhibitors such as APC or ATIII.
Thus, the human coagulation cascade is an ideal test case; coagulation is challenging be-
cause it contains both fast and slow dynamics, but also accessible because of the availabil-
ity of comprehensive data sets for model identification and validation. In this study, we
used the coagulation model of Luan et al. [244], which is a coupled system of non-linear
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ordinary differential equations where biochemical interactions were modeled using mass
action kinetics. The Luan model contained 148 parameters and 92 species and has been
validated using 21 published experimental datasets.
DOPS estimated the parameters of a human coagulation model for TF/VIIa initiated
coagulation without anticoagulants (Fig. 6.7). The objective function was an unweighted
linear combination of two error functions, representing coagulation initiated with differ-
ent concentrations of TF/FVIIa (5pM, 5nM) [241]. We restricted the number of function
evaluations toN = 4000 for each algorithm we tested, and performed T = 25 trials of each
experiment to collect average performance data (Table 6.1). DOPS converged faster and
had a lower final error compared to the other algorithms (Fig. 6.6). Within the first 25%
of function evaluations, DOPS produced a rapid drop in error followed by a slower but
steady decline. Approximately between 500-1000 function evaluations DOPS switched
to the dynamically dimensioned search phase, however this transition varied from trial
to trial since the switch was based upon the local convergence rate. On average, DOPS
minimized the coagulation model error to a greater extent than the other meta-heuristics.
However, it was unclear if the parameters estimated by DOPS had predictive power on
unseen data. To address this question, we used the final parameters estimated by DOPS
to simulate data that was not used for training (coagulation initiated with 500pM, 50pM,
and 10pM TF/VIIa). The optimal or near optimal parameters obtained by DOPS pre-
dicted unseen coagulation datasets (Fig. 6.8). The normalized standard error for the
coagulation predictions was consistent with the training error, with the exception of the
50pM TF/VIIa case which was a factor 2.75 worse (Table 6.2). Coagulation initiation with
50pM TF/FVIIa was the farthest away from the training conditions. However, while the
50pM TF/FVIIa case was the worst of those tested, it still had an average error rate of
only 11% (which is near the margin of error for the experimental measurements). Taken
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together, DOPS estimated parameter sets with predictive power on unseen coagulation
data using fewer function iterations than other meta-heuristics. Next, we explored how
the number of sub-swarms and the switch to DDS influenced the performance of the ap-
proach.
Phase switching was critical to DOPS performance.
A differentiating feature of DOPS is the switch to dynamically dimensioned search fol-
lowing stagnation of the initial particle swarm phase. We quantified the influence of
the number of sub-swarms and the switch to DDS on error convergence by comparing
DOPS with and without DDS for different numbers of sub-swarms (Fig. 6.9). We con-
sidered multi swarm particle swarm optimization with and without the DDS phase for
N = 4000 function evaluations and T = 25 trials on the coagulation model. We used one,
two, four, five and eight sub-swarms, with a total of 40 particles divided evenly amongst
the swarms. Hence, we did not consider swarm numbers of three and seven. All other
algorithm parameters remained the same for all cases. Generally, the higher sub-swarm
numbers converged in fewer function evaluations, where the optimum particle partition-
ing was in the neighborhood of five sub-swarms. However, the difference in convergence
rate was qualitatively similar for four, five and eight sub-swarms, suggesting there was
an optimal number of particles per swarm beyond which there was no significant advan-
tage. The multi-swarm particle swarm optimization stagnated after 25% of the available
function evaluations irrespective of the number of sub-swarms. However, DOPS (with
five sub-swarms) switched to DDS after detecting the stagnation. The DDS phase refined
the globally best particle to produce significantly lower error on average when compared
to multi-swarm particle swarm optimization alone. Thus, the automated switching strat-
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egy was critical to the overall performance of DOPS.
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Figure 6.1: Schematic of the dynamic optimization with particle swarms
(DOPS) approach. A: Each particle represents an N dimen-
sional parameter vector. Particles are given randomly gener-
ated initial solutions and grouped into different sub-swarms.
Within each swarm the magnitude and direction of the move-
ment a particle is influenced by the position of the best parti-
cle and also by its own experience. After every g number of
function evaluations the particles are mixed and randomly as-
signed to different swarms. When the error due to the global
best particle (best particle amongst all the sub-swarms) does
not drop over a certain number of function evaluations, the
swarm search is stopped and the search switches to a Dynami-
cally Dimensioned Search with global best particle as the initial
solution vector or candidate vector. B: The candidate vector
performs a greedy global search for the remaining number of
function evaluations. The search neighborhood is dynamically
adjusted by varying the number of dimensions that are per-
turbed (in black) in each evaluation step. The probability that
a dimension is perturbed decreases as the number of function
evaluations increase.
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Figure 6.2: Performance of DOPS and other meta-heuristics for the Ack-
ley and Rastrigin functions. A: Mean scaled error versus the
number of function evaluations for the 10-dimensional Ackley
function. DOPS, DDS and DE find optimal or near optimal so-
lutions within the specified number of function evaluations. B:
Mean scaled error versus the number of function evaluations
for the 10-dimensional Rastrigin function. DOPS and DDS find
optimal or near optimal solutions within the specified num-
ber of function evaluations. C: Mean scaled error versus the
number of function evaluations for the 300-dimensional Rastri-
gin function. DOPS is the only algorithm that finds an optimal
or near optimal solution within the specified number of func-
tion evaluations. In all cases, the maximum number of function
evaluations was N = 4000. Mean and standard deviation were
calculated over T = 25 trials.
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6.3 Discussion
In this study, we developed dynamic optimization with particle swarms (DOPS), a novel
meta-heuristic for parameter estimation in models of biological systems. DOPS combined
multi-swarm particle swarm optimization, a global search approach, with the greedy
strategy of dynamically dimensioned search to estimate optimal or nearly optimal so-
lutions in a fixed number of function evaluations. We tested the performance of DOPS
and four widely used meta-heuristics on the Ackley and Rastrigin test functions, a set of
biochemical benchmark problems and a model of the human coagulation cascade. As the
number of parameters increased, DOPS outperformed the other meta-heuristics, gener-
ating optimal or nearly optimal solutions using significantly fewer function evaluations
compared with the other methods. We tested the solutions generated by DOPS by com-
paring the estimated and true parameters in the benchmark studies, and by using the
coagulation model to predict unseen experimental data. For both benchmark problems,
DOPS retrieved the true parameters in significantly fewer function evaluations than other
meta-heuristics. For the coagulation model, we used experimental coagulation measure-
ments under two different conditions to estimate optimal or nearly optimal parameters.
These parameters were then used to predict unseen coagulation data; the coagulation
model parameters estimated by DOPS predicted the correct thrombin dynamics follow-
ing TF/FVIIa induced coagulation without anticoagulants. Lastly, we showed the av-
erage performance of DOPS improved when combined with dynamically dimensioned
search phase, compared to an identical multi-swarm approach alone. Taken together,
DOPS is a promising meta-heuristic for the estimation of parameters in large biochemical
models.
Meta-heuristics can be effective techniques to estimate optimal or nearly optimal so-
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lutions for complex, multi-modal functions. However, meta-heuristics typically require a
large number of function evaluations to converge to a solution. DOPS is a combination of
particle swarm optimization, which is a global search method, and dynamically dimen-
sioned search, which is a greedy evolutionary technique. Particle swarm optimization
uses collective information shared amongst swarms of computational particles to search
for global extrema. Several particle swarm variants have been proposed to improve the
search ability and rate of convergence. These variations involve different neighborhood
structures, multi-swarms or adaptive parameters. Multi-swarm particle swarm optimiza-
tion with small particle neighborhoods has been shown to be better in searching on com-
plex multi-modal solutions [231]. Multi-swarm methods generate diverse solutions, and
avoid rapid convergence to local optima. However, at least for the coagulation problem
used in this study, multi-swarm methods stagnated after approximately 25% of the avail-
able function evaluations; only the introduction of dynamically dimensioned search im-
proved the rate of error convergence. Dynamically dimensioned search, which greedily
perturbs only a subset of parameter dimensions in high dimensional parameter spaces,
refined the globally best particle and produced significantly lower error on average when
compared to multi-swarm particle swarm optimization alone. However, dynamically di-
mensioned search, starting from a initial random parameter guess, was not as effective
on average as DOPS. The initial solutions generated by the multi swarm search had a
higher propensity to produce good parameter estimates when refined by dynamically
dimensioned search. Thus, our hybrid combination of two meta-heuristics produced bet-
ter results than either constituent approach, and better results than other meta-heuristic
approaches on average. This was true of not only the convergence rate on the coagula-
tion problem, but also the biochemical benchmark problems; DOPS required two-orders
of magnitude fewer function evaluations compared with enhanced Scatter Search (eSS)
to estimate the biochemical benchmark model parameters. Taken together, the combina-
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tion of particle swarm optimization and dynamically dimensioned search produced bet-
ter results than either of these constituent approaches alone, and required fewer function
evaluations compared with other common meta-heuristics.
DOPS performed well on many different systems with no pre-optimization of algo-
rithm parameters, however there are many research questions that should be pursued
further. DOPS comfortably outperformed existing, widely used meta-heuristics for high
dimensional global optimization functions, biochemical benchmark models and a model
of the human coagulation system. However, it is possible that highly optimized ver-
sions of common meta-heuristics could surpass DOPS; we should compare the perfor-
mance of DOPS with optimized versions of the common meta-heuristics on both test and
real-world problems to determine if a performance advantage exists in practice. Next,
DOPS has a hybrid architecture, thus the particle swarm phase could be combined with
other search strategies such as local derivative based approaches to improve convergence
rates. We could also consider multiple phases beyond particle swarm and dynamically
dimensioned search, for example switching to a gradient based search following the dy-
namically dimensioned search phase. Next, the current implementation of the algorithm
switches only once from the swarm phase to the dynamically dimensioned phase. An
obvious modification would be to allow multiple transitions between the swarm and dy-
namically dimensioned phases. Lastly, we should update DOPS to treat multi-objective
problems. The identification of large biochemical models sometimes requires training
using qualitative, conflicting or even contradictory data sets. One strategy to address
this challenge is to estimate experimentally constrained model ensembles using multi-
objective optimization. Previously, we developed Pareto Optimal Ensemble Techniques
(POETs) which integrates simulated annealing with Pareto optimality to identify mod-
els near the optimal tradeoff surface between competing training objectives [245]. Since
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DOPS consistently outperformed simulated annealing on both test and real-world prob-
lems, we expect a multi-objective form of DOPS would more quickly estimate solutions
which lie along high dimensional trade-off surfaces.
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6.4 Materials and Methods
Optimization problem formulation.
Model parameters were estimated by minimizing the difference between model simula-
tions and E experimental measurements. Simulation error is quantified by an objective
function K (p) (typically the Euclidean norm of the difference between simulations and
measurements) subject to problem and parameter constraints:
min
p
K(p) =
E∑
i=1
(gi(ti, x,p,u) − yi)2
subject to x˙ = f(t, x(t,p),u(t),p)
x(t0) = x0
c(t, x,p,u) > 0
pL 6 p 6 pU
(6.1)
The term K(p) denotes the objective function, t denotes time, gi(ti, x,p,u) is the model
output for experiment i, x (t,p) is the state variable vector with an initial state x0, u(t) is
a model input vector, f(t, x(t,p),u(t),p) is the system of model equations (e.g., differen-
tial equations or algebraic constraints) and p denotes the model parameter vector. The
parameter search (or model simulations) can be subject to c(t, x,p,u) linear or non-linear
constraints, and parameter bound constraints where pL and pU denote the lower and up-
per parameter bounds, respectively. Optimal model parameters are then given by:
p∗ = arg min
p
K (p) (6.2)
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6.4.1 Dynamic optimization with particle swarms (DOPS).
DOPS is a novel meta-heuristic which combines multi-swarm particle swarm optimiza-
tion with the dynamically dimensioned search (Fig. 6.3) and (Algo. 1). Particle swarm
optimization is an evolutionary algorithm that uses a population of particles (solu-
tions) to find an optimal solution. Each particle is updated based on its on experience
(particle best) and the experience of all other particles within the swarm (global best)
[246][247][248]. Multi-swarm particle swarm optimization is a variant of particle swarm
optimization that uses multiple swarms instead of a single swarm. DOPS uses a novel
update rule of particles within each swarm. This rule uses only particle positions but not
particle velocities in the update rule. This differs from existing PSO methods that rely
both on particle position and velocity for update. The update rule further described in
detail in the methods. The goal of DOPS is to estimate optimal or near optimal parame-
ter vectors for high-dimensional biological models within a specified number of function
evaluations. Toward this objective, DOPS begins by using a particle swarm search and
then dynamically switches, using an adaptive switching criteria, to a DDS search phase.
Dynamically Dimensioned Search (DDS) is a single solution based search algorithm. It
was developed by Tolson and Shoemaker to obtain good solutions to high-dimensional
search problems within a fixed number of function evaluations. DDS starts as a global
search algorithm by perturbing all the dimensions. Later the number of dimensions that
are perturbed is decreased with a certain probability. The probability that a certain di-
mension is perturbed reduces (a minimum of one dimension is always perturbed) as the
iterations increase. This causes the algorithm to behave as a local search algorithm as the
number of iterations increase. The perturbation magnitude of each dimension is from
normal distribution with zero mean. The standard deviation that was used in the original
DDS paper and the current study is 0.2. DDS performs a greedy search where the solution
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is updated only if it is better than the previous solution. The combination of perturbing
a subset of dimensions along with greedy search indirectly relies on model sensitivity to
a specific parameter combination. For the sake of brevity we are not providing the entire
pseudo code of DDS here. The reader is requested to refer to Figure 1 of the original paper
by Tolson and Shoemaker [21].
input : A randomized swarm of particles of size NP × K and fixed number of
function evaluations N
output: Optimized parameter vector of size 1 × K
1 Initialize the particles randomly and assign particles randomly to k sub-swarms;
2 while j ≤ N do
3 if mod(j,G)=0 then
4 Reassign particles to k sub-swarms;
5 end
6 for i← 1 to NS do
7 Update particles within sub-swarms according to equation 3;
8 end
9 Find best particle G amongst all sub-swarms;
10 if besterror( j) ≥ 0.99 ∗ besterror( j + 1) then
11 f ailurecounter ← f ailurecounter + 1;
12 else
13 f ailurecounter ← 0;
14 end
15 if f ailurecounter ≥ threshold then
16 G ← DDS (G,N − j);
17 return G
18 else
19 j← j + 1;
20 end
21 return G
22 end
Algorithm 1: Pseudo code for the dynamic optimization with particle
swarms (DOPS) method.
Phase 1: Particle swarm phase.
The particle swarm phase of DOPS begins by randomly initializing a swarm of K-
dimensional particles (represented as zi), wherein each particle corresponded to a K-
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dimensional parameter vector. After initialization, particles were randomly partitioned
into k equally sized sub-swarms S1, . . . ,Sk. Particles within each sub-swarm Sk were up-
dated according to the rule:
zi, j = θ1, j−1zi, j−1 + θ2r1
(
Li − zi, j−1
)
+ θ3r2
(
Gk − zi, j−1
)
(6.3)
where (θ1, θ2, θ3) were adjustable parameters, Li denotes the best solution found by par-
ticle i within sub-swarm Sk for function evaluation 1 → j − 1, and Gk denotes the best
solution found over all particles within sub-swarm Sk. The quantities r1 and r2 denote
uniform random vectors with the same dimension as the number of unknown model
parameters (K × 1). Equation (6.3) is similar to the general particle swarm update rule,
however, it does not contain velocity terms. In DOPS, the parameter θ1, j−1 is similar to
the inertia weight parameter for the velocity term described by Shi and Eberhart [249];
Shi and Eberhart proposed a linearly decreasing inertia weight to improve convergence
properties of particle swarm optimization. Our implementation of θ1, j−1 is inspired by this
and the decreasing perturbation probability proposed by Tolson and Shoemaker [21]. It
is an analogous equivalent to inertia weight on velocity. However θ1, j−1 places inertia on
the position rather than velocity and uses the same rule described by Shi and Eberhart to
adaptively change with the number of function evaluations:
θ1, j =
(N − j) ∗ (wmax − wmin))
(N − 1) + wmin (6.4)
where N represents the total number of function evaluations, wmax and wmin are the maxi-
mum and minimum inertia weights, respectively. While updating the particles, parame-
ter bounds were enforced using reflection boundary conditions (Algo. 2).
145
1 if zoldi, j < z
min
i then
2 znewi, j = z
old
i, j + (z
min
i − zoldi, j ) if znewi, j > zmaxi then
3 znewi, j = z
max
i
4 end
5 end
6 if zoldi, j > z
max
i then
7 znewi, j = z
old
i, j + (z
old
i, j − zmaxi ) if znewi, j < zmini then
8 znewi, j = z
min
i
9 end
10 end
Algorithm 2: Pseudo code for the reflective boundary conditions used
by the dynamic optimization with particle swarms (DOPS)
method.
After every M function evaluations, particles were randomly redistributed to a new
sub-swarm, and updated according to Eqn. (6.3). This process continued for a maximum
of F ∗ N functions evaluations, where F is the fraction of evaluations in the particle
swarm phase of DOPS. However, if the simulation error stagnated e.g., did not change
by more than 1% for a specified number of evaluations, the swarm phase was terminated
and DOPS switched to exploring parameter space using the DDS approach.
Phase 2: DDS phase.
input : Candidate vector G from swarm search and (1 − F ) ∗ N evaluations
output: Optimized parameter vector of size 1 × K
1 while j ≤ (1 − F ) ∗ N do
2 Assign probability of perturbation to each dimension Pi according to equation 7;
3 Select a subset of dimensions based on a threshold value for perturbation;
4 Update candidate solution G(J) according to equation 5;
5 Ensure updated solution Gnew(J) is within bounds using Algorithm 2;
6 end
Algorithm 3: Pseudo code for the Dynamically Dimensioned Search
(DDS) method.
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At the conclusion of the swarm phase, the overall best particle, Gk, over the k sub-
swarms was used to initialize the DDS phase. DOPS takes at least (1 − F ) ∗ N function
evaluations during the DDS phase and then terminates the search. For the DDS phase,
the best parameter estimate was updated using the rule:
Gnew(J) =

G(J) + rnormal(J)σ(J), if Gnew(J) < G(J).
G(J), otherwise.
(6.5)
where J is a vector representing the subset of dimensions that are being perturbed, rnormal
denotes a normal random vector of the same dimensions as G, and σ denotes the pertur-
bation amplitude:
σ = R(pU − pL) (6.6)
where R is the scalar perturbation size parameter, pU and pL are (K ×1) vectors that repre-
sent the maximum and minimum bounds on each dimension. The set J was constructed
using a probability function Pi that represents a threshold for determining whether a
specific dimension j was perturbed or not; Pi is monotonically decreasing function of
function evaluations:
Pi = 1 − log
[
i
(1 − F ) ∗ N
]
(6.7)
where i is the current iteration. After Pi is determined, we drew P j from a uniform
distribution for each dimension j. If P j < Pi was included in J. Thus, the probability
that a dimension j was perturbed was inversely proportional to the number of function
evaluations. DDS updates are greedy; Gnew becomes the new solution vector only if it
is better than G. DOPS source code is available for download under a MIT license at
http://www.varnerlab.org.
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Table 6.1: Table with optimization settings and results for the coagula-
tion problem, the benchmarks and test functions using DOPS.
For each problem the bounds on the parameter vector, the total
number of function evaluations, the best initial objective value
and the best final objective value are specified. Here pnom indi-
cates the nominal or true parameter vector of the model. Nomi-
nal objective value represents the objective value using the true
parameter vector or the nominal parameter vector. The CPU
time is the time taken for the problem on a 2.4GHz Intel Xeon
Architecture running Matlab 2014b.
Coagulation Yeast model CHO model Ackley Rastrigin
Evaluations 4000 4000 4000 4000 4000
Lower Bound 0.001.pnom 5.pnom 5.pnom 30 5.12
Upper Bound 1000.pnom 0.2.pnom 0.2.pnom -15 -5.12
CPU Time 10.1 hrs 38.3 hrs 6.2 min 2.8 s 2.6 s
Scaled initial error 1.0 1.0 1.0 1.0 1.0
Scaled final error < 0.01 < 0.01 < 0.01 < 0.01 < 0.01
Scaled nominal error 0.42 0.1 < 0.01 0 0
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Table 6.2: Error analysis for the human coagulation model. The coagula-
tion model was trained on coagulation initiated with TF/FVIIa
at 5 nM and the 5 pM to obtain the optimal parameters. Using
these optimal parameters, coagulation dynamics were predicted
for varying initiator concentrations (500 pM, 50 pM and 10 pM).
Model agreement with measurements was quantified using nor-
malized squared error. The normalized squared error is defined
as N.S .E. = (1/max(X)) ∗ (‖(Y,X)‖/sqrt(N)) where X is the exper-
imental data, Y is the model simulation data interpolated onto
the experimental time scale and N is the total number of experi-
mental time points.
TF/FVIIa concentration Normalized S.E. Category
5 nM 0.0376 Training
500 pM 0.0564 Prediction
50 pM 0.1125 Prediction
10 pM 0.0823 Prediction
5 pM 0.0338 Training
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Figure 6.3: Schematic of the dynamic optimization with particle swarms
(DOPS) approach. A: Each particle represents an N dimen-
sional parameter vector. Particles are given randomly gener-
ated initial solutions and grouped into different sub-swarms.
Within each swarm the magnitude and direction of the move-
ment a particle is influenced by the position of the best parti-
cle and also by its own experience. After every g number of
function evaluations the particles are mixed and randomly as-
signed to different swarms. When the error due to the global
best particle (best particle amongst all the sub-swarms) does
not drop over a certain number of function evaluations, the
swarm search is stopped and the search switches to a Dynami-
cally Dimensioned Search with global best particle as the initial
solution vector or candidate vector. B: The candidate vector
performs a greedy global search for the remaining number of
function evaluations. The search neighborhood is dynamically
adjusted by varying the number of dimensions that are per-
turbed (in black) in each evaluation step. The probability that
a dimension is perturbed decreases as the number of function
evaluations increase.
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Figure 6.4: Performance of DOPS and other meta-heuristics for the Ack-
ley and Rastrigin functions. A: Mean scaled error versus the
number of function evaluations for the 10-dimensional Ackley
function. DOPS, DDS and DE find optimal or near optimal so-
lutions within the specified number of function evaluations. B:
Mean scaled error versus the number of function evaluations
for the 10-dimensional Rastrigin function. DOPS and DDS find
optimal or near optimal solutions within the specified num-
ber of function evaluations. C: Mean scaled error versus the
number of function evaluations for the 300-dimensional Rastri-
gin function. DOPS is the only algorithm that finds an optimal
or near optimal solution within the specified number of func-
tion evaluations. In all cases, the maximum number of function
evaluations was N = 4000. Mean and standard deviation were
calculated over T = 25 trials.
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Figure 6.5: Schematic of the extrinsic and intrinsic coagulation cascade. In-
active zymogens upstream (grey) are activated by exposure to
tissue factor (TF) following vessel injury. Tissue factor and ac-
tivated factor VIIa (FVIIa) form a complex that activates fac-
tor X (fX) and IX (fIX). FXa activates downstream factors in-
cluding factor VIII (fVIII) and fIX. Factor V (fV) is primarily
activated by thrombin (FIIa). In addition, we included a sec-
ondary fV activation route involving FXa. FXa and FVa form a
complex (prothrombinase) on activated platelets that converts
prothrombin (fII) to FIIa. FIXa and FVIIIa can also form a com-
plex (tenase) on activated platelets which catalyzes FXa for-
mation. Thrombin also activates upstream coagulation factors,
forming a strong positive feedback ensuring rapid activation.
Tissue factor pathway inhibitor (TFPI) downregulates FXa for-
mation and activity by sequestering free FXa and TF-FVIIa in
a FXa-dependent manner. Antithrombin III (ATIII) inhibits all
proteases. Thrombin inhibits itself binding the surface protein
thrombomodulin (TM). The IIa-TM complex catalyzes the con-
version of protein C (PC) to activated protein C (APC), which
attenuates the coagulation response by the proteolytic cleavage
of fV/FVa and fVIII/FVIIIa.
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Figure 6.6: Error convergence rates of the five different algorithms on the
coagulation model. The objective error is the mean over T= 25
trials. DOPS, DDS and SA have the steepest drop in error dur-
ing first 300 function evaluations. Thereafter the error drop in
DDS and SA remains nearly constant whereas DOPS continues
to drops further. At the end of 4000 function evaluations DOPS
attains the lowest error. The next best estimate using DDS is
nearly three times greater than the lowest error using DDS.
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Figure 6.7: Model fits on experimental data using DOPS. The model pa-
rameters were estimated using DOPS. Solid black lines indi-
cate the simulated mean thrombin concentration using param-
eter vectors from 25 trials. The grey shaded region represents
the 99% confidence estimate of the mean simulated throm-
bin concentration. The experimental data is reproduced from
the synthetic plasma assays of Mann and co-workers. Throm-
bin generation is initiated by adding Factor TF/VIIa (5nM
and 5pM) to synthetic plasma containing 200 µmol/L of phos-
pholipid vesicles (PCPS) and a mixture of coagulation factors
(II,V,VII,VIII,IX,X and XI) at their mean plasma concentrations.
155
1600
1400
1200
1000
800
600
400
200
0
Th
ro
m
bin
 C
on
ce
nt
ra
tio
n 
(n
M
)
200150100500
 Time (seconds)
 10pM FVIIa-TF
 50pM FVIIa-TF
 500pM FVIIa-TF
Figure 6.8: Model predictions on unseen experimental data using parame-
ters obtained from DOPS. The parameter estimates that were
obtained using DOPS were tested against data that was not
used in the model training. Solid black lines indicate the sim-
ulated mean thrombin concentration using parameter vectors
from T = 25 trials. The grey shaded region represents the 99%
confidence estimate of the mean simulated thrombin concen-
tration. The experimental data is reproduced from the syn-
thetic plasma assays of Mann and co-workers. Thrombin gen-
eration is initiated by adding Factor VIIa-TF (500pM - Blue,
50pM - Pink and 10pM - orange, respectively) to synthetic
plasma containing 200 µmol/L of phospholipid vesicles (PCPS)
and a mixture of coagulation factors (II,V,VII,VIII,IX,X and XI)
at their mean plasma concentrations.
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Figure 6.9: Influence of the switching strategy and sub-swarms on DOPS
performance for the coagulation model. DOPS begins by using
a particle swarm search and then dynamically switches (switch
region), using an adaptive switching criteria, to the DDS search
phase. We compared the performance of DOPS with and with-
out DDS for different sub-swarm searches to quantify the effect
of number of sub-swarms and DDS. We used one, two, four,
five and eight sub-swarms, with a total of 40 particles divided
evenly amongst the swarms. The results presented are the av-
erage of T = 25 trials with N = 4000 function evaluations each.
The convergence rates with higher swarm numbers is typically
higher but there is no pronounced difference amongst four, five
and eight. The multi-swarm with DDS saturates while DOPS
shows a rapid drop due to a switch to the DDS phase.
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CHAPTER 7
SUMMARY AND FUTURE WORK
The objective of this work has been to provide a platform for building an integrated
These networks are complex and often require great degree of mechanistic detail for sim-
ulation. Thus building an integrated multi-scale framework is expensive. We use an ap-
proach that reduces mechanistic detail involved by using a combination of logical rules
with ODEs. In chapter 2 we illustrate this approach on a biochemical network of coagula-
tion. We capture the dynamics of thrombin generation in vitro under different conditions.
Specifically we quantify the regulatory role of protein C, a protein believed to have a cru-
cial role in trauma induced coagulopathy. We extend this approach to model cell-free
metabolic networks and captured complex allosteric patterns in chapter 3.
Chapter 4 describes perhaps the first model of complement that includes all the three
pathways of initiation. Importantly we describe a model that captures dynamics of C5a, a
key complement protein that interacts with proteins in coagulation and fibrinolysis under
trauma. The sensitivity analysis and robustness analysis validated some of the existing
current therapeutic strategies and also identified potentially important mechanisms that
can be used develop novel treatment strategies. In Chapter 5 we describe a model of co-
agulation and fibrinolysis. The model successfully predicts ROTEM data. ROTEM data is
perhaps the most important clinical metric in measuring coagulopathy. The ability to link
biochemical concentrations with a clinical measure is significant and can serve as an im-
portant tool for developing new treatment strategies. We conclude these series of papers
in traumatic coagulopathy with an algorithm that can train the large models of biochem-
ical networks rapidly without problem specific parameter setting. The combination of
particle swarm optimization and dynamically dimensioned search outperforms known
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metaheuristics on well known benchmarks as well as a large model of coagulation. This
method can utilized to obtain good starting solutions, if not optimal solutions for large
models.
The future directions of this work firstly involves a building a reduced order model
of coagulation that includes platelets. After building this model the next step would be
to describe a whole body model using a physiology based pharmacokinetic approach us-
ing physiological parameters about organ sizes, perfusion rates. Subsequently, using the
reduced order models of biochemical networks in coagulopathy dynamics of clot gen-
eration need to be captured in presence of an injury. The qualitative and quantitative
predictions need to be experimentally validated using the clinical data from our collabo-
rators.
The development and applications of whole body models is an exciting approach that
has been barely exploited. It presents an immense opportunity to investigate complex
biochemical and physiological phenomena. Successful application in this context will
certainly provide the researchers and clinicians with novel perspectives about trauma
induced coagulopathy.
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Figure A.1: (Data fits for Yeast Model (B1)) Pseudo-experimental data
(red circles) vs. optimal solution obtained using DOPS (solid
blue lines) for the 44 observed states. X axis: time [s]; Y axis:
metabolite concentrations [mM].
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Figure A.2: (Data fits for CHO Model (B4)) Pseudo-experimental data
(red x) vs. optimal solution obtained using DOPS (solid blue
lines) for the 13 observed states. X axis: time [s]; Y axis:
metabolite concentrations [mM].
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Figure A.3: (A) Difference between nominal and optimal parameters for
problem B1: Genome wide kinetic model of S.cerevisiae with
1759 unknown parameters. (B) Difference between experi-
mental (measured) data and data simulated with optimal pa-
rameters for yeast model: Genome wide kinetic model of
S.cerevisiae with 1759 unknown parameters. (C) Difference
between nominal and optimal parameters for problem B4:
Metabolic model of Chinese Hamster Ovary Cells (CHO) cells
with 117 parameters. (D) Difference between experimental
(measured) data and data simulated with optimal parameters
for CHO model: Metabolic model of Chinese Hamster Ovary
Cells (CHO) cells with 117 parameters.
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Figure A.4: (A) Difference between nominal and optimal parameters for
problem B1: Genome wide kinetic model of S.cerevisiae with
1759 unknown parameters. (B) Difference between experi-
mental (measured) data and data simulated with optimal pa-
rameters for yeast model: Genome wide kinetic model of
S.cerevisiae with 1759 unknown parameters. (C) Difference
between nominal and optimal parameters for problem B4:
Metabolic model of Chinese Hamster Ovary Cells (CHO) cells
with 117 parameters. (D) Difference between experimental
(measured) data and data simulated with optimal parameters
for CHO model: Metabolic model of Chinese Hamster Ovary
Cells (CHO) cells with 117 parameters.
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Figure A.5: Convergence curves for different metaheuristics along with
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Figure A.6: (Convergence curves for eSS and DOPS) Objective function
value versus the number of function evaluations plotted for
eSS and DOPS on (A) Coagulation (B) CHO Model (C) Ackley
300 dimensional and (D) Rastrigin 300 dimensional.
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Figure A.7: (Dispersion curves for DOPS) Objective function value (25
trials) versus the number of function evaluations plotted for
DOPS on (A) Ackley 300 dimensional (B) Rastrigin 300 dimen-
sional (C)CHO Model - B4 (D) Coagulation. For CHO Model
and Coagulation Y-axis is in log scale.
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